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 Kidney toxicity is the second highest cause of new drug candidate failure, after liver toxicity, 
leading to drug withdrawals from the market and failed clinical trials. Therefore, development of 
more reliable and accurate in vitro screening systems for assessing drug nephrotoxicity is of high 
importance. Ideally, future new drug toxicity testing models will be highly sensitive, minimize animal 
use, and allow for high-throughput screening modalities. Recent technologies emphasize a shift 
away from monolayer-cultured and immortalized cells on plastic plates to novel three-dimensional 
(3D) matrix-based culture systems more similar to actual tissue constructs (i.e., organoids, micro-
tissues, spheroids and cell/gels).  
 This dissertation focuses on characterization of a recently developed ex vivo 3D murine 
proximal tubule model and comparison to currently used two-dimensional (2D) kidney cell 
monocultures which are used for nephrotoxicity drug screening. The overall goal of this dissertation 
is to establish a scientific basis for justifying this ex vivo 3D model as a more reliable and predictive 
toxicity testing system for high-throughput drug screening in early drug development stages than 
currently available.  
Therefore, expression levels and profiles for key kidney proximal tubule markers and 
important proximal tubule transporters with known roles in drug transport were obtained from the 
ex vivo 3D proximal tubule model. These data demonstrate more abundant and enduring apical 
and basolateral transporter expression than transporters in 2D cell lines, suggesting that they will 
provide a more reliable response to pharmaceutical compounds in 3D cultures.  
To test the transporter functional ability and predictive toxicity, the model was further 
analyzed for its capability to detect nephrotoxicity in early stages using clinically relevant known 
nephrotoxic and nonnephrotoxic drugs. The obtained assay responses were compared to patient 
drug toxicity data from the clinic to assess the model’s translational capacity. Data collected during 
iv 
the concentration-response study demonstrate that the model is capable of accurately predicting 
nephrotoxicity for all tested compounds, producing toxicity responses highly correlated to known 
human clinical experience with the tested drugs. The 3D murine proximal tubule model’s predictive 
values were found to be highly improved compared with predictive values from the current industrial 
“gold standard” for 2D kidney cell cultures still widely used for similar toxicity assessments. 
Furthermore, this model could be used to gain insight into specific drug structural mechanisms that 
drive toxicity and facilitate rapid assay of different chemical moieties during structure activity 
relationship screening. 
The knowledge gained through this study provides greater understanding of how drug 
toxicity testing results compare between standard 2D cell assays, 3D assays, and human clinical 
data. The data underscore the 3D proximal tubule model’s promising future as an improved, more 
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INTRODUCTION TO THIS DISSERTATION 
 
Kidney toxicity is the second highest cause of new drug failure after liver toxicity and causes 
many new pharmaceutical drug performance issues in clinical trials [91]. Lack of reliable drug 
candidate identification and reliable toxicity screening methods result in costly consequences when 
drugs fail [92]. Currently, only 8% of new pharmaceutical compounds tested in clinical trials actually 
reach the market. This low success rate does not sufficiently balance the input of time (typical 
timeframes averaging 9 years) and expenses (around one to two billion dollars) [93]. Hence, the 
demand for improved, more reliable and more predictive testing models to screen drug toxicity in 
early research stages and eliminate toxic drug candidates before clinical trials is high [91]. Besides 
the liver, kidneys are the main drug metabolism and elimination site, making kidney cell cultures 
the predominant preliminary drug nephrotoxicity model. However, the currently used screening 
models for nephrotoxicity eliminate only about 7% of pharmaceutical compounds in preclinical 
tests, a low amount considering that drug-induced acute renal failure cases are estimated between 
30-50% [93-95]. This suggests that there is a significant gap between the screening data and real 
human in vivo response [93, 96, 97]. This discrepancy is mainly based on interspecies differences 
in drug response when animal in vivo models are used to predict human responses [97]. In addition 
to interspecies response differences, currently available two-dimensional (2D) drug toxicity 
screening models do not reliably screen physiologically relevant toxicity markers: 2D-cultured 
kidney cells lose native cellular phenotypes and in vivo-like properties, leading to the loss of in vivo-
relevant pharmacological indicators, like kidney cell gene expression up- or down-regulation based 
on drug exposure and toxicity [98]. 
Ideally, future new drug testing models will be highly sensitive to drug dose, minimize 
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animal use, and allow for high-throughput screening modalities. It is important to validate new drug 
toxicity models that respond accurately to pharmaceutical compounds and use clinically relevant 
toxicity and/or disease biomarkers [99]. 
This dissertation aims to characterize and compare our recently developed ex vivo three-
dimensional (3D) murine proximal tubule (PT) model against the current industrial standard of 2D 
monoculture kidney cell lines; to gain a greater understanding of the proximal tubule model’s 
advantages and limitations and assess how the 3D proximal tubule model bridges the current 
toxicity screening gap to translate predictions to human clinical data in a correlative matter. The 
overarching hypothesis for this dissertation is that 3D proximal tubule organoid culture will better 
maintain in vivo-like properties and create a more reliable model for toxicity screening than currently 
used 2D cell culture. Our 3D kidney PT culture model preserves native proximal tubule structure 
sufficiently to retain essential functions that are important in the nephron for drug-induced 
nephrotoxicity, and therefore has the potential for improved high-throughput toxicity screening. 
Proximal tubules are the primary site of drug-induced nephrotoxicity. This is due to the fact 
that proximal tubules have specialized transporters for the uptake of organic compounds (e.g., 
OAT1, OAT3, OCT2). This active transport then results in high levels of drug, drug metabolite or 
toxin inside the proximal tubule cell, leading to cell damage and death. Additional drug toxicity can 
be achieved by drug biotransformation. In proximal tubule cells, biotransformation can occur 
enzymatically (e.g., brush border enzyme γ-glutamyl-transferase, lysosomal enzyme N-acetyl-β-D-
glucosamine, cytosolic enzyme glutathione-S-transferase), or through metabolism through several 
cytochrome P450 enzymes. Cytochrome P450 is predominantly localized in the proximal tubule 
and not in other parts of the nephron. Therefore, nephrotoxic effects from compounds which require 
cytochrome P450 metabolism are ideally studied in the proximal tubules as well [100, 101]. These 
components play a major role in why proximal tubules are an ideal target for a drug toxicity 
screening models. Chapter 2 gives further insight into drug-induced nephrotoxicity. 
Previously, 3D cell culture has demonstrated many benefits compared to conventional 2D 
cell culture, which is the current toxicity testing standard in the pharmaceutical industry in 
combination with animal studies [14]. In 2D cell culture, primary proximal tubule cells lose their 
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polarization sometimes within min [102], while secondary cells are often missing important 
transporters critical for drug toxicity [98]. Therefore, recent technologies emphasize a shift away 
from monolayer-cultured cells on plastic plates to novel 3D matrix-based culture systems more 
similar to actual tissue constructs (i.e., organoids, micro-tissues, spheroids and cells in gels) [103, 
104].  
Our recently developed 3D kidney organoid toxicity model [60] fulfills many of these 
requirements and improves on current 2D kidney cell monocultures on plastic by using viable 
mouse kidney-derived proximal tubules [105]. This allows proximal tubule epithelial cells to remain 
in their native tertiary tissue-like structure, keep their cell-matrix and natural cell-cell communication 
intact, and maintain differentiated states and cell functionalities. Proximal tubule cells therefore 
reside and interact in a more natural environment and reflect toxicity states with more fidelity when 
interacting with drug compounds. In previous studies, we were able to show that our 3D organoid 
model shows more sensitive responses to drugs compared to secondary 2D kidney cell cultures. 
This was shown by enzyme release (γ-glutamyl-transferase, N-acetyl-β-D-glucosamine) and gene 
expression (KIM-1, VIM, CLU, HO-1) [47]. 
Currently used drug kidney toxicity markers in clinical trials are blood urea nitrogen (BUN) 
and serum creatinine. The drawback for these markers is that they are rather insensitive as a 50-
70% decrease in glomerular filtration rate (GFR) must first occur to see increases in BUN and 
serum creatinine amounts [100]. This slow response and the lack of better available markers lead 
the FDA’s Critical Path Initiative call for development of better tools and more predictive, early 
nephrotoxicity screening [84, 91]. More reliable models to detect drug toxicity early in development 
should be able to measure responses to compounds in a reliable and clinically relevant way with 
high predictive values, specificity and sensitivity. To exploit the advantages of the newly developed 
nephrotoxicity screening model, this dissertation seeks to provide greater insight to reliability, 
predictability, and interspecies comparability by assessing the 3D model drug responses against 
currently used 2D kidney cell culture lines and human clinical data, and analyze overall advantages 
and limitations. This will provide more detailed information to overcome the currently available 
toxicity assays’ challenges and better bridge the gap to human data and nephrotoxicity incidence 
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by creating a better, early-phase drug toxicity screening model. 
Validation of the ex vivo 3D proximal tubule organoid model as a reliable drug screening 
tool used gene expression analyses relevant to asserting proximal tubule cell phenotypes, 
molecular and biochemical renal biomarkers via quantitative real-time PCR (qPCR) (Chapter 4) 
and verification of proximal tubule cell membrane protein and pump genotypes necessary to 
produce the toxicity responses reported in Chapter 5. The necessity of using a commercial Utah-
developed hyaluronic acid-based hydrogel (HA-gel) matrix for encapsulating harvested viable 
proximal tubule organoid fragments was assessed against media-only cultured fragments.  
Encapsulation in 3D gel matrices is often proposed to mimic extracellular matrix and allow 
proximal tubule epithelial cells to remain in their native tertiary tissue-like structure with added 
support (Chapter 3). Therefore, transporter and metabolism enzyme expression levels were 
compared not only to published 2D kidney cell culture lines but also between 3D HA-gel embedded 
proximal tubules versus proximal tubule fragment suspension cultures (Chapter 4). Even though 
most toxicity screening tests are performed after 24h of compound exposure, expression levels for 
proximal tubule markers in cultures was assayed for out to seven days (Chapter 4). 
To validate the drug toxicity screening capability of the ex vivo 3D proximal tubule model, 
clinically relevant, known nephrotoxic (cidofovir, cisplatin, doxorubicin, polymyxin B, polymyxin B 
nonapeptide, and vancomycin) and nonnephrotoxic (cimetidine and probenecid) drugs were used 
in validation assays described in Chapter 5. Model sensitivity and specificity at different therapeutic 
index (TI) cutoff values were analyzed by using compound concentration-PT response curves and 
the molar concentration of each test compound producing 50% inhibition (IC50), lowest effective 
concentration (LEC) and area under the concentration-response curve (AUC) values were 
calculated as standard clinically relevant drug therapy parameters. Additionally, the model’s 
predictive values were analyzed and receiver operating characteristic (ROC) analysis was 
performed and data compared to currently used 2D kidney cell culture lines (Chapter 5). 
Significantly, the toxicity data from the ex vivo 3D model was compared to known reported human 
clinical toxicity incidence data for each compound, and the correlation/translation was analyzed 
(Chapter 5).  
5 
 
Clinical therapy strategies seek to minimize drug nephrotoxicity by using co-administered 
specific proximal tubule transporter competitive inhibitors. Hence, the 3D assay model’s ability to 
reveal kidney tubule epithelial cell substrate-inhibitor competitive interactions was assayed by 
comparing response with the toxic drug alone versus the same drug in combination with a potent, 
receptor-specific inhibitor/competitor selected from the 9 compounds was tested. This analysis was 
performed to substantiate if the model could eventually provide more specific information on  drug 
structure-activity relationships  that drive toxicity, and facilitate rapid assay of different new chemical 
entities (NCEs) during drug candidate screening (Chapter 5). 
Overall, this kidney proximal tubule fragment culture approach provides a unique 
opportunity to gain greater insight in the much-needed correlations between known nephrotoxic 
and nonnephrotoxic compound toxicity results found in animals and humans versus in vitro kidney 
cell culture assays. Results of this study address some long-standing challenges of reliably sorting 
through libraries of therapeutically relevant molecules, and provide a better, more reliable toxicity 
testing model for high-throughput screening and ultimately reducing costly clinical trial failures and 
late-stage drug product withdrawals. The data described in this dissertation clearly support the 
study hypothesis that this ex vivo 3D proximal tubule model is more reliable and allows for better 
predictive toxicity values than the simplified 2D kidney cell culture lines, and that the data obtained 
are more relevant and impacting to modern drug screening assays. 
Furthermore, this model validation opens up future capabilities for exploiting specifically 
designed proximal tubule mutations in transgenic knock-in mice, as well as new, analogous 
investigations in other organ toxicity studies (e.g., hepatotoxicity and cardiotoxicity studies). 
Approaches to these studies are outlined in Chapter 6. Also, while this current kidney toxicity model 
relies on harvest of proximal tubules from mice, requiring murine sacrifices, this approach could 
avoid animal use by exploiting new vitro functional kidney organoids derived from stem cells [106-
109]. Additional validation of the model using human proximal tubules from discarded kidney 
harvests would provide even closer correlations, genomically profiled or specific screens, or even 











The kidney is a major target for drug-induced toxicity. Nephrotoxic drug use is often 
unavoidable in the clinic, and therefore, drug-induced nephrotoxicity is a recognized major problem 
[95, 110]. For pharmaceutical companies, development of ideal nonnephrotoxic drugs or at least 
those with a reduced toxicity potential is of high priority [94, 99]. To do so, predictive nephrotoxicity 
screening assays are needed to overcome the current challenges of late-stage human 
nephrotoxicity incidence. Current in vitro models are not successfully validated, standardized nor 
accepted, and animal testing is still used with some uncertainty to predict drug toxicity risks [111]. 
Nephrotoxic drug administration often leads to acute kidney injury (AKI) and is linked with 
increased patient morbidity and mortality. The late detection of nephrotoxic effects and the currently 
often underestimated nephrotoxic potential of newly developed drug candidates lead to increased 
development costs for pharmaceutical industries. Therefore, more reliable nephrotoxicity screening 
models are needed to predict adverse events early in development and avoid costly drug failures 
from toxicity late in clinical testing or even post-market approval.  
 
Pathological mechanisms of drug-induced nephrotoxicity 
Changes in intraglomerular hemodynamics 
The glomerular filtration rate (GFR) is defined as the total volume of filtered fluid by the 
glomeruli of both kidneys together per unit time. For healthy humans with normal blood pressure 
the GFR is approximately 120 ml per minute. Through the regulation of the blood flow in afferent 
and efferent arteries, the kidneys can maintain or adjust the intraglomerular pressure. This allows 
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them to maintain the filtration rate constant and preserve urine output. The expansion of afferent 
arteries relies on circulating prostaglandin. Therefore antiprostaglandin drugs (e.g., nonsteroidal 
anti-inflammatory drugs (NSAIDs)) show nephrotoxic effects in the glomeruli [112]. A second group 
of drugs that have been shown to induce nephrotoxicity are the angiotensin converting enzyme 
(ACE) inhibitors as well as angiotensin receptor blockers (ARBs) [113, 114]. Their toxicity 
mechanism is based on interfering with the angiotensin-II-mediated vasoconstriction of the efferent 
arteries which is an important pathway to maintain intraglomerular pressure [81, 115, 116].  
 
Tubular cell toxicity 
Renal tubule cells, especially proximal tubule cells, have an increased surface area created 
by microvilli and highly in-folded plasma membranes, which makes them susceptible to toxic drug 
exposure and effects. Additionally, proximal tubules are exposed to high levels of circulating 
toxicants due to their role in concentrating and reabsorbing the glomerular filtrate [81, 115, 116]. 
Furthermore, active transport of toxicants by specialized cellular transporters for uptake of organic 
compounds leads to high levels of toxicants inside proximal tubule cells, leading to cell damage 
and death [117, 118]. Drug cytotoxic effects arise from impairment of mitochondrial function, 
interference with tubular transport, increase in oxidative stress as well as formation of free radicals 
[115, 117, 118]. Another factor influencing proximal tubule toxicity is that cytochrome P450 is 
predominantly localized in the proximal tubule and not in other parts of the nephron. Therefore, 
nephrotoxic effects from drugs that utilize cytochrome P450 metabolic pathways mainly affect 
proximal tubules as well [87]. Drug classes known to induce tubular cell toxicity are 
aminoglycosides, antifungal compounds, antiretroviral, and chemotherapeutic drugs. 
 
Inflammation 
Inflammation in different parts of the nephron (glomerulus, proximal tubules as well as the 
surrounding matrix) is often caused by nephrotoxicants. This inflammation can lead to fibrosis and 
scarring of the affected kidney tissue and then changes normal kidney functions by inducing toxicity. 
Glomerulonephritis is primarily caused by immune responses and often associated with proteinuria 
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[119]. Drugs such as interferon-alfa, lithium, NSAIDs, hydralazine, and gold salts are known to 
cause this type of nephrotoxic response [117, 119]. Another type of inflammation-induced 
nephrotoxicity is acute interstitial nephritis, an allergic response triggered by NSAIDs and antibiotic 
drugs. This immune reaction is proposed to be caused by toxic compounds binding to antigens in 
the kidney, or drugs acting as antigens, which are then deposited into the interstitium [115, 120]. 
Even while it is less likely to be drug-induced, the development of chronic interstitial nephritis can 
be triggered by certain chemotherapeutic agents, calcineurin inhibitors, and lithium, but also by 
NSAIDs chronically used in high doses [112, 121]. Early detection and prevention of chronic 
interstitial nephritis is important as otherwise this can lead to end-stage renal diseases [122]. 
 
Crystal nephropathy 
Renal function can be altered by drugs that produce insoluble crystals in human urine. The 
formation of these crystals is dependent on urine acidity and drug concentration. Drug or metabolite 
crystals usually develop in the distal tubule, obstruct urine flow, and then induce an interstitial 
reaction [117]. Antiviral and antibiotic drugs can cause crystal nephropathy [81]. If patients have 




Rhabdomyolysis is the rapid break down of damaged skeletal muscle. When skeletal 
muscle is destroyed, muscle fiber contents, myoglobin, and serum creatine kinases are released 
into the blood stream. The myoglobin degrades and causes tubular obstruction and alterations in 
glomerular filtration rate, leading to acute tubular necrosis or renal failure [81, 115]. Drugs known 
to cause rhabdomyolysis are statins and methadone [81]. 
 
Thrombotic microangiopathy 
Circulating platelet thrombi cause organ damage through inflammation or direct renal 
epithelial cytotoxicity, which leads to thrombic microangiopathy (thrombosis in capillaries and 
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arterioles). Drugs causing thrombotic microangiopathy are antiplatelet agents and quinine [81, 115].  
 
Risk factors for nephrotoxicity 
Specific clinical situations and patient groups are more prone to develop drug-induced 
nephrotoxicity. Therefore, knowledge of patient-related risk factors, drug-related risk-factors and 
recognition, and early intervention are important to successfully prevent or limit drug-induced 
nephrotoxicity [116, 123].  
 
Patient-related risk factors 
Patient-related risk factors generally associated with nephrotoxins are advanced age (over 
60 years), GFR of less than 60 ml per minute (indicator for underlying renal insufficiency), diabetes, 
heart failure, metabolic disorders that alter the pH of the urine, sepsis, intravascular volume 
depletion, and exposure to multiple nephrotoxins simultaneously [115, 116, 124, 125]. Other risk 
factors like race, genetic variation, and gender are controversial, and could also depend and vary 
based on the toxicant [124]. Overall, the risk of drug-induced nephrotoxicity and acute renal failure 
generally increases with additional risk factors. Therefore, patients with any of these risk factors, 
especially with combinations of risk factors, should be closely monitored under drug exposure.  
 
Drug-related risk factors 
Several administrated agents are known to be intrinsically nephrotoxic, like 
aminoglycosides, cisplatin, imaging contrast dyes, cyclosporine, and amphotericin B [116, 124], 
while others exhibit dose-dependent or duration-dependent nephrotoxic effects [116, 124]. Drugs 
that affect tubular cells directly or induce crystal deposition are especially known to produce dose-
dependent nephrotoxicity [117, 126]. A therapy with multiple nephrotoxic drugs can result in 






Preventing drug-induced renal impairment 
Prevention 
To prevent the onset of drug-induced nephrotoxicity, the obvious first clinical intervention 
is to exploit nonnephrotoxic drugs (i.e., those lacking nephrotoxic effects, or those exhibiting a high 
therapeutic index) whenever possible. Additionally, it is important to address risk factors as well as 
determine baseline renal function values before therapy start, which allows for drug dose 
adjustments [115, 116]. It is highly recommended to avoid combinations of multiple nephrotoxic 
drugs because of the previously mentioned potentiating effect [115]. Some nephrotoxic effects can 
be avoided by adequate hydration (e.g., doxorubicin, ACE inhibitors, and NSAIDs) [113, 114].  
 
Recognition and early intervention 
As most drug-induced renal impairments are reversible, early recognition and intervention 
is important. Reductions in renal function noted clinically by decreased GFR or increased serum 
creatinine levels after drug administration are common signs of drug-induced nephrotoxicity. Drugs 
that compete with creatinine for tubular secretion (e.g., cimetidine) can lead to false positive results 
and are not associated with kidney damage [115, 127]. If changes in GFR or serum creatinine 
levels are observed, the drug dose should be adjusted or if necessary, drug administration needs 
to be stopped. Additionally, blood pressure should be monitored, hydration levels should be 
adequate, other possible nephrotoxins should be discontinued, and a staggered drug 
administration approach should be adopted [115, 128]. 
 
Assessing nephrotoxicity 
Clinical nephrotoxicity markers 
Clinical nephrotoxicity detection commonly uses laboratory measurements of increased 
serum creatinine and plasma urea in patient blood samples [129-131]. Also, measurement of urine 
output is used clinically in AKI diagnostics [129-131]. All of these measurements, especially urine 
output, are insensitive markers of decreased GFR, the clinical indicator of toxicity. Actually, 50-70% 
reduction in GFR must first occur to observe increases in blood urea nitrogen (BUN, normal range: 
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7-20mg/dl) and serum creatinine (SCr, normal range: 0.6-1.3 mg/dl). Additionally, the levels of BUN 
and SCr can be influenced by unrelated factors like food and fluid intake, muscle mass and injury, 
gender, age, and drugs like steroids [111]. 
This slow and insensitive clinical response, and the lack of better available kidney toxicity 
markers, both limit the clinical detection and possible therapeutic options to prevent AKI. This 
scenario has prompted the FDA’s Critical Path Initiative call for the development of better tools and 
more predictive early nephrotoxicity markers [84, 91]. Based on this initiative, the following novel 
predictive markers for drug-induced nephrotoxicity were proposed and remain under investigation 
[54, 84]: KIM-1 [68], NGAL [75], GST [69], and cytokines IL-6 and IL-8 [86, 132]. All of these markers 
demonstrate increased sensitivity to nephrotoxicity and present earlier than BUN and serum 
creatinine. Correlation of their clinical presentation with AKI with validated preclinical assays 
showing predictive use in drug-induced nephrotoxicity are required.  
 
Preclinical in vitro testing approaches for predicting drug-induced nephrotoxicity 
The problem with most current in vitro testing approaches for predicting drug-induced 
nephrotoxicity is the lack of validation with clinical pathology, and that the number of tested 
nephrotoxic compounds is too small in most studies to produce clinical reliability and relevance 
[111, 133]. Additionally, few studies include major analytical performance metrics like sensitivity, 
specificity, positive predictive value (PPV), and negative predictive value (NPV). In vitro assays 
allow for ready manipulation of variables and measurements, and therefore, mechanistic aspects 
of toxicity can also be investigated. It must be kept in mind though, that results from cell-based 
assays must be interpreted carefully: no model to date represents the fully functional status or 
complex homeostatic or pathological mechanisms of kidney cells in vivo. Therefore, drug 
processing in vitro and subsequent toxicity results must be analyzed, verified, and compared to in 
vivo results to validate proper translation.  
Newer, advanced in vitro 3D cell culture systems, multicell type co-culture systems, 
organoid cultures, and microfluidic models are more complex than conventional cell cultures [133] 
but remain largely early phase nonvalidated experimental innovations. Limitations of these 
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approaches lie in their slow, often low-throughput performance. They are more expensive and 
complicated to set up, resulting in intrinsic variability and lack of reliability, and incompatibilities with 
current cell culture assay read-outs and quantitative endpoints. These issues limit the number of 
compounds screened and also require special optimization of assays to assure performance and 
reliability [111, 133]. Assay standardization and validation to clinical endpoints in nephrotoxicity are 
currently lacking. For a detailed overview on currently used in vitro approaches for drug-induced 
nephrotoxicity see the review by Tiong et al. [111].  
Kidney proximal tubule cells remain the preferred cell type for drug-induced nephrotoxicity 
screening assays because they are the major target for toxic drug effects clinically. Traditional cell-
based assays are monocultured secondary kidney cell lines on plastic plates (i.e., 2D). Cell line 
functional validations are often lacking and many kidney cells do not represent the proper or stable 
phenotype to yield reliable kidney-drug toxicity predictions [111]. Recent shifts to primary kidney 
cell 3D cultures improve phenotypic fidelity and assay responses to drugs [19, 47, 60].  
Transitioning to three-dimensional (3D) kidney cell cultures is a recent innovation [19]. 
Different approaches to 3D cell culture exploit various matrices to suspend and embed cells, which 
promotes cell-cell interactions more typical of an in vivo microenvironment [19, 133]. Additionally, 
microfluidic devices provide, versatile interfaced fluidics and electronic controls, multiple co-culture 
chambers and capabilities to alter assay inputs and output as well as exploit miniaturization benefits 
(so-called organ-on-a-chip). These approaches generally seek to investigate cell-drug behaviors in 
more complex culture environments to compare to in vivo drug responses. For a detailed overview 
on current kidney-on-a-chip approaches for drug-induced nephrotoxicity screening, see review from 
Wilmer et al. [133]. 
2D cell culture systems are routine, simple, and inexpensive to maintain, and have the 
benefit that most drug response performance assays are developed and validated for 2D cell 
culture systems. The downside is that 2D cell culture system responses are often very different 
than in vivo response due cell phenotypic behavior on rigid 2D plastic culture dishes. This culture 
condition influences cellular responses to drugs as well as cell transporter expression known to be 
critical to drug-induced nephrotoxicity [12, 47]. The typical 2D assay endpoint is a cell viability 
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assessment under arbitrary drug dosing conditions in monoculture with cells that often lack proper 
in vivo phenotypes [103]. This naturally leads to predictions that are not clinically correlated. More 
complex 3D or microfluidic systems incorporate more biomimetic features seeking to achieve more 
normal in vivo-like cell behavior but are also more complex to perform, more variable, and more 
expensive. Organ-on-a-chip systems use varying combinations of cell layers in 2D cultures or 
exploit 3D gel matrices and applied shear forces through microfluidic systems [61, 133-136] but 
remain unverified, early-stage experimental systems. The use of stem cell-derived organoid 
cultures for kidney physiological recapitulation is now increasing [106, 108, 109, 137-139]. While 
organoids are in general understood to be functional parts of an organ (i.e., independently 
functioning if harvested or self-grown), stem cell-derived organoids derive from a few stem cells 
and are achieved by either self-organization in 3D structures or by using gel or scaffold templates 
to enforce specific culture organization and morphologies that yield specific limited organ-like 
functions. While many different approaches and designs are reported, no fully biomimetic models 
exhibiting drug responses similar to human in vivo drug-induced toxicities are known. The main 
performance criteria for all such approaches is to establish reliable in vitro-in vivo correlations 
(IVIVC) for diverse drug classes, as well as validate the models thoroughly using diverse human-
derived cells (e.g., iPS cells, human explants, primary cell lines). Assay metrics (e.g., figures of 
merit) should be produced to assert such validation. These important assay criteria include assay 
sensitivity, specificity, limits of detection, dynamic range, coefficient of variation, positive predictive 
validation, and negative predictive value (NPV). If that validation is done successfully in new in vitro 
models of drug-induced nephrotoxicity, then in vitro toxicity results can be interpreted properly and 
confidently, to allow more reliable and predictive responses in early drug candidate screens to 
predict anticipated human toxicity responses. This unmet challenge provides the primary motivation 










POLYSACCHARIDE MATRICES USED IN 3D IN VITRO  
CELL CULTURE SYSTEMS1 
 
Abstract 
Polysaccharides comprise a diverse class of polymeric materials with a history of proven 
biocompatibility and continual use as biomaterials. Recent focus on new matrices appropriate for 
three-dimensional (3D) cell culture offers new opportunities to apply polysaccharides as 
extracellular matrix mimics. However, chemical and structural bases for specific cell-polysaccharide 
interactions essential for their utility as 3-D cell matrices are not well defined. This review describes 
how these naturally sourced biomaterials satisfy several key properties for current 3D cell culture 
needs and can also be synthetically modified or blended with additional components to tailor their 
cell engagement properties. Beyond their benign interactions with many cell types in cultures, their 
economical and high quality sourcing, optical clarity for ex situ analytical interrogation and in situ 
gelation represent important properties of these polymers for 3D cell culture applications. 
Continued diversification of their versatile glycan chemistry, new biosynthetic sourcing strategies 
and elucidation of new cell-specific properties are attractive to expand the polysaccharide polymer 
utility for cell culture needs. Many 3D cell culture priorities are addressed with the portfolio of 
polysaccharide materials available and under development. This review provides a critical analysis 
of their properties, capabilities and challenges in 3D cell culture applications. 
 
 
                                                     
1 Reprinted with permission from Biomaterials: Diekjürgen, Dorina and Grainger, David. Polysaccharide matrices 




Three-dimensional (3D) cell culture has many known research benefits compared to 
normal conventional two-dimensional (2D) cell culture [14, 15, 19, 21]. One commonly observed 
difference is the change in cell morphology witnessed across diverse cell types: cells seeded in 2D 
grow flat and widely spread, eliciting a forced, apical-basal polarity; this lacks requisite support to 
grow in a vertical dimension [21]. While this is normal behavior for some cell types (e.g., epithelial 
cells), other cells (e.g., mesenchymal cells) grow in a stellate manner in 3D matrices, polarizing 
simply for migration purposes [21, 140]. Cells forced unnaturally into artificial morphologies can 
exhibit altered functions and phenotypes [21, 141]. Major differences can be seen in gene and 
protein expression, viability, enzymatic and biological activities, differentiation and proliferation, 
motility, and general response to stimuli and metabolism.  
The majority of cells functioning in the native in vivo environment are integrated within a 
3D, hydrated, flexible, porous gel, surrounded by other cells, called the extracellular matrix (ECM) 
(Figure 3.1). Both technological and scientific objectives attempt to recapitulate native cellular 
microenvironments to most reliably reproduce cell phenotypes in cultures that best duplicate in vivo 
behaviors. This has stimulated recent approaches that emphasize a shift away from monocultured 
cells on rigid plastic plates to novel 3D matrix-based culture systems more similar to actual tissue 
constructs (i.e., organoids, micro-tissue, spheroids and cell/gels) [103]. These strategies seek to 
produce and sustain certain cell behaviors and technical performance advantages, compiled in 
Table 3.1. An overview of commonly used 3D cell culture methods and some examples of 
commercially available products are provided in Table 3.2.  
Scaffold-free culture platforms like spheroids provide no ECM or matrix in culture [27, 28, 
30-33]. Therefore, cells must produce and organize their own matrix in these systems. Spheroid 
cultures have no physical support structure nor porosity, and the overall multicellular spheroid size 
has a limit of approximately 0.5-0.6 mm [32], whereby size can be adjusted by cell seeding amounts 
and drop volume. Spheroids are shown to mimic developmental aspects of tissues, tumors, and 
embryoid bodies, therefore showing physiologic relevance in studies of cancer and stem cells [142]. 
Given their size and lack of diffusive obstruction, spheroids exhibit metabolic (e.g., via gases, 
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nutrients, wastes) and proliferative gradients that duplicate some in vivo contexts.  
The second 3D culture method comprises physical 3D matrices or scaffolds fabricated from 
many different types of materials exhibiting different chemistries, porosities, permeabilities, 
architectures, and mechanical characteristics intended to mimic aspects of native ECM [25, 67]. 
Scaffolds can be cast or polymerized in the absence or presence of living cells and media, or 
fabricated from these materials in 3D by techniques like electrospinning, particulate leaching, soft 
lithography, or bioprinting [25, 43]. Within these matrices that mimic features of native ECM, cells, 
tissues and organoids are encapsulated in tissue-like microporous, soft 3D structures. This 
approach seeks to maintain matrix and natural cell-cell communications and differentiated states 
and cell functionalities. ECM-like architectural, mechanical, and chemical properties (see Figure 
3.1) are critical for duplicating natural ECM environmental properties, and often reflect these native 
scenarios much more than 2D cell cultures [143]. While not all matrices are equivalent in properties 
or performance, cells are often shown to reflect this 3D ECM context in producing more in vivo-like 
behaviors; for example more reliable phenotypes to tissues and diseases, and toxicity responses 
to exogenous compounds [13, 14, 103, 144]. 
 
In vitro matrix requirements for 3D cultures 
Three-dimensional cell culture models that effectively and reliably produce the cellular 
advantages of native ECM in vitro require biomimetic scaffold materials and architectures to support 
cells in appropriate in vivo context. Many different naturally derived and synthetic materials are 
currently available to mimic select properties of extracellular matrix (ECM) [16, 42, 43, 145, 146]. 
Despite the plethora of cell culture materials published and their claims to ECM-like fidelity for 
improved 3D cell culture, few claims are validated beyond isolated examples or select short-term, 
arbitrary culture conditions, and requirements. Cell culture matrix materials commonly need to be: 
1) nontoxic, with high mass fractions of water to produce “soft” mechanical properties, 2) allow free 
diffusion of nutrients, oxygen, and cell waste products, 3) promote normal cell growth, proliferation, 
natural cell cycle control, and migration, and 4) preserve cell-matrix physical and chemical 
engagements to promote specific phenotypic states [67, 147]. As a class of well-studied 
17 
 
biomaterials, hydrogels are attractive for 3D matrix applications, They swell spontaneously in water 
to high levels without being water soluble, and provide readily chemically modified, cross-linked, 
hydrated, elastic networks [148, 149]. Historically, 3D culture matrices are physically characterized 
for gel-like properties and architectures. More relevant 3D culture assessments include specific 
matrix interactions with cultured cells, drug responses, time-dependent matrix changes (i.e., 
degradation or cell-induced modifications), and cell phenotypic stability [19]. Furthermore, optical 
transparency for in situ microscopy and noninvasive optical assays of cell behaviors are also 
increasingly sought for matrix utility and reporting needs: many cell-based viability, phenotyping 
and cytotoxicity assays use luminescence or fluorescence signals propagating through optically 
transparent media. Table 3.3 collates previously formulated requirements for 3D cell culture 
systems, assembled from diverse literature sources. 
One prominent example of a commercially available ECM product for 3D cell culture 
applications is MatrigelTM (Corning Life Sciences and Becton Dickinson, USA), derived from 
Engelbreth-Holm-Swarm mouse sarcoma. This natural ECM extract includes growth factors, 
proteins, and glycoproteins similar to those found in connective tissues [37]. MatrigelTM cultures 
successfully reproduce useful 3D aspects of many cell types for cell cultures of various applications 
[77, 79, 109, 150], including developmental biology, epithelial polarization, and tumor invasion and 
colonization, even moving from 3D tumor culture into immune-deficient rodents xenografts. Its 
legacy and performance has provided an important benchmark that defines 3D cell culture matrix 
success as a prototype for synthetic ECM duplication. Nonetheless, Matrigel is a highly 
heterogenous blend of millions of molecular components of diverse biochemistry. Moreover, 
significant concerns about Matrigel’s batch-batch variability, immunogenicity, pathogen 
transmission, animal tumor origin, and limited availability at significant cost limit its general use [2, 
16]. Other commercial cell culture matrices extracted from natural, living materials are PureColTM, 
PurematrixTM, alginate and ExtracelTM [2, 151]. These simpler hydrogel matrices achieve gelation, 
hydration, and 3D architectures amenable to cell culture by changing aqueous solution temperature 
or pH, peptide self-assembly or ionic or covalent crosslinking [2]. None, however, intrinsically 
reproduce all aspects of native ECM, nor of Matrigel, including their molecular complexity. This 
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then defines the current “designer challenges” for fabricating biologically derived, synthetic, or 
biohybrid materials for 3D cell culture. Significantly, what is required compositionally for a minimally 
competent ECM mimic for cell culture currently lacks a detailed recipe.  
Advantages and disadvantages of currently used natural polymer matrices in 3D cell 
culture systems are summarized in Table 3.4. Known deficiencies of most 3D culture systems to 
date are recognized to include suboptimal 3D matrix compositions for recapitulating precise ECM 
structure-function relationships in 3D, suboptimal support of specific cell type(s), lack of rigorously 
determined or defined matrix compositions or requirements, complex materials origins with lot-to-
lot variability or residual animal-derived components and cytotoxic degradation products. 
Therefore, while many naturally derived complete ECMs apparently recapitulate essential features 
for 3D cell cultures, reproduction of precise molecular and microstructural features essential to 
reproducing these features in simpler materials systems are not well described. For example, ECM 
is well-known to universally comprise networks of many matricellular proteins, diverse growth 
factors (morphogens and mitogens), and several glycosamino- and proteo- glycans. Compositional 
roadmaps for 3D culture matrices are proposed based on this analysis. Yet what from ECM is 
essential and minimally defining for 3D cell culture remains confusing: many isolated components 
(e.g., hyaluronan, collagen I, laminin, heparin sulfate, among many others) can each support 
aspects of 3D cell culture. Analogously, the micro-architectural and mechanical properties for native 
ECM are known in many regards. However, how to control this in vitro, and how finely it must 
duplicate ECM in a synthetic 3D matrix to be effective for culture are not possible currently. These 
criteria collectively represent critical benchmark design criteria for fabricating effective 3D cell 
culture materials. 
Precise mimicry of the exact native ECM structure and biochemistry may not in fact be 
necessary for many aspects desired for faithful 3D cell culture. Hence, a more pragmatic, cell line-
dependent and outcome-related, biomimetic approach may lie in satisfying only selective cell 
culture needs to guarantee cell qualities sufficient for certain research needs [2]. For example, type 
I collagen has a substantial history in 3D cell culture and tissue engineering efforts [152], despite 
the observation that it represents only one of many matricellular components of native ECM [43, 
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153-155]. Other materials such as alginates [156-159] and self-assembling synthetic peptides [160-
162] bear little resemblance chemically to native human polymers or ECM, yet produce hydrogel 
materials with substantial practical 3D culture value. It is essential to distinguish what is necessary 
versus what is sufficient in ECM structure and function to adapt for 3D culture use.  For example, 
native ECM proteoglycans present their glycosaminoglycans (e.g., dermatans, heparans, 
chondroitins) in a bottle-brush morphology, covalently attached and extended from a protein core. 
Classical use of glycosaminoglycans in 3D cultures to date, does not exploit ECM proteoglycan 
chemistry or morphology. Instead purified, homogeneous glycan polymers lacking protein cores 
are used as matrices. 
Defining minimally acceptable performance requirements for these cell culture materials 
requires assays and assertions for equivalence and validation in the context of a specific 3D culture 
application. As long as this technical vetting is thoroughly performed using prescriptive 
requirements and technical criteria, and with logical connections between desired in vivo cell 
behavior and their in vitro equivalence in culture, many biomaterials may qualify as valuable 3D 
culture materials. Future studies must assert these qualities and seek to converge on common, 
accepted consensus 3D matrix standards for matrix qualifications and necessary validation.  
 
Cell-specific polysaccharide binding 
ECM, with its many (>300) matricellular proteins, is well-recognized for cell-specific 
recognition and cell receptor-specific binding of selected protein chemistries and peptide motifs, 
typically involving primarily integrins, but also membrane glycoproteins, proteoglycans and 
glycolipids,[163-166]. Cell receptor engagement with specific ECM ligands is well recognized to 
modulate and control cell signaling, phenotypic fate, differentiation potential and functional fidelity 
[167, 168]. By contrast, glycosaminoglycan network engagement with many ECM proteins (e.g., 
laminins, collagens, and fibronectins) is ubiquitous and essential to normal chemical and physical 
ECM involvement with cells. Nonetheless, despite specific matricellular protein-glycan interactions, 
specific receptor-ligand motifs and signaling functions from cell receptor-glycan ligand binding is 
less described compared to ECM protein analogs. Many polysaccharides are not known to have 
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specific receptor engagements with mammalian cells (e.g., alginates [169]; and agarose [67, 170]. 
Reasons for their empirical acceptance as 3D materials are largely physical, not biochemical. 
Beyond more generic hydrogel properties, molecular design features in the chemistry of many 
polysaccharides that convey useful 3D cell culture engagement is not that obvious. Hence, custom 
synthesis efforts require improved structure-activity relationships to rationally pursue ECM 3D 
material mimics. 
 
Polysaccharides used in 3D culture systems 
Due to the extensive use of diverse polysaccharide and glycan-based materials in 3D cell 
culture, both historically and presently, full review of their documented vetting in 3D cell culture 
applications and their recognized matrix properties in vitro is provided here.  
Generally, polysaccharides are biopolymers comprising multiple saccharide units in 
covalently linked chains. Each polysaccharide has between 10 to 10 million monosaccharide units 
connected by O-glycosidic bonds [171, 172]. Based on their diversity, polysaccharides can be 
divided into 1) homopolysaccharides containing only one kind of monosaccharide repeat unit, and 
2) heteropolysaccharides, having 2 or more different monosaccharide repeats linked in the 
polymer. Polysaccharides form either linear or branched structures; branched structures can vary 
from multiple short side chains to just a few, long side chains or also bush-like highly branched 
structures [173, 174]. Overall, more branched polysaccharides are known than linear 
polysaccharides but on a mass basis, linear polysaccharides dominate natural sources as they are 
important structural components for higher plants and marine algae.  
Polysaccharides are also called “glycans” and their systematic nomenclature is based on 
that term. Nevertheless, multiple polysaccharides were named before systematic nomenclature 
was invoked and therefore do not follow these rules in recognized, common naming conventions. 
Examples include celluloses, hyaluronic acids, heparins, and alginic acids.  
Many mammalian polysaccharides are also only found chemically attached to core 
proteins. These complexes are called protein-polysaccharides or glycoproteins [175]. A subgroup 
of the glycoproteins of animal origin and high glycan mass fraction are the proteoglycans [176]. For 
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polysaccharides produced by bacteria, two more classifications are used as they are either derived 
from their cell walls (in capsules, hence capsular polysaccharides) or excreted into extracellular 
medium (exopolysaccharides) [172]. 
In general, natural polysaccharides are polydisperse, meaning that their molecular weight 
from a single source varies. Additionally, their finer molecular structure and monomer sequences 
varies from molecule to molecule, making them polymolecular. Polysaccharides with regularly 
repeating single saccharide units (i.e., homoglycans lacking polymolecularity) are typically bacterial 
in origin, with the exception of cellulose, and a few other plant polysaccharides. Overall, the 
structure of polysaccharides is highly influenced by the growth conditions and taxa, and can vary 
even between tissues of the same plant [172]. All polysaccharides are solvated by water and can 
be depolymerized by acids and heat, high pH followed by oxidation and specific enzymes [172]. 
At least 90% of all carbohydrates found in nature reside in polysaccharides. 
Polysaccharides serve various diverse biological functions, but with many still unknown: they are 
structural components in primary and secondary cell walls and middle lamella, and serve as reserve 
food material in leaves, stems, roots, seeds, and other plants tissues. In bacteria they can be 
extracellular constituents [172]. Polysaccharides used for food or nonfood industrial applications 
and commercially available are also called hydrocolloids or gums [177]. As no ideal system exists 
for classification of polysaccharides, those industrially used are classified by source [172, 173]. 
Some polysaccharides can form gels alone, while others require additional substrates or co-
additives to gel. This review focuses on polysaccharides that form gel matrices useful for 3D cell 
culture. 
 
Polysaccharides used currently in 3D cell culture systems 
Alginate (algal/seaweed-derived polysaccharide).  Alginate refers to alginic acid and its 
derivatives/salts, a natural polysaccharide extracted from the cell walls of brown algae 
(Phaeophyceae). Commercial harvests of alginate, commonly exploit Laminaria, Macrocystis, 
Lessonia, Ascophylum, Durvillea, and Ecklonia algae. Alginate comprise two saccharides 
monomers: β-(1-4)-D-mannuronic acid and α-(1,4)-L-guluronic acid, connected as linear chains in 
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blocks of D-mannuronic acid repeats and blocks of L-guluronic acid repeats (Figure 3.2). These 
blocks form a folded structure that plays an important role in alginate gelling processes. Gels 
formed from alginate with high D-mannuronic acid contents have high flexibility but poor rigidity, 
while gels from high L-guluronic acid contents are much more rigid. By adjusting the polysaccharide 
ratio of these blocks, gel properties can be adjusted as well. Alginate gels can be somewhat 
modified and controlled by different molecular weights, concentration and composition [178]. Alginic 
acid and salt derivates from polyvalent metal cations (e.g., calcium ions) are insoluble in water, with 
the exception of magnesium salts. Sodium, potassium, and ammonium salts are water-soluble, 
while sodium alginate is the most used derivate. Alginates degrade through heat, oxygen, and 
metallic ions, with their stability decreasing from sodium alginate to ammonium alginate to alginic 
acid. Bouhadir et al. developed a biodegradable alginate by partial oxidation. Modified alginate 
macromers provided controlled gel degradation by their degree of oxidation [179]. Alginate has 
many different uses in food and pharma industry, but the controlled drug release field takes much 
advantage of this material as well as numerous cell culture studies [157-159, 169, 180, 181]. 
Alginate will gel spontaneously in situ if divalent cations are present [19, 178, 182]. The 
cations bridge and electrostatically shield the electrostatic repulsion of repeated monomer 
carboxylate groups [183-190]. Divalent cations facilitate gelation more than monovalent cations 
[182, 188, 190]. These alginate hydrogels can be redissolved in the absence of cations, leading to 
unpredictable and uncontrolled network dynamics in cell media conditions, but chemical 
degradation is generally not observed in physiological conditions [148].  
Alginate hydrogels intrinsically lack cell adhesion capability, and have low serum protein 
absorption so that cells can be encapsulated within gels but do not spread, move, or undergo 
haptotactic responses typical of cells in ECM [157-159, 169, 178, 191]. Multiple different 
approaches are employed to overcome these cell culture limitations. To improve alginate-cell 
engagement, Mooney’s group incorporated the well-known cell adhesion peptide, RGD, into the 
alginate network [169, 192] and Balakrishnan et al. incorporated gelatin [193]. Gelatin-incorporated 
alginate hydrogels degraded after 5 weeks in phosphate buffered saline (PBS) solution and were 
used to encapsulate hepatocytes. Increased albumin secretion in culture confirmed hydrogel 
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support for cultured hepatocytes [193]. The RGD peptide-incorporated alginate was further studied 
as a potential scaffold for skeletal muscle engineering [194]. Another study used light-sensitive 
liposomes that release calcium chloride to trigger gelation of the alginate hydrogel with optical 
triggers [195]. Light-activated gelation was then used to encapsulate bone marrow cells from rats 
[196]. Alginate has been exploited as an injectable cell delivery vehicle [197, 198] and alginate gel 
beads were used to transplant chondrocytes [199, 200], hepatocytes [201] and islets of Langerhans 
[156]. In several studies alginate hydrogels have been mixed with chondrocytes and then been 
injected or formed into an implantable scaffold for cartilage treatment [197, 200, 202, 203]. Pangas 
et al. showed that reproductive follicles encapsulated in an alginate in vitro in culture were able to 
develop normally and could be fertilized [204]. A recent study used sulfated alginate hydrogels as 
well as sulfated alginate microspheres to culture human chondrocytes, showing suppressed 
inflammatory cytokine (e.g., IL-1β, TNF, IL-6, IL-8, MIP-1α) production from this protective 
microenvironment for encapsulated chondrocytes [205, 206]. Gel anti-inflammatory properties were 
noted in addition to increased gel stability and gel network swelling [205]. 
Alginate hydrogel is also commercially available under the brand name AlgiMatrixTM by Life 
Technologies [207] and NovaMatrix ®-3D (www.novamatrix.biz) [208], as well as alginate-coated 
core magnetic beads under the name GEMTM (Global Cell Solutions). Godugu et al. used previously 
lyophilized, sterile AlgiMatrixTM scaffold plates to develop a 3D lung cancer model and tested 
different chemotherapeutics on different types of stem cells seeded into the AlgiMatrixTM scaffold 
[209]. Their results showed that the 3D cultured cells were more resistant to the drugs tested, and 
therefore, this system exhibited a high potential for further drug screening and evaluation of 
chemotherapeutic drug activity [209]. Global Cell Solutions developed beads that exploit the highly 
anionic alginate core but combined with a gelatin coating to enhance cell adhesion. The beads also 
consist of a magnetic core, which is beneficial for downstream applications (e.g., separations and 
collection for media changes) [39]. Mellor et al. used these beads to successfully culture primary 
chondrocytes in a rotating wall vessel bioreactor and found that cells better maintained their 
phenotypic morphology as well as gene expression patterns [210]. 
Overall, alginate hydrogels have a substantial record in cell culture gels as a transparent, 
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nontoxic, relatively biologically inert substrates. It can be further modified with specific cell reactivity 
based on culture needs. Its optical transparency is well-suited to ex situ interrogation by microscopy 
and other optical reporting assays on cell phenotyping and metabolism. Gelation under mild 
conditions in the presence of culture media, assay reagents, and living cells is a primary attraction. 
Additionally, gel stiffness is important to control, and cells must be recovered from within the gel 
when required. Endotoxin and residual protein contaminant removal is also required for all 
polysaccharides obtained from natural sources and fermentation cultures. Alginate purity has high 
batch-to-batch variation that makes it necessary to test and characterize every batch [157]. Otterlei 
et al. show that alginates high in D-mannuronic acids are immunogenic and have an increased 
ability to induce cytokine production compared to alginates with high L-guluronic contents [211]. 
Zimmermann et al. reported in contrast that they found no immuno-response to alginates [212]. 
Different study conclusions reflect differences in cellular response to alginates, depending on the 
purity, and underscore the necessity of more standardized approaches for impurity removal and 
characterization to verify batch materials cell culture requirements [157, 213-215]. 
Carrageenan (algal/seaweed-derived polysaccharide).  Carrageenan is the collective 
term for a group of linear, anionic hydrocolloids extracted from Rhodophyta marine plants, namely 
Gigartina, Eucheuma, Chondrus, Iridaea, and Hypnea. As an algae cell wall extract and intercellular 
matrix, depending on the sourcing species, different carrageenan types are produced. Chemical 
structures of the different carrageenans (shown in Figure 3.2) differ as do the resulting properties. 
All carrageenans are formed by alternating repeats of D-galactose and 3,6-anhydro-galactose 
connected by α-1,3 and β-1,4-glycosidic linkers. Primary carrageenan differences are both the 
position and number of ester sulfate groups and amounts of 3,6-anhydro-galactose. Increased 
ester sulfate groups reduce the solubility temperature and gel strength. The three main types of 
carrageenan are κ-carrageenan (25-30% ester sulfate and 28-35% 3,6-anhydro-galactose), ι-
carrageenan (28-30% ester sulfate and 25-30% 3,6-anhydro-galactose) and λ-carrageenan (32-
39% ester sulfate and no 3,6-anhydro-galactose). Thermo-reversible gels are formed in the 
presence of potassium ions (κ-carrageenan) and calcium ions (ι-carrageenan), respectively, by 
forming double helix cationic-bridged structures. κ-carrageenan produces rigid and brittle gels with 
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a high gel strength and syneresis, while ι-carrageenan gels are elastic and thixotropic, showing no 
syneresis. 
Carrageenans differ from other hydrocolloids in their substantial interactions with milk 
proteins. This is based on strong electrostatic interactions between the positively charged casein 
protein in milk and carrageenan negatively charged ester sulfate groups. Additionally, carrageenan 
ester sulfate groups form links with protein acidic amino acid carboxylate groups. This interaction 
is a function of temperature, pH, type of protein, and carrageenan concentration [216]. 
Carrageenan’s mild gelation properties make them interesting candidates for 3D cell 
culture. The thixotropic behavior of κ-carrageenan makes it relevant for injectable matrices for cell 
delivery [217-219] and inclusion of other macromolecules [220, 221]. Challenges with high gel 
swelling ratios and stability issues in physiological conditions are overcome by different 
approaches, like mixing with other biopolymers [217, 222-224], adding photo-cross linkers [225] 
and polyelectrolyte complexation [226]. Combinations of κ-carrageenan and chitosan influence cell 
viability and behavior [227-230]. Mihaila et al. tried using κ-carrageenan fibers produced by 
ionotropic gelation followed by chitosan polyelectrolyte complexation to increase fiber stability, 
incorporating these enforced fibers into a hydrogel and applying these constructs for micro-
vascularized bone tissue engineering applications [230]. A similar approach was used for 
encapsulating chondrocytes in alginate-carrageenan beads and fibers [217]. Rocha et al. used 
carrageenan-based hydrogels to successfully encapsulate human adipose-derived stem cells in 
combination with transforming growth factor-β1, observing cultured cell differentiation to cartilage 
phenotypes [231]. 
Agar (algal/seaweed-derived polysaccharide).  Agar, also called agar-agar, is a 
galactose polymer derived from the cell walls of agarophytes algae, more precisely Rhodophyta. 
Commercially relevant species are primarily Gracilaria, Pterocladia, Gelidiopsis. and Gelidium. 
Agar comprises mixtures of different polysaccharides, with agarose and agaropectin as primary 
components (Figure 3.2). Agarose serves as agar’s gelling fraction, forming aggregates of double 
helices to form 3D structures. Agaropectin is the nongelling fraction and consists of agarose with 
different percentages of ester sulfate, D-glucuronic acid, and pyruvic acids. The ratio of agarose 
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and agaropectin varies depending on algae species but most are at least two-thirds are agarose. 
Agar-agar’s gelling strength is high even at very low concentrations, holding about 20 times 
its own weight in water, forming gels that are thermos-reversible. It is insoluble in cold water while 
soluble in water and other solvents at 95-100°C. The gel point is around 32-34°C and the melting 
point from a formed gel is approximately 85-95°C. Agar’s thermal reversible hydrogels formed with 
agarose can be controlled by using different agarose concentrations. This then leads to different 
gel pore (mesh) sizes.  
Dillon et al. found that large gel pore sizes combined gel softness enhances neurite cell 
growth, migration, and proliferation [232]. Another effort incorporated chitosan to agar to show that 
this modification significantly improved neurite growth [233]. A different approach increased gel cell 
interaction by adding a common cell adhesion peptide [234]. Agar is also applied as an cell 
adhesion-preventing surface coating used in spheroid in vitro culture models [19]. Agar is 
commonly used as a media in microbiology bacterial cultures, as well as in the food industry and 
used intensively in pharmaceutical products as laxatives, drug carrier and suspension or stabilizing 
substrate in solutions [216]. 
Dextran (microbial-derived polysaccharide).  Dextrans are exopolysaccharides with a 
high molecular weight from ≥1000 Da and consisting only of glucose repeat units (Figure 3.3) [172]. 
These homoglycans are extracted from extracellular matrices of bacterial strains including 
Leuconostoc mesenteroides, Lactobacillus brevis, and Streptococcus mutans. Dextran secretion is 
used by bacteria to form biofilms or also protective microbial coatings [235, 236]. 
Dextrans are divided into three classes depending on their structure. Class 1 dextrans like 
the oligosaccharide, isomaltose, have a α-1,6-linked-d-glucopyranosyl backbone modified with 
small α-1,2-, α-1,3-, or α-1,4-linked side chains of D-glucose branches. This dextran varies in 
molecular weight, degree and type of branching, length of branch, and spatial arrangement with 
their microbial producing strain and culture conditions [237-241]. Class 2 dextrans are also called 
alternans and have an alternating α-1,3- and α-1,6- linked d-glucopyranosyl structure with α-1,3-
linked branches. Class 3 dextrans are called mutans and their backbone consists of consecutive 
α-1,3-linked d-glucopyranosyl elements with α-1,6- linked branches. The dextran pyranose ring is 
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the key structural unit for controlling chain elasticity based on a force-induced elongation and a 
conformation transition from chair to boat-like repeat unit structure. Dextrans can thereby withstand 
mechanical stress and play an important role in ligand binding modulation in biological systems 
[242]. All dextrans are highly soluble in water and behave like Newtonian fluids [243]. 
Van Tomme at el. developed and analyzed a dextran hydrogel comprising dextran 
microspheres modified with either dimethylaminoethyl methacrylate or poly(sodium methacrylate). 
Negatively and positively charged particles form gels that useful for encapsulation of proteins 
and/or cells [244]. A methacrylate and lysine-functionalized dextran combined with gelatin forms a 
hydrogel for smooth muscle cell culture, with a mechanical stiffness and amount of swelling 
dependent on the amount of functionalized groups added to the dextran and the dextran/ gelatin 
ratio. Softer gels of this dextran derivative promoted rapid cell spreading and formation of cellular 
networks [245]. Commercially available dextran-based beads are sold as Cytodex (GE Heathcare). 
Xanthan gum (microbial-derived polysaccharide).  Xanthan gum is a natural 
extracellular, high molecular weight polysaccharide (300-8000 kDa) produced by Xanthomonas 
campestris bacteria. Xantum gum has a β-1,4-d-glucose backbone with a β-D-mannopyranosyl-
(1,4)-β-D-glucuronopyranosyl-(1,2)-6-O-acetyl-α-D-mannopranosyl trisaccharide branch on every 
other glucose unit (α-1,3-linked) (Figure 3.3). Additionally, ~50% of the terminal mannose units form 
a ketal with the 4,6-hydroxyl groups and pyruvic acid. Xanthan gum is polyanionic from acetic and 
pyruvic acid groups [246-250]. The amount of pyruvic acid influences the viscosity of xanthan gum 
solutions and varies by Xanthomonas campestris strain. High concentration xanthan gum solutions 
exhibit weak gel-like properties [251, 252]. 
Mendes et al. used a novel micro-droplet generator to form microcapsules (average 
diameter 500 µm) of xanthan gum-encapsulated chondrocytes. Cells remained viable and 
proliferated for 21 days with enhanced metabolic activity [252]. This group was also able to create 
a matrix consisting of xanthan gum and cationic multidomain peptides, using this 3D environment 
to encapsulate chondrocytes and showing their viability and proliferation over 21 days [162]. 
Gellan gum (microbial-derived polysaccharide).  Gellan gum is a linear anionic 
extracellular polysaccharide produced by microbial fermentation of Sphingomonas paucimobilis. 
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The polymer is a tetra-saccharide repeating unit of β-1,3-D-glucose, β-1,4-D-glucuronic acid, β-1,4-
D-glucose, and α-1,4-L-rhamnose, also including one carboxyatel side group (Figure 3.3) [253, 
254]. Two different forms of gellan gum are used: the acetylated gellan gum that forms soft and 
elastic thermoreversible gels, and the deacetylated form forming hard and brittle thermoreversible 
gels [183, 255]. While gellan gum exists in coil form at high solution temperatures, it transitions into 
a double-helix form when temperature decreases. At that transition point, so-called junction zones 
form by creating oriented bundles of antiparallel aligned double helices. Finally, links between these 
junction zones and extended helicial chains of coiled polysaccharide chains form and facilitate gel 
formation [184]. These gel junctions provide heat resistance, withstanding up to 120°C before 
unfolding [188]. Consistent with previously mentioned alginate gelation and in general with all 
glucuronic-containing polysaccharides, stable gellan gum gels require cations in solution, as the 
cations bridge and electrostatically shield anionic carboxylate groups [157, 169, 182-190].   
Gellan gum crosslinked with cations created self-supporting hydrogels by simply mixing 
gellan gum and alpha-modified minimum essential cell culture medium. This allowed direct 
encapsulation of rat bone marrow cells within the gel, showing viability for 21 days [256]. Oliveira 
et al. used gellan gum to create hydrogel disks with encapsulated human nasal chondrocytes in 
the context of cartilage regeneration, showing that cells remained viable in culture for 14 days [257]. 
Pullulan (microbial-derived polysaccharide).  Pullulan is an exopolysaccharide 
produced by fermentation by the fungus Aureobasidium pullulans [258]. These intracellular 
homoglycans are linear, neutral, nontoxic, noncarcinogenic, and ostensibly hemocompatible, 
consisting of α-1,6- and α-1,4-glucosidic-bonded glucose repeat units (Figure 3.3) [259-261]. This 
unique α-1,6 to α-1,4 interchanging maltotriose pattern endows pullulan with useful physical 
properties: biodegradability, high adhesion, fiber formation, solubility, and structural flexibility [259, 
260, 262]. Even though it is considered primarily as a maltotriose polymer, pullulan can also consist 
of panose or isopanose subunits [260]. Dry pullulan powder can easily be dissolved in cold and hot 
water [260]. Depending on fermentation conditions, pullulan molecular weight varies between 10-
2000 kDa [177, 263]. 
Autissier et al. created a transparent pullulan gel by crosslinking aqueous pullulan solutions 
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with sodium trimetaphosphate. Resulting gels exhibited higher than 90% water content [264]. 
Seeded with rabbit vascular smooth muscle cells, gels were monitored for growth and proliferation 
for 7 days [264]. Bae et al. developed a pullulan methacrylate hydrogel controlled by the degree of 
methacrylation and polymer concentration. They then encapsulated NIH 3T3 fibroblasts and 
HepG2 cells and reported cell proliferation and organization into cell clusters, but no cell elongation. 
By incorporating gelatin methacrylate into these gels, they reported enhanced cell morphological 
behaviors and elongation [263]. Fricain et al. developed a hydrogel consisting of nano-
hydroxypatite pullulan/dextran and encapsulated human bone marrow stromal cells in cultures for 
up to 21 days [265]. Bulman et al. reported that the retention of MSCs on the fibrillated surface of 
osteoarthritic articular cartilage is highly improved by using pullulan and that the transmembrane 
Dectin-2 C-type lectin complex expression is upregulated [266]. 
Cellulose (plant-derived polysaccharide).  Cellulose is the main component of higher 
plant cell walls and most abundant organic compound on the planet [172, 267-270]. Cellulose is 
also found in algae (brown, red, green) and some fungi, and excreted extracellulary by some 
bacteria. Cellulose polymer consists only of (1,4)-β-D-glucopyranosyl repeat units representing a 
homoglycan with just one type of linkage (Figure 3.4). It is partially crystalline with high molecular 
weight. Additionally, so-called hemicelluloses comprise all other polysaccharides in which cellulose 
is mixed as found in primary and secondary cell walls. Hemicellulose is like the name implies: 
similar to cellulose. However, this is true only for its physical properties and not structural properties. 
While cellulose is a homo-glycan, hemicellulose polysaccharides are mostly hetero-
polysaccharides, with the exception of β-glucans and some polysaccharides consisting of D-xylose. 
Hemicellulose can be linear or brush-like with many branches [172, 271-276]. 
Cellulose can be made thermoresponsive by transforming it into cellulose ethers, namely 
methyl cellulose, hydroxypropyl cellulose, and hydroxymethyl propyl cellulose [277, 278]. The 
induced hydrophobic zones from alkoxy ether modifications are needed to create hydrogels by 
thermal dehydration [278]. These materials have substantial biomaterials use, including gelation 
and cell culture. Bhattacharya et al. used nanofibrillar cellulose hydrogels to culture human hepatic 
progenitor HepaRG and HepG2 cells with added bioactive components. While they observed no 
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cytotoxicity, nonexponential growth of the cells was described, contrasting normal standard cell 
culture exponential growth in 2D plasticware cultures [279]. This was supported by mRNA 
expression showing changes in hepatocyte markers and improvements in their 3D model over 
normal 2D hepatocyte cell culture [280]. Recently, nanofibrillar cellulose hydrogels were used for 
culturing human pluripotent stem cells. Cell cultures over 26 days with expression of important cell 
markers were reported [281]. A different approach to use cellulose material in cell culture was 
pursued by Derda et al. who seeded cells on cellulose paper sheets and stacked these as seeded 
layers in cultures. Cellulose stacks created a cell-seeded gradient for HS-5 cell motility monitoring 
[282]. Modulevsky et al. found that three different mammalian cell types (mouse NIH3T3 fibroblasts, 
human HeLa epithelial cells and mouse C2C12 myoblasts) proliferated normally, produced distrinct 
actin stress fibers (a morphological characteristic of substrate-adherent cells) and remained viable 
in 3D cellulose scaffolds derived from decellularized apple hypanthium tissue for up to 12 weeks 
[283]. Overall, the natural porosity and ability to modify cellulose mechanical properties as well as 
the ease of production of these materials as scaffolds makes cellulose a promising biomaterial for 
3D cell culture systems. A commercially available cellulose-based hydrogel is GrowDex® (UPM 
Biochemicals). 
Pectin (plant-derived polysaccharide).  Pectins can be found in the middle lamellae and 
in primary cell walls of plants. They are especially abundant in fruits and vegetables [177]. Pectins 
can exhibit more complex structures with different types of polysaccharide chains in a single 
molecule [272]. The primary structure of pectins, also called rhamnogalacturonans, comprises α-
D-galacturonopyranosyluronic acid sequences, but other monosaccharides have also been found 
(Figure 3.4) [172]. Pectins are mostly water soluble and exist as anionic random coil confirmations 
in solution with some rigidity [177]. The anionic chemical structure of pectin is similar to alginate, 
and therefore the viscosity of pectin solutions can be also increased by adding polyvalent cations 
to the solution, producing ionic bridging across accessible pectin carboxylate groups, and therefore 
chelated pectin hydrogels [284].  
Munarin et al. used pectin either with or without added RGD oligopeptides to encapsulate 
MC3T3-E1 preosteoblast cells. In both cases, cells maintained constant viability and differentiation 
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for 29 days. In RGD-containing pectin cell adhesion and proliferation was improved [285]. 
Promising results were also seen for preosteoblasts growing out from the gel microspheres, 
expressing their own extracellular matrix [285]. Embedded human mesenchymal stem cells in both 
pectin variations are comparable to results from the first study: the cells in pure pectin stayed in 
round-shaped and isolated, while cells in the RGD-modified pectin hydrogel spread, established 
cell-to-cell contacts and migrated out while producing their own extracellular matrix [286]. 
As pectin is similar to alginate in many properties, it is also nontoxic and biocompatible 
after removal of impurities. Additionally, pectin gel networks can degrade under physiological 
conditions based their hydrophilic nature, yielding a benefit (e.g, short-term cell delivery) or 
downside (e.g., long-term 3D cell culture matrix stability issues). Currently, no ultrapure pectins are 
commercially available and therefore purification steps to remove impurities (e.g., proteins, 
endotoxins) are needed. 
Starch (plant-derived polysaccharide).  Starch is the main energy-storage carbohydrate 
form in higher plants, and second most abundant carbohydrate after cellulose [287-289]. In addition 
to being the energy-storage form for plants, starch also serves as an energy source for animals 
when consumed (i.e., supplying about 70% of human caloric intake) [172]. The unique aspect of 
starch is that it is naturally produced as dense and insoluble granules that include two 
polysaccharides: amylose, a linear polysaccharide composed of α-1,4-linked D-glucopyranose, and 
amylopectin, a highly branched polysaccharide of α-1,4-linked glucose segments with α-1,6-linked 
branch points (Figure 3.4). The ratio of these two varies by plant source but commonly starch 
comprises 20-25% amylose and 75-80% amylopectin [290]. Amylose is the gel-forming part of 
starch. To form hydrogels aqueous starch solutions must first be boiled and gelation occurs 
spontaneously through reassociation of solubilized starch polymer chains upon cooling. In contrast 
to cellulose gels, starch gels have a high nutritional energy and can be easier degraded [283]. 
Gomes et al. compared two starch-containing scaffolds under static and flow conditions: 1) 
an extruded hybrid of starch with ethylene vinyl alcohol copolymer, and 2) a combination of starch 
and polycaprolactone obtained by a fiber bonding process. After seeding rat bone marrow stromal 
cells in both matrices under both conditions, they showed that static conditions led to cell 
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monolayers while flow conditions distributed cells throughout the scaffold that differentiated better. 
The cell distribution was increased in the starch-polycaprolactone scaffolds over the starch-
ethylene vinyl alcohol scaffolds, likely due to limited pore interconnectivity in the latter scaffolds 
[291]. These starch polycaprolactone scaffolds were then used to grow human umbilical vein 
endothelial cells after argon plasma treatment. Cells adhered, proliferated, maintained morphology 
and remained viable for the 7-day study period, behaving much the same as cells on adhesive 
protein precoated scaffolds [292]. Liau’s group crosslinked poly(vinyl alcohol) and starch to form a 
scaffold polymer for fibroblast 3D culture. Scaffolds of different composition supported differing 
fibroblast growth and different extents of degradation over 3 days of culture [293]. 
Chitin and Chitosan (fungal, insect and crustacean derived).  The only naturally 
occurring cationic polysaccharides are chitin and chitosan. Chitin is found in primary cell walls of 
certain fungi and a major structural component of insect and crustacean exoskeletons [294]. Both 
are structurally closely related to cellulose, consisting of 1,4-linked-2-acetamido-2-deoxy-β-D-
glucopyranosyl (N-acetyl-β-D-glucosaminyl) units (Figure 3.4). Both are therefore poly-β-1,4-
glucosamines that only differ in their respective degrees of acetylation at the sugar C2 position. 
Chitin forms fibrils and is water-insoluble despite its cationic nature. Most often chitin is bound to 
protein, existing as a proteoglycan [172].  
N-acetyl groups are removed (deacetylated) after treating chitin with strong alkali, and 
converted to amino groups. This process yields chitosan, the more cationic deacetylated derivative 
of chitosan, and water-soluble under diluted acid conditions (< pH 6) [148]. As deacetylation is 
rarely complete, chitosan is often a copolymer of (deacetylated) glucosamine and natural intact N-
acetylglucosamine units. Given its amine pKa ~ 6.5, chitosan is partially cationically charged under 
physiological pH conditions. Chitosan however can form physically cross-linked hydrogels with 
added polyvalent anions (e.g., citrate, phosphate) and transition metal cations, and also through 
careful treatments with base that convert some charged groups to neutral more hydrophobic, self-
associating strands. Additionally, chitosan can form thermo-irreversible gels via chemical and 
enzymatic reactions, or by additions of large organic counterions, and can be used for cell 
encapsulation in their natural environment [177, 295]. After chitin deacetylation, the resulting 
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chitosan has a high homology to mammalian polysaccharides, with good biocompatibility and low 
toxicity, making it an interesting matrix for cell encapsulation [296, 297]. Changing the degree of 
chitosan deacetylation alters the chitosan matrix properties at physiological pH, changing 
degradation times from lysozyme-mediated hydrolysis [298], and altering cell adhesion properties 
[148, 299].  
The lack of endogenous chitin or chitosan production in mammalian cells makes these 
polymers potential targets for innate immune system recognition. Both chitin and chitosan particles 
are readily phagocytosed [300, 301], supporting their possible recognition via specific cell receptors 
mediating phagocytosis, but putative receptors that induce these phagocytic responses are not yet 
identified. Certain cell proteins are known to exhibit affinities for chitin or chitin oligosaccharides, 
including intestinal FIBCD1 [302]; NK cell-specific NKR-P1 [303]; and RegIIIγ, a secreted C-type 
lectin [304]; and galectin-3, a lectin with affinity for β-galactosides [301, 305]. Their roles as a chitin-
specific receptor as opposed to a protein that binds chitin have not been delineated. 
Due to both polymer amino and hydroxyl groups, chitosan offers many approaches for 
potential modifications to increase or optimize cell culture usage. Yeo et al. modified chitosan with 
photo-reactive azido benzoic acid groups to create a photopolymerizable macromer that formed 
azo crosslink after UV exposure [306, 307]. This was exploited to encapsulate cardiomyocytes and 
myoblast cells after additional incorporation of RGD to the photopolymerizable chitosan [307]. A 
different study added polylysine to the chitosan backbone and was better able to grow neural cells 
within it and show neurite extension growth [308]. Other approaches to increase its cell-specific 
acceptance include adding sugar residues like fructose and galactose to successfully culture 
hepatocytes [309, 310] or blended composite proteins like collagen, albumin and gelatin for neural 
cells [311]. The creation of methylpyrrolidinone-derivatized chitosan facilitated bone formation 
studies in vivo [312]. Chitosan fibers and 3D fiber meshes were produced by wet spinning [313] 
and electrospinning [314] and tested for tissue engineering applications. Fukuda et al. used a 
photocrosslinkable chitosan hydrogel to co-culture different cell types to better mimic the natural 
environment of cells by allowing both 3D environment and multiple different cell types [315]. Also 
cytotoxicity studies have been reported using chitosan 3D scaffolds [315, 316]. To increase 
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chitosan scaffold properties and cell acceptance even more, two efforts have combined chitosan 
with chondroitin sulfate, gelatin and/or dermatan sulfate [317, 318]. A similar approach used a blend 
of chitosan and collagen to create a lyophilized scaffold capable of culturing 4T1 cancer cells. 
Comparisons of cells between 3D and 2D plate cultures showed slower proliferation rates and 
enhanced cell resistance to chemotherapeutic drugs and x-ray irradiation in 3D scaffolds [319]. Cho 
et al. developed a thermo-reversible glycol chitosan hydrogel which allowed them to form consistent 
cell-containing gel spheroids that maintained their shape and cellular functions as well allowing cell 
retrieval without enzymatic digestion, a benefit to cell quality as the method avoids cell surface 
protein degradation by trypsinization that produces phenotypic problems [320]. 
 
Glycosaminoglycans used in 3D cell culture systems 
Glycosaminoglycans (GAGs) are specific polysaccharides comprising only 2-amino-2-
deoxy sugar units. With the exception of hyaluronic acid, glycosaminoglycans are covalently bound 
to proteins to form proteoglycans [321-324]. GAGs are prominently featured side chains in 
extracellular matrix proteoglycans and connective tissue in mammalian tissue, and are integral in 
forming the extracellular macromolecular framework [172, 325]. Based on their strong negative 
charge density arising both from their carboxylate and sulfate groups, and glycosidic linkages, 
GAGs form extended anionic helices with the ability to extend and occupy large, hydrated polymer 
domains [326]. Additionally, they can bind and hold cations [325]. Proteoglycans play important 
roles in homeostatic and physiological processes like inflammation and immune response [172]. 
Actually many diseases (e.g., some kinds of cancers and Alzheimer’s disease) are related to 
changes in biosynthesis and processing of proteoglycans [327, 328]. 
Chondroitin sulfate (animal-derived polysaccharide).  Chondroitin sulfates have 
repeating units of disaccharide units: D-glucuronic acid and 2-acetamido-2-deoxy-D-galactose, 
also called N-acetylgalactosamine (Figure 3.5). Chondroitin sulfate is glycosidically linked by a D-
xylopranosylserine to the core protein to form the proteoglycan. These proteoglycans are mainly 
present in cartilage and intervertebral disc tissue but also in other varieties of mammalian tissues. 
Mammalian chondroitin sulfate is stored in mast cell granules [172, 325]. Chondroitin sulfate 
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classification is based on the sulfate group location and content, and this composition depends on 
the chondroitin sulfate source organism [329]. 
Chondroitin sulfate was synthetically modified with methacrylate groups to make it 
photocrosslinkable and to control resulting hydrogel properties through methacrylate group density 
and polymer concentrations. Independent of this modification, chondroitinase enzyme can still 
degrade the hydrogel [330, 331]. These chondroitin sulfate hydrogels were used both for direct 
chondrocyte encapsulation [332], and also as an adhesive to attach encapsulated chondrocyte 
scaffolds to host tissue surfaces [333]. As with chitosan, multiple approaches exist to improve cell-
matrix interactions by combining chondroitin sulfate with chitosan, gelatin and/or dermatan sulfate 
[317, 318]. Varghese et al. grew and differentiated mesenchymal stem cells in chondroitin sulfate-
PEG hydrogels [334]. Lee et al. reported that PVA hydrogels with chondroitin sulfate increased cell 
culture efficiency over pure PVA hydrogels [335]. In a different study, Conovaloff et al. compared 
nerve root regeneration in chondroitin sulfate hydrogels versus hyaluronic acid hydrogels. Cultured 
E8 chick dorsal root ganglia in chondroitin sulfate hydrogels exhibited growth than those in 
hyaluronic acid (i.e, their control). They hypothesized that this was due to stronger affinity of the 
applied nerve growth factor for hyaluronic acid and that hyaluronic acid chains potentially also 
serves as a growth inhibitor [336]. Cell culture and regenerative medicine applications for 
chondroitin sulfate continuously increase due to intrinsically attractive properties and commercial 
availability [329]. A downside is that chondroitin sulfate varies in concentration and purity depending 
on its source, and also impurities either from the source (e.g., proteins, nucleic acids) or from the 
isolation procedure (e.g., chemical solvents, detergents, endotoxins) [329]. Published evidence 
suggests that chondroitin sulfate from fish (e.g., shark) is a preferred source over mammals due to 
its sulfation pattern and safety [329]. More recently, microbial fermentation-based production of 
chondroitin sulfates has been commercialized. E. coli fermentation and chemical modification (e.g., 
sulfation and hydrolysis of fructose monomer) produced an alternative chrondroitin sulfate source 
and composition [329]. 
Dermatan sulfate (animal-derived polysaccharide).  Dermatan sulfate is structurally 
similar to chondroitin sulfate, with the difference dermatan sulfate has some D-glucuronic acids 
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replaced by L-iduronic acid (Figure 3.5). This change distinguishes dermatan sulfate from 
chondroitin sulfates and more similar to heparin and heparan sulfates, as they also contain iduronic 
acid residues [337]. Iduronic acid is important for the binding site specificity for glycosaminoglycan 
(GAG)-binding proteins [337, 338]. The influence of the iduronic acid residue on cellular behavior 
has been previously reported to show that fibroblast proliferation was strongly inhibited when GAG 
chains with high amounts of iduronic acid residues were used [339]. Dermatan sulfate is also 
glycosidically linked by a D-xylopranosylserine to the core protein to form proteoglycans found in 
fibrous connective tissue, the cornea and some fibrous cartilage [172, 325]. 
Chen et al. analyzed the effects of adding dermatan sulfate to a previously tested 
chondroitin-6-sulfate-chitosan scaffold, comparing the two scaffold types after seeding 
chondrocytes. Dermatan sulfate was found to increase scaffold-cell interactions, and influence cell 
morphology, gene expression, GAG and collagen production positively [317]. Not many studies 
report in vitro cell culture data with dermatan sulfate materials, possibly due to sourcing and cost 
issues.  
Heparin/Heparan sulfate (animal-derived polysaccharide).  Structurally, heparin and 
heparan sulfate are very similar (Figure 3.5) [340], comprising glucosamine saccharides alternating 
with glucuronic acid or iduronic acid units in linear GAG chains that span polydisperse molecular 
weights ranging from heparin’s 15kDa to heparan sulfate’s 30kDa. While substantial structural 
heterogeneity exists in both molecules, heparan sulfates contain more glucuronic acid while 
heparin contains more iduronic acid in their respective disaccharide repeats with glucosamine. Key 
to their bioactivity seems to be their relative degrees of sulfation, with heparin bearing more anionic 
sulfate charge density and correlated abilities to bind growth factors and peptides [337, 338, 341]. 
A heparin disaccharide averages ~2.7 sulfate groups, whereas heparan sulfate disaccharide bears 
≥1 sulfate group [342]. Heparan sulfates exist primarily as proteoglycans in extracellular matrix and 
expressed on many cell membrane surfaces, while heparins are secreted from mast cell granules 
and can dissociate from proteins to present extracellularly as GAGs [172, 325].  
Feijen’s group used heparin-tyramine conjugates and dextran-tyramine conjugates to form 
hydrogels for 3D cell chondrocyte culture. They observed optimal cell proliferation and viability in 
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gels with a 50/50 ratio of heparin-tyramine and dextran-tyramine, which made them promising 
scaffolds for injectable cartilage regeneration studies [343]. Tae et al. developed a modified heparin 
hydrogel by thiol modification of the heparin and then cross-linking with poly(ethylene glycol) 
diacrylate. They used this gel to successfully encapsulate fibroblasts and observe cell proliferation 
within the gel, with 5-fold higher cell proliferation after adding fibrinogen to the gel [344]. Further, 
they encapsulated hepatocytes in heparin-PEG diacrylate gels and maintained hepatocyte cultures 
with high levels of albumin and urea synthesis over a 3-week in vitro period [345]. Heparin-
hyaluronan hydrogels were used to improve survival of stem/progenitor cells in transplantation. 
Two different neural progenitor cell lines, derived either from embryonic stem cells or embryonic 
cortex, in these hydrogels exhibited extended survival, attributed to cell stress reduction in the 
hydrogel compared to cell culture without hydrogel encapsulation [346]. Benoit et al. used 
poly(ethylene glycol) gels functionalized with heparin to encapsulate human mesenchymal stem 
cells. The cells remained viable in the hydrogel and underwent osteogenic differentiation over a 
study period of 5 weeks [347]. A different approach using heparin-mimetic peptide nanofiber 
scaffold demonstrated effective simulation of natural ECM heparan sulfates and allowed for spatial 
presentation of important growth factors [348]. Roberts et al. used a poly(vinyl alcohol)-heparin 
hydrogel for simultaneous encapsulation of basic fibroblast growth factor and vascular endothelial 
growth factor and were able to show controlled release of both growth factors which lead to a 
significantly higher human umbilical vein endothelial cell outgrowth with their model cell line, BaF32 
[349]. 
Hyaluronic acid (animal-derived polysaccharide).  Hyaluronic acid (HA) is the only GAG 
which is not a proteoglycan – not covalently bound to a core protein. Hyaluronic acids consist of 
linear repeats of a β-1,4-glucuronic acid-1,3-N-acetylglucosamine disaccharide unit (Figure 3.5) 
with wide ranging molecular weights. They are found naturally in vitreous humor, synovial fluid, 
skin, and diverse connective tissue, often as a high mass-fraction component. HA is the primary 
component in cartilage and central to many proteoglycan aggregates [172, 325]. It has normal 
biological activities in wound healing, angiogenesis, and embryonic development [350, 351].  
HA was originally isolated for biotechnology and biomedical use from animal sources, 
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mainly rooster combs, hen crests, synovial fluid, vitreous humor, and umbilical cords [352]. More 
recently, several in vitro bioreactor, scalable microbial fermentation technologies exploit 
streptococcus bacteria to produce HA [353]. This fermentation approach yields higher 
concentrations of HA while reducing unit costs and allowing for more effective downstream 
processes [329, 354, 355]. As with other natural polysaccharide biomaterials, complete, validated 
removal of impurities and endotoxins prior to use is essential for HA use in hydrogels for cell culture 
applications [356, 357]. 
HA is ubiquitous in human tissues and has an important role in cellular events including 
cell motility, cell adhesion, cell proliferation, and tissue structuring, mainly due to HA interactions 
with two major signal-transducing cell surface HA-receptors: CD44 and RHAMM [358]. Many cells 
express specific cell surface binding proteins, or receptors, for hyaluronan.  Hyaluronan receptors 
are reported for chondrocytes [359, 360], endothelial cells, macrophages, SV-40-transformed 3T3, 
BHK, and human bladder carcinoma cells [361-363]. These putative hyaluronan receptors 
comprise related hydrophobic membrane proteins, named hyaladherins [364], with biochemistries 
and functional structures distinct from integrin receptors. Hyaluronan receptors are grouped by 
similar physical and functional properties including high affinity binding for hyaluronan (Kd -10-9M) 
that increases with increasing ionic strength and is off-competed with hyaluronan oligosaccharides 
of minimum size of six monosaccharides (i.e., hyaluronan hexasaccharide, HA6), as well as high 
specificity for hyaluronan. Importantly, these and other properties distinguish hyaluronan binding 
proteins/receptors from other hyaluronan-binding proteins, including aggrecan and link proteins that 
require minimally 10-12 monosaccharides for effective binding competition [176, 365-367]. 
Cellular hyaluronan receptors are related to the CD44 family of receptors expressed by 
many cell types and varying widely in their glycosylation, oligomerization, and protein sequences 
[368, 369]. Many cells also express the cell surface receptor and hyaluronan binding protein, 
RHAMM (receptor for hyaluronan-mediated motility) involved in cell motility and cell transformation. 
RHAMM induces focal adhesions to signal the cytoskeletal changes required for elevated cell 
motility seen in tumor progression, invasion, and metastasis. CD44 and RHAMM are involved in 
growth factor-regulated as well as hyaluronan signaling and can be involved in different aspects of 
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cell signal regulation: e.g., CD44 is involved in endothelial cell adhesion to hyaluronan as well as 
proliferation regulation while RHAMM is needed for migration and activation of the protein tyrosine 
kinase cascade of endothelial cells in response to hyaluronan [370-372]. Endothelial cells of the 
lymph node and liver sinusoids remove hyaluronan via specific receptors LYVE-1 (a CD44 
homolog) and HARE (hyaluronan receptor for endocytosis).  
Structurally, many hyaluronan-binding proteins and receptors commonly share a protein 
motif called the link module, first described in cartilage link protein [373]. Link proteins belong to 
the subfamily of hyaluronan and proteoglycan link proteins (HAPLN) found in many tissues. Four 
hyaluronan binding receptors have extracellular domains with link module motifs: CD44, LYVE-1 
(lymphatic vessel endothelial hyaluronan receptor), HARE/STABILIN-2 (hepatic hyaluronan 
clearance receptor), and STA-BILIN-1, all expressed on discontinuous endothelial cells and some 
activated macrophages.  
Functionally, hyaluronans are proposed to exhibit important roles in cell proliferation, 
migration, and invasion, and pathologically in inflammation and tumorigenesis. To produce these 
signals, hyaluronan receptors serve to bind cell membranes with extracellular glycosaminoglycans 
[370]. Previous studies have shown that the effect of hyaluronan is strongly dependent on cell type 
as well as the size of the hyaluronan [370, 374, 375]. With its high natural abundance in most 
connective tissue, hyaluronic acid is commonly used in cultures for cell encapsulation in the context 
of extracellular matrices rich in hyaluronic acid (e.g., chondrocytes) [67, 376]. 
This cell engagement with HA imparts HA with requisite materials properties attractive to 
exploit for 3D cell culture constructs [350, 351, 377]. As a weakly acidic biopolymer, HA does not 
effectively gel with calcium ions but can be gelled with other polyvalent cations, like iron [378]. 
Acidic HA and basic chitosan, for example, form complex polymer-polymer coacervates that yield 
nanoparticles, hydrogels, microspheres, sponges, and films [379]. HA is often chemically modified 
to effectively gel or polymerize in vitro [19]. Such cross-linking efforts include physical, ionic, or 
covalent HA network formation [378]. To improve cell encapsulation, multiple HA studies 
incorporate covalent polymerizable groups, for example, methacrylates [380-382] or thiols [383, 
384], forming gels from these materials by direct polymerization or with diverse crosslinkers. Some 
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HA gels can be degraded into diverse oligosaccharide fragments by disulfide reducing agents or 
using hyaluronidase enzymatic activity [381, 384]. Master et al. showed that cell-mediated HA 
degradation improved heart valve tissue growth [381].  
Crosslinked HA hydrogels are also created using photopolymerization [380, 385, 386]. 
Chung et al. reported that implantation of photocrosslinked HA gel-encapsulated articular 
chondrocytes into subcutaneous pockets showed better tissue growth in HA gels of lower 
macromer concentration having lower crosslink density. They also showed that HA molecular 
weight had less influence on tissue growth [382].  
Acrylated HA reacts in aqueous media with derivatized PEG-tetrathiol [387] or, conversely, 
thiol-modified HA can analogously react with PEG diacrylate (PEGda) [383, 384, 388] both via 
Michael addition. Using these approaches, Kim et al. used HA hydrogels formed by Michael 
addition to encapsulate mesenchymal stem cells (MSC), claiming increased bone regeneration and 
growth after implantation compared to “blank” HA hydrogels [387]. HA Michael addition-type gels 
allowed adipose-derived stem cells to better differentiate compared to decellularized protein matrix 
surfaces [388]. Similarly, elevated neurite outgrowth was reported for HA encapsulation of dorsal 
root ganglia [389]. Specific to drug toxicity screening in vitro, a recent 3D kidney proximal tubule 
culture model improves toxicity predictive capacity compared to current 2D kidney cell 
monocultures on plastic [13, 47, 60]. Viable mouse kidney-derived proximal tubule fragments (PTs) 
are embedded in a commercial biomedical grade HA-based crosslinked hydrogel matrix. 
Encapsulation of PT fragments in this semisynthetic hydrogel mimics ECM and encourages 
endogenous PT epithelial cells to remain in their native tertiary tissue-like PT structure to maintain 
differentiated states and cell functionalities in vitro for extended periods [12, 47, 60]. PT cells 
therefore reflect toxicity states with more fidelity when interacting with drug compounds [13, 60].  
Another approach to HA hydrogels for cell encapsulation is using click chemistry. HA 
derivatives containing azide and alkyne chemistry can react together to form crosslinks in aqueous 
media [390, 391]. DeForest et al. used this HA chemistry and successfully encapsulated 3T3 
fibroblasts [392]. 
Similar to approaches with other natural polysaccharide gels in cell culture, HA is also 
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combined with other natural or synthetic materials in gel networks to increase cell engagement and 
enhance cell culture properties. Thiol-modified HA was combined with thiol-modified gelatin to 
create an ECM-like environment when crosslinked with diacrylated PEG [383]. This combined 
matrix provided advanced tissue regeneration with cartilage, similar to native architecture with 
encapsulated MSCs [393-395]. A different approach combines HA and collagen in a semi-
interpenetrating network to achieve mechanical robustness with bioadhesive properties. Brigham 
et al. showed fibroblasts seeded inside this scaffold maintained high levels of viability and that the 
scaffold supported both cell adhesion and proliferation [396, 397]. Suri et al. embedded Schwann 
cells in a similarly engineered collagen/HA interpenetrating polymer network to show that cells 
spread out and proliferated over a 14-day study. Furthermore, these cells were functional and 
actively secreted nerve growth factor and brain-derived neurotropic factor [398].  
Synthetically modified HA is commercially available under different brand names, e.g., 
Hyaff® (Fidia Advanced Biopolymers) and Glycosil® (ESI Bio). A combination product of thiol-
modified HA, thiol-modified gelatin, and PEG-based crosslinker is available under the brand name, 
HyStemTM (ESI Bio). Overall, HA gels demonstrate excellent chemical versatility, good 
biocompatibility and optical properties, and readily modified mechanical properties (using molecular 
weights and crosslinking variables) suitable for in vitro 3D cell culture as well as for regenerative 
medicine [399]. 
 
Synthetic polysaccharides   
All glycosaminoglycans are biosynthetic products of native glycan-specific enzymes (e.g., 
hydrolases, oxidoreductases and transferases) that selectively utilize carbohydrate substrates: 
polysaccharides are formed by repeated enzyme-catalyzed, highly enzyme-specific glycosylation 
reactions between glycosyl donor and glycosyl acceptor substrates of the enzyme. Unlike all natural 
proteins, no polysaccharides are encoded by genes. Mammalian polysaccharides for example 
comprise only ten different monosaccharide monomer units, most frequently encountered in nature 
as glycoconjugates (i.e., glycol-peptides, -proteins, and -lipids). In these natural products, the 
oligosaccharide component is more chemically complex than either peptides or oligonucleotides 
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are as families of analogous bioderived polymers. In polymerizing glycan monomers, each 
glycosidic bond produces a new stereogenic center. This chemistry is unlike amide and phosphate 
diester linkages in protein and nucleotide polymers, respectively. Copying this unique 
stereochemical control in polysaccharide glycosidic bond formation remains largely an unsolved 
challenge. The array of reactive amine and hydroxyl groups decorating each glycan ring is not yet 
effectively addressed by protective group strategies for automated synthesis [400]. While most well-
studied natural glycosaminoglycans comprise controlled, polymerized repeats of a few chemically 
distinct glycan monomer units in alternate sequence or short blocks, simplified and automated 
approaches to prepare synthetic analogs, or more ambitiously, exotic “designer carbohydrates”, 
are lacking.  
To date, however, the most powerful methods reported for polysaccharide total synthesis 
combine chemical and enzymatic approaches. This provides access to many different shorter 
oligosaccharides of mammalian origins, in addition to some glycolipids and simpler glycoproteins 
[401]. Kobayshi et al. achieved the first chemical synthesis of cellulose using enzymatic 
polymerization with cellulase and a fluorinated cellulose monomer derivative (β-CF) as a substrate 
[402]. Success with this enzyme–substrate polymerization of starch then stimulated other 
polysaccharide polymerization efforts using hydrolases, oxidoruductases and transferases as 
catalysts [403-406]. Kobayashi’s group subsequently reported using a hydrolase enzyme to 
polymerize synthetic glycan-like monomers designed as “transition-state analogue substrates” 
(TSAS), fluoridated glycan monomers for polycondensation and oxazoline-based sugar monomers 
suited for ring-opening polyaddition reactions. This enzymatic polymerization was shown to yield in 
vitro synthesis of several natural polysaccharides including cellulose, xylan, chitin, hyaluronan and 
chondroitin, and also of unnatural polysaccharides such as a cellulose–chitin hybrid, a hyaluronan–
chondroitin hybrid, and others [407]. His further efforts were using ring-opening polymerization of 
bicyclic anhydro sugar derivatives and via enzyme-catalyzed polymerization with phosphorylases 
[408]. 
Native proteins and nucleotides both represent linear biopolymers assembled from either 
twenty different amino acids monomers or four unique nucleotide monomers, respectively. By 
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contrast, evolving the library of glycan monomers available in nature, and their unique coupling 
stereogenic chemistry is more daunting. In particular, growing techniques such as native chemical 
ligation (NCL), sugar-assisted ligation, Staudinger ligation, expressed protein ligation (EPL), and 
pathway engineering are now shown to effectively produce homogeneous glycoproteins with 
reliable glycan content. In a protein polymer-analog synthetic approach, Wong et al. showed that 
unnatural amino acids containing a keto group could be site-specifically incorporated into a target 
protein by exploiting the amber nonsense codon [409]. Aminooxy saccharide derivatives were then 
selectively coupled to this genetically encoded keto group in the expressed protein. The resulting 
saccharide core was transformed to full glycan chemistry with glycosyltransferases. Alternatively, 
aminooxy analogues of more complicated glycans were prepared and directly attached to the keto 
group. This represents a general approach for synthesizing homogeneous glycoprotein mimetics 
containing well-defined reactive saccharide substituents. 
Significantly, improvements in glycan synthesis and coupling strategies, including chemo-
enzymatic, one-pot and solid-phase synthetic methods have created improved processes that yield 
various pure glycans in quantities feasible for more than exotic carbohydrate research in 
biopolymer synthesis. Seeberger et al. demonstrated the combination of an automated 
carbohydrate synthesizer and photolabile linkers cleaved in a continuous-flow photoreactor to 
synthesize two chondroitin hexasaccharides as examples for a general polysaccharide method 
[410]. Other glycan oligosaccharides (e.g., heparin, heparin sulfate, dermatan sulfate, or keratin 
sulfate) might follow suit with this approach. Seeberger et al. also developed a generalized and 
modular strategy claiming the first completely stereoselective synthesis of defined heparin 
oligosaccharides, producing stereochemical control of α-glucosamine glycoside formation as a 
precedent [411]. 
Nonetheless, despite monomer feedstocks in limited quantities and some success in 
oligosaccharide synthetic hallmark examples, long stereochemically controlled glycan-based 
polymers analogous to natural hyaluronan, alginic acids and other polysaccharides escape modern 
synthetic approaches. Instead, glyco-mimetic polymers based on protein- or polymer- glycan 
coupling [412] or polymerization of vinyl- or acryl- derivatized glycan monomers is reported in 
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several forms [413, 414]. These approaches are generally limited in biomimetic heterogeneity and 
diversity by polymerization method limitations on monomer compositional and sequence control, 
polymer blockiness, or alternating chemistry and resulting product stereochemistry. Production of 
monomer precursors that impose requisite stereochemical regularity on high molecular weight 
glycan polymer products is simply not affordable or practical currently. 
 
Perspectives and future outlook 
Polysaccharides represent an increasingly popular materials choice for 3D cell culture 
studies, but the reasons for their selection are more pragmatic than biomimetic. Most available 
polysaccharides are gentle, benign biomaterials convenient for cell encapsulation using aqueous 
encapsulation methods and crosslinking by diverse physical and chemical means to control 
mechanical integrity, morphologies, and hydrogel properties. Some glycan-based materials are 
commercially available in high-purity forms suitable for biomedical studies and many are optically 
transparent to permit external interrogation using microscopy and spectroscopy. From this record, 
proven benefits for 3D cell culture include nontoxic matrix formation and degradation profiles, 
general biocompatibility in culture, commercial materials availability in quantity and quality at 
reasonable cost, optical transparency of noninvasive monitoring, and structural support for cells 
and organoids to allow for in vivo-like cell differentiation, attachment, proliferation and cell-cell and 
cell-matrix interactions. These matrix factors combine to produce successful cell culture systems 
that show in vivo-like gene expression profiles and toxicity responses. Hence, the requirements for 
3D culture matrices shown in Tables 3.1, 3.3, and 3.4 are often satisfied by a diverse array of 
chemically unrelated polysaccharide biomaterials in 3D gels. This reflects perhaps more general 
properties attributable to hydrogels, nonspecifically supporting cell-matrix interactions. 
Several polysaccharides are derived from their native presence in mammalian extracellular 
matrix and as natural products, require no synthesis. Other materials have nonmammalian origins 
(e.g., seaweed/algae and plant-derived biopolymers) yet exhibit suitable properties and structural 
homologies sufficiently similar to mammalian polysaccharides to serve as suitable surrogate gel 
materials for 3D cell culture. Notably, no polysaccharides mentioned exhibit complete ECM cell-
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support equivalence in either their structure or function: modes of specific cell engagement with 
polysaccharides are weak and rare (e.g., CD44 for HA). Specific ECM ligands (i.e., for cell 
membrane integrins) are often missing. Cell encapsulation within polysaccharide 3D gels provides 
cells with a hydrated, porous, soft matrix with some similarity to ECM physically. Chemically, this 
3D matrix is often nonoptimal to promote normal cell function, and therefore, hybrid and blended 
gel matrices with matricellular proteins with cell-specific binding motifs (e.g., gels with gelatin, 
laminins, collagens) are used to enhance polysaccharide physical gel properties in cell cultures.  
Other suboptimal polysaccharide materials properties are primarily in batch-to-batch 
materials variability, endotoxin purity and variable final gel mechanical properties. Additionally, 
downstream in vitro testing including ex situ optical issues and cell assay interference, remain to 
be vetted. 
A different approach to optimize structure of 3D cell cultures is the use of 3D printing 
technologies. This fabrication method is used and studied now in several different formats to 
produce new materials scaffolds from natural polysaccharides [415-417]. Additionally, the printed 
approach also allows the precise combinations of different polysaccharides and biopolymer blends 
to optimize different properties from each polysaccharide. He et al. recently successfully analyzed 
the printability of alginate/gelatin hydrogels and the effects on cell viability of L929 mouse fibroblasts 
[418]. Axpe et al. reviewed the use of alginate for 3D bioprinting, currently the most commonly used 
material for bioinks [419]. Overall bioink use in 3D printed matrices opens new doors into the 
options of possible shapes and structures of future in vitro 3D cell culture designs from natural 
polysaccharides, 
No one single technique/material will be optimal in satisfying all needs of different 3D cell 
cultures; users should select and validate the most appropriate model for their specific cell-based 
needs and requirements. Overall, fabrication of hydrogels from natural polysaccharides has already 
proven experimentally versatile and successful. Many attributes attractive to in vitro 3D cell studies, 
drug and toxin screening assays and tissue engineering, and advanced fluidics and co-culture 
designs are identified. Such novel 3D matrix-based culture systems exhibit greater similarity to 
actual tissue constructs (i.e., organoids, micro-tissues, spheroids, and cell/gels) [19] and enable 
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platform technologies currently sought for drug development, developmental biology studies, 
improved disease models, and regenerative medicine research and development beyond the scope 
of this review.  
Despite substantial precedent use and history of development, a number of technical 
challenges represent significant barriers to rational use of polysaccharides in 3D cell culture 
systems in vitro. Few available polysaccharide biomaterials are mammalian sourced – most are 
from algal or plant sources (e.g., alginates, agaroses, gums and cellulosics). Most 
glycosaminoglycans lack known cell receptor adhesion ligands that trigger cell signaling and normal 
phenotypic behaviors known from native ECM. For example, few polysaccharides compete with 
collagen, a popular cell culture protein substrate, for availability and pricing, as well as known cell 
receptor binding behaviors. No glycan analogies to well-known cell-ECM engagement through 
integrin-receptor interactions exist. As a result, many polysaccharide materials in 3D culture provide 
a highly hydrated, permeable and noninteractive culture environments, and lack specific receptor-
mediated cell interactions important to cell phenotypic stability, differentiation and renewal. To 
overcome this deficit, many polysaccharides are blended with ECM proteins to provide the 
advantages of both materials in culture, including the mild physical and tailored processing 
advantages of polysaccharides as hydrogels with the biochemical cell engagement specificities of 
ECM matricellular proteins. Future research should work to identify cell-specific glycan ligand 
biochemistry and receptor biochemistry in order to define chemistries important to future synthetic 
biomimetic polysaccharide-like materials for 3D cell culture. This is also important to distinguish 
important 3D cell culture properties in natural polysaccharide materials from other traditional 
hydrogel classes. This glycan-specific cell culture evidence to date is not that distinguishing.  
Obtaining this evidence of interaction and cell engagement would also benefit current 
efforts to design synthetic polysaccharides with the proper stereochemical features to emulate 
natural biopolymer properties important to 3D cultures. This should focus on what features are 
necessary versus what are sufficient to adopt from ECM prototype materials for effective 3D use.   
While synthetic methods are still challenged to couple a limited library of sugar-based monomers 
in native configurations, an essential challenge to the 3D cell culture field is to define polymer 
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chemical features important to cell phenotypic stability and proliferative capabilities. These then 
identify the unknown chemical and structural design features currently unavailable in synthetic 
polysaccharide mimetic polymers.  
A remaining challenge is a materials sourcing issue: improving both the ability to procure 
and produce pure natural polysaccharides at a lower cost of goods and greater batch-batch quality 
control. This could result from shifts away from current natural materials batch-wise production from 









Table 3.1 Cell characteristics and performance benefits desired in 3D cell culture systems. 
Cell Characteristics 3D cell culture benefits References 
Morphology In vivo-like cell shape [10, 20, 21] 
Proliferation Cell type and 3D model dependent [25, 26] 
Motility Cell type and 3D model dependent [63] 
Cell-cell communications 3D paracrine and autocrine signaling [64] 
Drug/medium/O2 exposure Potential penetration gradients toward center [10, 66, 67] 
Cell cycle staging Cells of different stages (proliferating, hypoxic, 
quiescent and necrotic) possible 
[10, 11, 16] 
Gene expression More similar to in vivo expression profiles [12, 25, 77, 78] 
Toxicity responses Better predictive values to in vivo compound 
responses 
[13, 25, 79] 
 
Table 3.2 Current 3D cell culture methods including commercially available products. 
3D cell culture method Commercial source References 
Spheroids/ scaffold-free platforms 
• Forced-floating 
• Hanging drop 
• Agitation-based approach 
o Spinner flask bioreactors 
o Rotational culture systems 
PrimeSurface (Sumitomo Bakelite) 
Lipidure-coated plates 
MicroWell MiniTray (Nunc) 
3D Biomatrix (http://3dbiomatrix.com) 
InSphero (www.insphero.com) 
Wheaton Spinner Flask (Wheaton) 
Spinner Flasks (Corning) 
Synthecon (www.synthecon.com) 
Rotary Cell Culture Systems 
[10, 27-33] 
Matrices, gels and scaffolds Matrigel (BD Biosciences) 
PathClear Grade Basement Membrane 
Extract (Amsbio) 
ECM gel (Sigma-Aldrich) 
ECL Cell Attachment Matrix (Millipore) 
Geltrex (Invitrogen) 
HuBiogel (Vivo Biosciences) 
Cytodex 3 microcarrier (GE Healthcare) 
ProNectin F (Solohill) 
[37-40] 
Microfluidic cell culture platforms/ 
microchips (organ-on-a-chip) 
MiCA plate (CellASIC) 
Iuvo Microconduit Array Platform (BellBrook) 
Quasi Vivo (Kirkstall)  
Organovo (ONVO) 
HepatoPac (Hepregen) 







Table 3.3 Gel/matrix general technical requirements for use in 3D culture systems. [1, 2] 
Maintenance of organ features critical for their function and tissue-tissue interfacing 
Control of gradients of media, chemicals and oxygen essential for 3D viability 
Mechanically active microenvironment important for organ functionality 
Duplication of matrix microstructure that yields normal tissue microarchitecture  
Incorporation of versatile biochemical cues recapitulating the natural ECM microenvironment 
Endotoxin free 
Scalable in mass and volume 
Highly reproducible material properties and compositions batch-to-batch and location-to-location 
User-friendly in preparation and deployment in culture 
Manufacturable to a quality standard 
Approvable, possibility of regulatory approval 
Affordable, competitive cost/economy 
User-initiated degradability (enzymatically, nonenzymatically) under mild conditions 
(biodegradable) 
Sterilizable, low bioburden 
Low contraction and expansion 
Usable and cross-linkable under physiological conditions (e.g., temperature, pH) 
Optically transparent 
High-throughput screening (HTS) applicable with fluidics interface and stability under fluid shear 
Potential for translational applications beyond in vitro culture 
Nontoxic degradation 
 
Table 3.4 Common advantages and disadvantages of natural polymer matrices used for 3D cell 
culture systems. [3-19] 
Advantages Disadvantages 
• Natural origin 
• Complex geometric structure and shapes 
• Structural support for cells/organoids 
• Support in vivo-like cell differentiation 
(functional and morphological) 
• Encourage cellular attachment 
• Encourage cell proliferation 
• Encourage intercellular and cell-ECM 
interactions 
• Promote cell diversity 
• More in vivo-like gene expression profiles 
and cellular behavior 
• Simple to use 
• HTS compatibility 
• Bioreactor applicability 
• Economical 
• Abundant commercial providers 
• Bridges gap between in vitro and in vivo 
drug screening needs 
• Possible decreasing the use of animal 
models 
• Nontoxic degradation 
• Optical issues due to:  
o Density 
o Light scattering 
o Curvature (non-line-of-sight) 
o Assay interference 
o Signal-to-noise ratio 
• Assay read out 
o Termination of culture needed 
o Culture disassemble needed 
• Lack of ECM complexity  
o Limitation of adhesion molecules 
o Limitation of cellular ligands 
• Lack of tissue-like organization 
• Lack of vasculature 
• Diffusion/transport issues (necrotic core) 
• Batch-to-batch variability 
• Contamination risks  
• Endotoxin and impurities removal 
• More expensive than 2D cell culture 
• Risk of absorption/interaction of 

























Figure 3.2 Chemical structures of algal/seaweed-derived polysaccharides 
Native ECM consists of covalent and noncovalent heterogeneous molecular interactions 
between matrix proteins (primarily collagens), glycoproteins, and diverse glycosaminoglycans 
(GAGs) [2], like chondroitin and heparan sulfates. The resulting ECM network contains both 
essential physical and chemical cues that engage cell receptors and provide proper context for 
native cell behaviors in three dimensions. Native ECM spatially displays, stores and secretes 
growth factors, provides physical structure and mechanical context, and enables cellular 
communications. ECM has an important role in controlling the distribution of nutrients and 
gases. The ECM hereby creates signal gradients essential for cell processes (e.g., migration, 
homing and tissue organization and patterning) [21, 35, 36]. More detailed information on ECM’s 
complex structure, importance and use are found in recent reviews [42, 43]. 
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DRUG TRANSPORTER EXPRESSION PROFILING IN A THREE DIMENSIONAL 
KIDNEY PROXIMAL TUBULE IN VITRO NEPHROTOXICITY MODEL2 
 
Abstract 
Given currently poor toxicity translational predictions for drug candidates, improved 
mechanistic understanding underlying nephrotoxicity and drug renal clearance is needed to 
improve drug development and safety screening. Therefore, better relevant and well-characterized 
in vitro screening models are required to reliably predict human nephrotoxicity. Because kidney 
proximal tubules are central to active drug uptake and secretion processes, and therefore to 
nephrotoxicity, this study acquired regio-specific expression data from recently reported primary 
proximal tubule three-dimensional (3D) hyaluronic acid gel culture and nongel embedded cultured 
murine proximal tubule suspensions. Quantitative assessment of the mRNA expression of 21 
known kidney tubule markers and important proximal tubule transporters with known roles in drug 
transport was obtained. Asserting superior gene expression levels over current commonly used 
two-dimensional (2D) kidney cell culture lines was the study objective. Hence, we compare gel-
based 3D proximal tubule fragment culture and their nongel suspensions for up to one week, and 
demonstrate that 3D tubule culture exhibits superior gene expression levels and profiles compared 
to published commonly used 2D kidney cell lines (Caki-1 and HK-2) in plastic monocultures. 
Additionally, nearly all tested genes retain mRNA expression after seven days in both proximal 
tubule cultures, a limitation of 2D cell culture lines. Importantly, gel presence is shown not to 
interfere with gene expression assay. Overall, results validate retention of essential toxicity-relevant 
                                                     
2
 Diekjürgen, Dorina and Grainger, David. Drug transporter expression profiling in a three-dimensional kidney 
proximal tubule in vitro nephrotoxicity model. Under revision 2017 
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transporters in this 3D proximal tubule model over conventional 2D kidney cell cultures, producing 
opportunities for more reliable and comprehensive drug toxicity studies relevant to drug 
development and nephrotoxicity goals. 
 
Introduction 
Kidney proximal tubules play a major role in the secretion of xenobiotics and metabolites 
from the body, and are the primary target sites of drug-induced nephrotoxicity. This results from the 
action of specialized transporters (e.g., OAT1, OAT3, OCT2) in the proximal tubule that uptake 
organic compounds and biotransformed metabolites across the basolateral membrane [420-422]. 
This active transport system results in high levels of toxins within proximal tubule cells, leading to 
cell damage and necrosis [423, 424]. Additionally, proximal tubule cells have polarized distributions 
of transporters. Apical side transporters facilitate exit of compounds into the tubule lumen, 
specifically, the known efflux transporters, MDR1, MRP2, and MRP4 [425-427]. These transporters 
play a major role in nephrotoxicity models and why proximal tubules are an ideal focus for drug 
toxicity screening. Previous work has identified drug transporters and their functions [428-431]. 
However, the mechanistic processes and importance of individual transporters on both sides of the 
proximal tubule and their effects on nephrotoxicity are largely unclarified. Therefore, a detailed 
characterization of the transporter expression profiles is critical for developing relevant drug toxicity 
models. This study focuses on profiling mRNA expression levels of 21 known tubule markers (Table 
4.1) as well as important proximal tubule transporters with known roles in drug transport in a 3D 
tubule culture model (Figure 4.1). These are then compared to routine 2D kidney cell cultures 
reported in the literature.  
Three-dimensional (3D) cell culture has been previously shown to be superior to 
conventional 2D cell cultures: their cell morphology and physiology differ [432, 433], and 3D cell 
cultures demonstrate more similar responses to in vivo behaviors than 2D cell cultures [434, 435]. 
Despite this, 2D cell monoculture on flat, rigid plastic supports remains the current standard for 
drug screening in the pharmaceutical industry in combination with animal in vivo studies [14]. 
Currently, immortalized renal epithelial cell lines of nonhuman origin (LLC-PK1 [436], OK [437], 
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MDCK [436]) or human cell lines (HK-2 [44, 438], Caki-1 [59], RPTEC-TERT [70, 439]) are routinely 
used in vitro for pharmacological studies (Table 4.2). Two-dimensional primary proximal tubule cells 
lose their polarization within minutes to weeks of monoculture [102], while secondary (transformed, 
immortalized) cell lines often are missing important kidney transporters required for drug toxicity 
[98]. Therefore, recent technologies emphasize a shift away from monolayer-cultured cells on 
plastic plates to 3D matrix-based culture systems more resembling in vivo tissue mechanics, 
hydration and architecture (i.e., organoids, micro-tissues, spheroids, and cells in gels) [39, 103, 
104].  
A recently developed 3D kidney organoid toxicity model [60] fulfills many of these 
requirements and improves on current 2D kidney cell monocultures on plastic by using viable 
mouse kidney-derived intact proximal tubules embedded in a commercially available hyaluronic 
acid-based hydrogel matrix [105]. Within these gels, encapsulation of harvested viable proximal 
tubule organoid fragments preserves the natural kidney tubule extracellular matrix, allowing 
proximal tubule epithelial cells to remain within their native tissue structures while suspended in 
highly hydrated 3D biopolymer culture media. Furthermore, these gels facilitate cell-matrix and 
natural cell-cell communication, maintain differentiated states and cell functionalities [104, 440], 
and allow for similar cellular heterogeneities seen in vivo [25, 441, 442]. Proximal tubule cells in 
these cultures therefore reside and interact in their more natural 3D extracellular matrix 
environment, and are proposed to produce toxicity responses to soluble species with more fidelity 
when interacting with drug compounds [47, 60, 103].  
In this study, we characterize intact cultured proximal tubule transporter mRNA expression 
levels to determine how this proximal tubule model might be able to better retain and recapitulate 
drug transport and nephrotoxicity responses in vitro. Results provide more insight into the reliability 
of this in vitro model beyond functional equivalence evidence reported previously for a select 
nephrotoxic proof-of-concept demonstration of this model [47, 60]. Understanding the expression 
profiles for critical kidney tubule transporters should facilitate future in vitro-in vivo correlations 
(IVIVC) and interspecies comparisons to validate nephrotoxic assays. Data for transport expression 
in vitro in 3D cultures to 7 days supports the value of this in vitro culture system for toxicity screening 
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of compounds that are substrates or inhibitors of known specific kidney transporter proteins. 
 
Materials and methods 
Murine proximal tubule harvest and isolation 
Male C57BL/6 mice were purchased (age 6-8 weeks, Charles River Laboratories 
International, Inc., Wilmington, USA). All animals were euthanized using carbon dioxide (CO2) in 
accordance with University of Utah Institutional Animal Care and Use Committee (IACUC)-
approved protocols. Kidneys were harvested and proximal tubules were isolated using a 
mechanical technique followed by enzymatic digestion as previously described [60, 443]. Briefly, 
kidneys were removed surgically under standard aseptic conditions in a BSL2-certified laminar flow 
hood. The kidney capsule, ureter and blood vessels were removed and the isolated kidneys were 
mechanically disrupted by using a sterilized razor blade followed by enzymatic digestion in 2 mg/ml 
hyaluronidase (Worthington Biochemical Corporation, USA), 3 mg/ml collagenase IV (Worthington 
Biochemical Corporation, USA), and 0.1 mg/ml DNase I (Sigma Aldrich, USA) KREBS solution 
(145 mM NaCl, 10 mM HEPES, 5 mM KCl, 1 mM NaH2PO4, 2.5 mM CaCl2, 1.8 mM MgSO4, 5 mM 
glucose, pH 7.3) at 37 °C [444]. To isolate the proximal tubules from the digested sections, 
sequential 250 µm and 70 µm sieving was used [443]. Proximal tubules were pelleted by 
centrifugation and yields were estimated using a hemocytometer. 
 
Proximal tubule cultures 
Nonembedded proximal tubule cultures (nongel PT).  Proximal tubules were 
resuspended in proximal tubule media comprising Dulbecco’s Modified Eagle Medium/Nutrient 
Mixture F-12 with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid and L-glutamine (Invitrogen, 
USA). Additionally, 1% fetal calf serum (Invitrogen, USA), 5% sodium pyruvate (Invitrogen, USA), 
10% nonessential amino acids (Invitrogen, USA), 10% insulin/transferrin/selenium (Invitrogen, 
USA), 1% antibiotic-antimycotic (Invitrogen, USA) and 0.9 µg hydrocortisone (Invitrogen, USA) 
were added [443]. Finally, 100 µl proximal tubule media containing approximately 5000 proximal 
tubules was added to each well of a 96-well plate well. Plates were then incubated for up to 7 days 
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in cell culture incubators under 5% CO2 and 95% air at 37 °C. Media was exchanged every 2 days 
for maximum cell viability.  
3D gel proximal tubule cultures.  Proximal tubules were encapsulated immediately after 
isolation within a 1.5% semisynthetic, thiol-modified biomedical-grade carboxymethylated 
hyaluronic acid (CMHA-S, SentrX Animal Care, Salt Lake City, USA) and 7.5% poly(ethylene 
glycol) diacrylate (PEGDA, SentrX Animal Care, Salt Lake City, USA) hydrogel (4:1 v/v). PEGDA 
is used as a bifunctional electrophile in situ cross-linker to produce in situ gelation in PBS with 
proximal tubules [105, 445, 446]. Hyaluronic acid-PEGDA 3D tubule organoid culture constructs 
(HA gel PT) were made with approximately 5000 proximal tubules/well in a 50 µl total volume HA 
gel matrix. Gel-tubule constructs in 96-well plates were allowed to gel for 30 min in a cell incubator 
at 37 °C (5% CO2, 95% air). After gelation, 100 µl proximal tubule media (vide supra) was added 
onto gel constructs [60]. Constructs were incubated for up to 7 days in cell culture incubators under 
5% CO2 and 95% air at 37 °C. Media was exchanged every 2 days for maximum cell viability.  
 
RNA extraction 
Total tubule RNA was isolated and purified from cultures using the PureLink® RNA Mini Kit 
(Ambion® by Life Technologies, Carlsbad, USA) according to manufacturer’s protocol. Final RNA 
elution was done in 30 µl of RNase-free H2O. The quality and quantity of each RNA sample was 
determined using a NanoDrop 2000 Spectrophotometer (Thermo Scientific, Carlsbad, USA).  
 
cDNA preparation 
cDNA was synthesized using High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems® by Life Technologies, Carlsbad, USA) according to manufacturer’s protocol on the 
ProFlexTM Base PCR System (Applied Biosystems®, Life Technologies, Carlsbad, USA) using the 
following program: step 1: 10 min at 25 °C, step 2: 120 min at 37 °C, step 3: 5 min at 85 °C, step 
4: 4 °C. 50 ng of cDNA was preamplified using the TagMan® PreAmp Master Mix Kit (Applied 
Biosystems®, Life Technologies, Carlsbad, USA) with 14 cycles (holding stage: 10 min at 95 °C, 
cycling stage: 14 cycles of 15 s at 95 °C and 4 min at 60 °C). Preamplification linearity was 
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successfully verified previously. 
 
Quantitative real-time RT-PCR (qPCR) 
Gene sets representing key important classes of cation, anion, protein endocytosis, 
glucose transporters, and metabolizing enzymes with known roles in drug transport or proximal 
tubule function were selected. Quantitative Real-Time RT-PCR was performed using a 1:30 dilution 
of the PreAmp product on the StepOnePlusTM Real-Time PCR System (Applied Biosystems®, Life 
Technologies, Carlsbad, USA) using the following program: 2 min at 50 °C followed by 10 min at 
95 °C (holding stage), then a cycling stage of 40 cycles with 15 s at 95 °C and 1 min at 60 °C. 
TaqMan® Gene Expression Assays (Applied Biosystems®, Carlsbad, USA) were used for all genes 
of interest and endogenous controls (Table 4.1).  
 
Relative expression analysis 
Quantitative Real-Time RT-PCR data were analyzed using the StepOneTM Software 
(Applied Biosystems® by Life Technologies Corporation, Carlsbad, USA) and relative gene 
expression was analyzed using the 2-∆∆Ct method [447]. Potential endogenous control genes were 
tested for their stability by commonly used software methods: BestKeeper [448], NormFinder [449], 
GeNorm [450], and comparative delta-Ct method [451], as well as for their potentially statistically 
significant differences. Using these methods, the three most stable endogenous controls were 
chosen (GAPDH, RPL19, and PPIA) and their geometric mean and standard deviation of the entire 
reference gene sample size was calculated for further quantification of all genes of interest.  
 
Data analysis/ statistical analysis 
All data were analyzed with Microsoft Excel® 2013 (Microsoft Corporation, Redmond, USA) 
and GraphPad Prism 6 software (GraphPad Software Inc., San Diego, USA). All experiments were 
performed on three independent biological samples with three technical replicates each. All data 
are shown with mean (average) and standard deviation (SD). One-way analysis of variance 
(ANOVA) followed by Tukey’s multiple comparison post-hoc test or unpaired Student’s t-test were 
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performed to analyze statistically significant differences. Results were considered as statistically 
significant differences with a confidence interval of 95% (p<0.05).  
 
Results 
Validation of reference genes 
Quantitative RT-PCR indicates no statistically significant differences between the three 
time points of each reference gene (Figure 4.2). Furthermore, no statistically significant difference 
is observed between the two culture conditions at each time point for each reference gene (Figure 
4.3).  
To determine which reference gene to apply for data analysis, Bestkeeper, geNorm, and 
NormFinder Software were used to analyze reference gene Ct values [448-450]. Each analysis 
method consistently ascertained GAPDH, PPIA, and RPL19 as the most stable genes in proximal 
tubule fragments across the two different culture conditions and three culture time points used. 
Therefore, the geometric mean of these three reference genes is an appropriate choice for an 
accurate normalization strategy in proximal tubule expression analysis and was used for gene 
normalizations in this study. 
 
Transporter xpression in murine proximal tubule fragments 
Quantitative RT-PCR results showed that twenty (95%) of the 21 transporter genes tested 
from Table 4.1 were expressed in the harvested proximal tubule fragments after 3 days of culture 
and 19 (90%) were expressed after 7 days of culture. These results, normalized to endogenous 
control and expression at day 1 using the 2-∆∆Ct method, are consistent for both culture conditions: 








Comparison of mRNA expression in 3D proximal tubule HA gel versus  
nongel PT suspension cultures 
Figure 4.4 compares proximal tubule fragment gene expression as quantified for Table 4.1 
transporters for tubules cultured in 3D modified HA gel versus liquid media suspension. With the 
exception of MRP4, all genes were significantly downregulated when normalized to the geometric 
mean of the endogenous control genes GAPDH, PPIA, and RPL19. All genes show no statistically 
significant differences between the different culture conditions (analyzed by unpaired Student’s t-
tests, 95% confidence interval). Correlation of these data for the two proximal tubule culture 
systems is shown in Figure 4.5 (linear correlation factor shown is R2=0.97). 
 
Time-dependent changes in proximal tubule mRNA expression in different  
culture conditions 
Expression of OCT3 and PepT1 are significantly reduced (as analyzed by unpaired 
Student’s t-tests, 95% confidence interval) from the 3-day time point to the 7-day time point (Figure 
4.6). Similar down-regulation of gene expression over this time can be observed in all genes, 
though not statistically different from each other. 
 
Discussion 
Proximal tubule cell differentiation and transporter expression functionality is essential for 
validation of proximal tubules as screening tools for drug screening and toxicity testing. Therefore, 
gene expression profiles for 21 important proximal tubule transporters with known roles in drug 
transport or normal proximal tubule function [429, 452-455] are compared in 3D gel versus nongel 
cultures for proximal tubule isolates from murine primary kidney harvests. As 3D cell culture 
techniques are increasingly asserted to improve cell culture translational relevance for toxicity 
screening [1, 14], few studies actually compare critical phenotypic functional aspects of these 
models. Previous reports describe limitations or lack of equivalence between 2D cell monocultures 
with actual in vivo conditions and cell phenotypes [14, 58, 434, 435]. For example, HK-2 and Caki-
1, commonly used 2D cell lines [44, 59] for nephrotoxicity assays, lack expression of important 
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uptake transporters OAT1, OAT3, and OCT2 [58, 59]. Lack of phenotypic fidelity has been asserted 
to be an important limitation to the accuracy and predictability of in vitro cell-based toxicity assays 
[16, 25, 456, 457]. Hence, retention of key functional and phenotypic markers linked to relevant 
cell, tissue, and organ toxicity must be proven for model systems used for such screening. Cell 
source (e.g., primary versus immortalized), passage number, culture time, media-dependence and 
culture type all contribute to phenotypic fidelity and stability for such assays [16, 457, 458].  
Hydrogel and extracellular matrix mimicking polymer supports are often proposed to 
support cells and organoids in culture to preserve or enhance cell functional performance over 
standard 2D culture methods [16]. While many such 3D culture matrices are described, and even 
commercially available [14, 19, 103], few are validated to show improvements over 2D cell culture 
analogs [77, 78], including both existence and preservation of functional cellular markers relevant 
to each toxicity assay/cell type. 
Previous studies recently reported the 3D hydrogel-based murine proximal tubule drug 
toxicity assay and select responses to known nephrotoxic drugs [60, 65]. While demonstrating the 
value of this new culture concept to improve predictability of nephrotoxicity screening in general, 
those studies did not provide comprehensive analyses of key genes associated with known 
proximal tubule transporters and associated nephrotoxicity. This study’s mRNA expression data for 
the same system now support the longevity of the 3D HA gel and nongel, media-based proximal 
tubule models up to 7 days. Moreover, the similarities of 3D HA gel gene expression with nongel 
expression indicates that gel embedding does not affect gene expression in these constructs. 
Expression of functioning, encoded proteins for these 21 genes is not reported due to the difficulties 
in quantifying membrane protein abundance – a major technical challenge for proteomics. mRNA 
expression data remains the most qualified alternative and studies have shown correlations 
between mRNA and protein expression levels [459, 460]. 
Results in Figure 4.4 show that after 3 days in both culture systems, 95% of the 21 
transporter genes remain expressed in the proximal tubule fragments, and 90% after 7 days but at 
reduced levels. This shows superiority of these proximal tubule models to traditional 2D kidney cell 
lines, like HK-2 and Caki-1 that do not exhibit relevant gene expression profiles. Hilgendorf et al. 
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showed that transporter expression levels are not only lower in Caki-1 cell lines, but also that these 
cell lines showed narrower transporter expression profiles than kidney tissue [59]. On a statistical 
basis, their rank correlation analysis between kidney tissue expression levels and Caki-1 cell line 
expression levels shows only a coefficient of k’=0.12 [59] due to a general trend of lower expression 
levels in 2D cell line cultures. Similarly, Jenkinson et al. found that HK-2 cells, commonly used for 
nephrotoxicity studies [44] have limited value due to their low mRNA expression profiles of 
important drug transporters compared to renal cortex samples [58]. Their results show that mRNA 
expression of the SLC22 transporter family (OAT1, OAT3, and OCT2) is absent in HK-2 cells [58].  
In contrast, the primary proximal tubule models demonstrate significant expression of these 
transporters for up to a week, and perhaps longer. Significantly, expression of important efflux 
transporters MDR1, MRP2, and MRP4 located at the tubule apical membrane surface and also 
uptake transporters OAT1, OAT3, and OCT2 on the basolateral membrane surface is shown, 
improving on the limited retention of proximal tubule characteristics reported by Jenkinson et al. for 
HK-2 cells [58]. OAT1, OAT3, and OCT2 in particular are key transporters in kidney drug transport 
and filtration [431, 461, 462] and highly expressed in human tissue samples [58, 59]. Lack of their 
expression in HK-2 cells [58, 463] as well as in Caki-1 cells [59] limits the relevance and predictive 
value of these culture models for nephrotoxicity studies. More relevant nephrotoxicity models that 
represent functional equivalents to proximal tubules in vivo are therefore required. Data presented 
here support the presence of requisite kidney transporters in an intact proximal tubule organoid-
type 3D model, and therefore further completes our previous characterization data for this model 
[47, 60]. This also improves the knowledge that supports the importance of this model in further 
validation against known nephrotoxic drugs so that a meaningful translation/correlation between 
this model’s data and human in vivo data can be made. We assert that this model can yield 
important information about potential mechanisms of toxicity, one of the most important criteria for 
useful in vitro toxicity models [464, 465].  
To enable this proximal tubule in vitro model for handling in high throughput screening 
formats (e.g., multiwell plates, robotics fluid handling systems, screening platforms), we previously 
investigated encapsulation of harvested proximal tubule fragments in a modified, biomedical-grade 
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hyaluronic acid and PEG-diacrylate hydrogel [47, 60]. This 3D matrix encapsulation provides 
several culture enhancements, including direct gel formation in the presence of added proximal 
tubules, improving downstream handling of cultures through fluidics dispensing into 96-well plates, 
media exchange and drug candidate additions and dispersion of known amounts of proximal 
tubules within a viscous 3D matrix without settling, or compromising tubule integrity or amount. 
Additionally, this hyaluronic acid hydrogel limited the out-migration of proximal tubule cells from 
fragments into the gel matrix in culture, a complication of using collagen-based gels for this 
application [151, 466, 467]. The result of this approach was retention of several important 
nephrotoxic-relevant attributes in these proximal tubule 3D hydrogel cultures in toxicity assays 
compared to secondary kidney cell line 2D cultures [47, 60]. 
This study now adds additional veracity to these previous claims for functional and more 
reliable nephrotoxicity improvements to this culture method, showing that intact proximal tubules 
retain relevant gene expression profiles for kidney transport and toxicity processing, and addition 
of the 3D hydrogel embedding matrix does not compromise or alter gene expression profiles (see 
Figures 4.3-4.5). Analysis of the gel matrix on the endogenous mRNA expression controls (Figures 
4.2 and 4.3) also shows that the gel matrix has no observable influence on reference gene stability, 
and therefore risks of data artifacts or falsification from varying reference gene expression are 
minimized (Figure 4.3). The correlation analysis for the two different proximal cell culture conditions 
supports their comparable expression profiles (correlation factor of R2=0.97, Figure 4.5). The plot’s 
y-intercept close to zero (-0.86) and the plot slope close to one (1.07) indicate that there is no 
difference between the relative gene expression profile of the HA gel embedded PT cultures and 
the nongel PT cultures.  
Although most nephrotoxicity screens are performed within 24 h, mRNA expression levels 
for critical transporters are shown here to be measurable to 7 days in these cultures (e.g., see 
Figure 4.4) – further time points might even be possible. Figure 4.6 shows an overall trend of down-
regulation of expression levels from 3 to 7 days and, with the exception of OCT3, all genes retain 
expression to 7 days. In vitro drug toxicity studies in these proximal tubule cultures could therefore 
be conducted up to 7 days depending on the genes of interest, and the drug or toxin applied. 
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In conclusion, this study extends earlier assertions of functional equivalence of primary 3D 
gel-based proximal tubule cultures for improving the predictability and reliability of in vitro 
nephrotoxicity screening over existing 2D kidney monocultures [47, 58-60]. Broad proximal tubule 
cell transporter expression known to be critical for nephrotoxicity is shown over extended culture 
times. While it is known that some transporters in rodents are different than in humans [455], these 
phenotypic and genotypic comparisons are essential to validate these (and any) in vitro assay 
system seeking to improve the quality and reliability of nephrotoxicity predictions from in vitro 
models to humans by using predictive correlation, and not a 1:1 identical response. Further 3D 
nephrotoxicity assay enhancements might include fluidics interfacing, miniaturization, and 
interfacing with other in vivo-mimicking biotransformation pathways (e.g., cytochrome p450 
metabolic processing from gut and liver microsomes). Additionally, the 3D kidney-based model can 
be extended to understand the impact of new drug candidate structure-activity relationships in 
proximal tubule pharmacology and exploiting proximal tubule mutations in driving mechanism for 
drug toxicity.  
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Table 4.1 TaqMan® Gene Expression Assays used for qPCR analysis in this study. The table 





























Gapdh Mm99999915_g1 NM_001289726.1 Mm.304088 14433 Chr.6: 125161338 
- 125166511 2-3 117 107
PPIA peptidylprolyl isomerase A Ppia Mm02342429_g1 NM_008907.1 Mm.5246 268373
Chr.11: 6415870 
- 6419810 3-4 232 112
RPL19 ribosomal protein L19 Rpl19 Mm02601633_g1 NM_001159483.1 Mm.10247 19921 Chr.11: 98023080 
- 98030493 5-6 517 69
OCT1
solute carrier family 22 
(organic cation 
transporter), member 1
Slc22a1 Mm00456303_m1 NM_009202.5 Mm.594 20517 Chr.17: 12648874 
- 12675838 3-4 856 69
OCT2
solute carrier family 22 
(organic cation 
transporter), member 2
Slc22a2 Mm00457295_m1 NM_013667.2 Mm.17322 20518 Chr.17: 12583958





Abcb1b Mm00440736_m1 NM_011075.2 Mm.146649 18669 Chr.5: 8798147
- 8866315 20-21 2624 70
OCTN1
solute carrier family 22 
(organic cation 
transporter), member 4
Slc22a4 Mm00457739_m1 NM_019687.3 Mm.274590 30805 Chr.11: 53983123
- 54028662 8-9 1568 73
OCTN2
solute carrier family 22 
(organic cation 
transporter), member 5
Slc22a5 Mm00441468_m1 NM_011396.3 Mm.42253 20520 Chr.11: 53864542
- 53891799 5-6 1109 74
OCT3
solute carrier family 22 
(organic cation 
transporter), member 3
Slc22a3 Mm00488294_m1 NM_011395.2 Mm.99252 20519 Chr.17: 12419972





Abcc2 Mm00496899_m1 NM_013806.2 Mm.39054 12780 Chr.19: 43782308





Abcc4 Mm01226381_m1 NM_001033336.3 Mm.40537 239273 Chr.14: 118482692
- 118707620 30-31 3978 99
OAT1
solute carrier family 22 
(organic anion 
transporter), member 6
Slc22a6 Mm00456258_m1 NM_008766.3 Mm.30090 18399 Chr.19: 8617996
- 8628299 8-9 1644 95
OAT3
solute carrier family 22 
(organic anion 
transporter), member 8
Slc22a8 Mm00459534_m1 NM_001164634.1 Mm.285294 19879 Chr.19: 8591254
- 8611835 5-6 983 63
SGLT2
solute carrier family 5 
(sodium/glucose 
cotransporter), member 2
Slc5a2 Mm00453831_m1 NM_133254.3 Mm.38870 246787 Chr.7: 128265697
- 128272433 3-4 298 79
Megalin low density lipoprotein 
receptor-related protein 2 Lrp2 Mm01328171_m1 NM_001081088.1 Mm.23847 14725
Chr.2: 69424335
- 69586067 77-78 13926 91
Cubilin cubilin (intrinsic factor-
cobalamin receptor) Cubn Mm01325077_m1 NM_001081084.2 Mm.313915 65969
Chr.2: 13276338
- 13491876 64-65 10418 64
PepT1
solute carrier family 15 
(oligopeptide 
transporter), member 1
Slc15a1 Mm04209483_m1 NM_053079.2 Mm.155618 56643 Chr.14: 121459621
- 121505254 14-15 1096 80
PepT2
solute carrier family 15 
(H+/peptide transporter), 
member 2
Slc15a2 Mm00451610_m1 NM_001145899.1 Mm.281804 57738 Chr.16: 36750164
- 36785157 5-6 738 69
AQP1 aquaporin 1 Aqp1 Mm00431834_m1 NM_007472.2 Mm.18625 11826 Chr.6: 55336299
- 55348555 1-2 581 64
AQP2 aquaporin 2 Aqp2 Mm00437575_m1 NM_009699.3 Mm.20206 11827 Chr.15: 99579056




transporting, alpha 1 
polypeptide
Atp1a1 Mm00523255_m1 NM_144900.2 Mm.193670 11928 Chr.3: 101576219





Abcb1a Mm00440761_m1 NM_011076.2 Mm.207354 18671 Chr.5: 8567091
- 8748575 20-21 2610 82
CYP3A11
cytochrome P450, family 
3, subfamily a, 
polypeptide 11
Cyp3a11 Mm00731567_m1 NM_007818.3 Mm.332844 13112 Chr.5: 145854607
- 145879854 10-11 1108 128
GGT gamma-glutamyltransferase 1 Ggt1 Mm00492322_m1 AK079235.1 Mm.4559 14598
Chr.10: 75564114






Table 4.2 Common renal cell sources used in drug screening assays. 
Cell 



























































Primary  [57, 61, 62] 
 











































Figure 4.2 Reference gene controls. Endogenous control stability over time (1, 3, and 7 days) 
determined by qPCR in either nongel media suspension (A-C) or HA gel-embedded (D-F) 
isolated proximal tubule fragments. Used endogenous controls: GAPDH (A,D), PPIA (B,E) and 
RPL19 (C,F). Raw Ct values (y-axis) of each reference gene per time point (x-axis) are 
displayed. Each bar shows mean ± standard deviation (SD) from three individual biological 
samples (n=3) analyzed in triplicates. One-way analysis of variance (ANOVA) followed by 
Tukey’s multiple comparison post-hoc test between all time points was performed. No 





















































Figure 4.1 PT transporters with known roles in drug transport or PT function and their location. 
Gene sets used in this study represent important classes of cation (green), anion (blue), protein 
endocytosis (red), glucose (gray) transporters, metabolizing enzymes (white) and other 
transporters (yellow). Proximal tubule epithelial cells enclose the lumen in a monolayer of 
polarized cells. The microvilli-rich, apical membrane is facing the lumen, while the basolateral 
membrane faces the blood side. (Figure modified with permission from SOLVO Biotechnology 













Figure 4.3 Replot of Figure 4.2 data.  Comparison of the 
endogenous control stability between culture conditions 
(nonembedded proximal tubules shown in black, HA gel-
embedded proximal tubule shown in white) determined at 
different time points.Raw Ct values (y-axis) of each 
reference gene (GAPDH (A), PPIA (B), RPL19 (C)) per 
time point (x-axis) are displayed. The bars show the mean 
± standard deviation (SD) from three individual biological 
samples (n=3) analyzed in triplicates. Unpaired Student’s 
t-tests were performed between each culture condition on 
each time point. No statistically significant differences 




































Figure 4.4 qPCR analysis of transporter gene expression in proximal tubule fragments. Relative 
expression of proximal tubule transporters with known roles in drug transport or proximal tubule 
function of embedded (shown in white) or nonembedded (shown in black) proximal tubule 
fragments. Expression levels are shown after (A) 3 days and (B) 7 days in culture. The bars 
represent the mean relative expression level and the error bars indicate the standard deviation 
(SD) from three individual biological samples (n=3) analyzed in triplicate. ≠ indicates absence of 
gene expression. Unpaired Student’s t-tests were performed for each gene between the two culture 
conditions. No statistically significant differences between the embedded and nonembedded 







Figure 4.5 Correlation analysis of relative expression levels. Relative expression levels in modified 
HA gel embedded proximal tubule fragments (y-axis) and proximal tubule fragments suspended in 
media (x-axis).Correlation coefficient (R2) is provided 
 
Figure 4.6 qPCR analysis of transporter gene expression in proximal tubule fragments. Relative 
expression change over time (3 days expression levels shown in white, 7 days expression levels 
shown in black). Expression levels are shown of (A) in modified HA gel embedded proximal tubules 
and (B) nonembedded proximal tubules. The bars represent the mean relative expression level 
and the error bars indicate the standard deviation (SD) from three individual biological samples 
(n=3) analyzed in triplicate. ≠ indicates absence of gene expression. Unpaired Student’s t-tests 
were performed for each gene between the two time points. Statistically significant differences 
(p<0.05) between the two different time points are indicated by asterisks 







AN EX VIVO 3D KIDNEY PROXIMAL TUBULE MODEL IMPROVES PREDICTIONS 
OF CLINICAL DRUG-INDUCED NEPHROTOXICITY3 
 
Abstract 
The inhibitor constant, Ki, is an indication of how potent an inhibitor is; it is the concentration 
required to produce half maximum inhibition. The inhibitor constant, Ki, is an indication of how 
potent an inhibitor is; it is the concentration required to produce half maximum inhibition. Drug 
attrition and clinical product withdrawals due to nephrotoxicity remain a major challenge for 
pharmaceutical drug development pipelines. Currently, no reliable high-throughput in vitro 
screening models are available that provide reliable, predictive toxicology data for clinical 
nephrotoxicity. The fidelity of drug screening assays to predict toxicity and desired pharmacology 
assessments is compromised by standard two-dimensional (2D) cell monoculture models common 
to drug development. Here we extend the use of our previously reported murine three-dimensional 
(3D) kidney organoid proximal tubule model to provide ex vivo drug toxicity data that reliably 
compare to clinical experiences and that improve nephrotoxicity predictions. Proximal tubule 
cytotoxicity (via ATP depletion) was monitored for 9 compounds (cimetidine, cidofovir, cisplatin, 
doxorubicin, gentamicin, polymyxin B, polymyxin B nonapeptide, probenecid, and vancomycin) in 
the 3D proximal tubule ex vivo model. Drug concentration-response curves and their IC50, LEC, 
and AUC values were calculated and compared to clinical therapeutic exposure levels (Cmax). The 
100-fold Cmax threshold demonstrated the most sensitivity (96.6%) and specificity (88.9%) for this 
assay with a high positive (96.6%) and negative (88.9%) predictive value for nephrotoxicity. These 
                                                     
3
 Diekjürgen, Dorina and Grainger, David. An ex vivo 3D kidney proximal tubule model improves predictions of 
clinical drug-induced nephrotoxicity. Toxicological Sciences, submitted 2017 
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results support the model’s capability to predict substrate-inhibitor/competitor interactions, in 
addition to yielding changes in toxicity similar to those in vivo. Our approach demonstrates the utility 
of 3D proximal tubule cultures in drug screening assays that better predict nephrotoxicity and yield 
more insight into the complex mechanisms implicated in nephrotoxicity. This study offers a new 
approach for rapid drug toxicity testing with more reliable clinical comparisons than current 2D cell 
culture screening models.  
 
Introduction 
Kidney toxicity is the second highest cause of new drug failure after liver toxicity, resulting 
in many adverse pharmaceutical drug performance issues in clinical trials [91]. The lack of reliable 
drug candidate identification and reliable toxicity screening methods result in costly consequences 
when drugs fail late in the development process [92]. Currently, only 8% of new pharmaceutical 
compounds tested in clinical trials receive regulatory approval [65]. This low success rate does not 
sufficiently balance against drug development efforts (typical timeframes averaging 9 years) and 
associated expenses (~$1-2 billion) [65]. Hence, improved predictive testing models to screen drug 
toxicity in early research stages that facilitate more reliable elimination of toxic drug candidates well 
before clinical trials is required [91]. 
Besides the liver, the kidney is a primary drug metabolism and elimination site. Therefore, 
kidney cells are essential components for many systemic drug toxicity models. The currently used 
screening models for nephrotoxicity eliminate only about 7% of pharmaceutical compounds in 
preclinical tests, correlating poorly to drug-induced acute renal failure cases estimated between 30-
50% [93-95]. This suggests that a considerable validity gap exists between current in vitro 
screening approaches and physiological responses seen both in clinical trials and after drugs reach 
the marketplace [93, 96, 97].  
Kidney proximal tubules play a major role in xenobiotic secretion and metabolism, and 
therefore are primary target sites of drug-induced nephrotoxicity. This is attributed to specialized 
transporters (e.g., OAT1, OAT3, OCT2) within proximal tubules responsible for the uptake of 
organic compounds on their basolateral membrane [420-422]. This active transport then results in 
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high levels of toxins within proximal tubule epithelial cells, leading to cellular damage and death 
[423, 424]. Proximal tubule physiology figures prominently into their practical and predictive utility 
as drug toxicity screening model, yet is poorly accommodated in cell monocultures on plastic 
cultureware in vitro.  
Previously, many different three-dimensional (3D) cell culture systems have exhibited 
performance advantages over conventional two-dimensional (2D) cell monocultures in vitro drug 
screening standards in pharmaceutical industry currently used in combination with animal studies 
[14]. In 2D cell culture, primary proximal tubule cells lose their apical-basal polarization rapidly, 
sometimes within minutes of culture [102, 468, 469]. Immortalized kidney secondary cell lines (e.g., 
HK-2, Caki-1, LLC-PK1, OK) are often missing important transporters relevant to drug toxicity [98]. 
By contrast, 3D cultures of renal proximal tubule cells demonstrate more abundant and enduring 
apical and basal transporter expression than transporters in 2D cell lines [12], suggesting their 
more reliable response to pharmaceutical compounds. 3D cell culture models generally exhibit cell 
morphology and physiology better resembling in vivo characteristics versus 2D cell culture lines 
[432, 433]. Furthermore, 3D cell cultures respond with more in vivo-like behaviors than 2D cell 
cultures [434, 435]. Therefore, recent strategies emphasize a shift away from homogenous 
monolayer-cultured cells on rigid plastic plates to more promising 3D culture systems with 
biomaterials architectures similar to tissue constructs (i.e., organoids, micro-tissues, spheroids and 
cells in hydrogel matrices of various chemistries) [103, 104]. 
To enhance proximal tubule epithelial cells to retain their native proximal tubule organ 
structure, we recently developed a murine 3D kidney organoid toxicity ex vivo model fulfilling many 
functional drug screening criteria and improvements over current 2D kidney cell monocultures on 
plastic. This model comprises viable mouse kidney-derived proximal tubule fragments in 
suspension culture amenable to multiwell scaling and screening assays [12, 60]. This 3D approach 
keeps the proximal tubule extracellular matrix with innate natural cell-cell communications intact, 
maintains differentiated cellular states, and preserves cell-specific tubule functionalities [60]. 
Kidney proximal tubule cells therefore reside and interact in these 3D cultures in a more natural 
environment, reflecting toxicity responses with more fidelity when interacting with administered drug 
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compounds. Additionally, previous work has shown that known proximal tubule markers and 
important proximal tubule transporters with known roles in drug transport are retained in this 3D 
proximal tubule culture model, exhibiting better expression levels and profiles than commonly used 
2D kidney cell lines [12]. 
Given the current high rates and high costs of drug failures, and poor predictive capacities 
and costs of animal testing, new drug testing models must be highly sensitive to drug concentration, 
minimize animal use, and be suitable for high-throughput screening modalities. New testing models 
that respond accurately to pharmaceutical compounds and allow for human clinical comparison 
must be validated. To do so for our newly developed 3D proximal tubule organoid model [12, 60], 
3D proximal tubule fragment cultures were exposed in this present work to known nephrotoxins 
(cidofovir, polymyxin B, gentamicin, cisplatin, doxorubicin, vancomycin, and polymyxin B 
nonapeptide) and also nonnephrotoxins (probenecid and cimetidine) and analyzed for toxicity dose-
response outcomes. This model is shown to be capable of accurately predicting nephrotoxicity for 
all tested compounds and produced toxicity responses highly correlated to known human clinical 
experiences with the same agents. Therefore, the model is most promising for reliable toxicity 
screening of novel compounds during early phases of drug development. Furthermore, this model 
could be further used to gain insight into specific drug structural mechanisms that drive toxicity, and 
facilitate rapid assay of different chemical moieties during structure activity relationship screening.  
 
Materials and methods 
Materials 
All reagents and compounds were purchased from Sigma-Aldrich (St. Louis, USA) or 
Invitrogen (Carlsbad, USA). Cell culture consumables were purchased from ThermoFisher 
Scientific (Hampton, USA) unless noted otherwise. The CellTiter-Glo® 3D Cell Viability Assay was 







Compound nephrotoxin classifications were collected from Micromedex 
(www.micromedex.com). Classical terminologies for renal injury (e.g., nephrotoxicity, renal 
damage) were used to identify compounds with reported clinical adverse events. If no reports for 
nephrotoxicity were evident, then the compound was classified as nonnephrotoxic. Maximum 
plasma concentrations (Cmax) and nephrotoxicity incidences were acquired from Micromedex, 
PubMed, and FDA drug labels for all compounds used here unless otherwise stated. Collected Cmax 
values were after single-dose administration at commonly recommended therapeutic doses as 
previously described [470]. The compounds were selected to represent different therapeutic drug 
classes.  
 
Murine proximal tubule harvest and isolation 
Male C57BL/6 mice were purchased (age 6-8 weeks, Charles River Laboratories 
International, Inc., Wilmington, USA) and fed and housed and acclimated in climate and light cycle 
controlled, approved murine vivarium conditions. All animals were euthanized using carbon dioxide 
(CO2) in accordance with University of Utah IACUC-approved protocols. Kidneys were harvested 
and proximal tubules were isolated using a mechanical technique followed by enzymatic digestion 
as previously described [60, 443]. Briefly, kidneys were removed surgically under standard aseptic 
conditions in a BSL2-certified laminar flow hood. The kidney capsule, ureter and blood vessels 
were removed and the isolated kidneys were mechanically disrupted by using a sterilized razor 
blade followed by enzymatic digestion with 2 mg/ml hyaluronidase (Worthington Biochemical 
Corporation, USA), 3 mg/ml collagenase IV (Worthington Biochemical Corporation, USA), and 
0.1 mg/ml DNase I (Sigma Aldrich, USA) in KREBS solution (145 mM NaCl, 10 mM HEPES, 5 mM 
KCl, 1 mM NaH2PO4, 2.5 mM CaCl2, 1.8 mM MgSO4, 5 mM glucose, pH 7.3) at 37 °C [444]. To 
isolate the proximal tubules from the digested sections, sequential 250 µm and 70 µm mechanical 
sieving was used [443]. Resulting proximal tubule fragments were pelleted by centrifugation and 




Proximal tubule (PT) cultures 
Murine proximal tubule fragments (approximate size range of 70-250 µm) were 
resuspended in proximal tubule media comprising Dulbecco’s Modified Eagle Medium/Nutrient 
Mixture F-12 with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid and L-glutamine (Invitrogen, 
USA). Additionally, 1% fetal calf serum (Invitrogen, USA), 5% sodium pyruvate (Invitrogen, USA), 
10% nonessential amino acids (Invitrogen, USA), 10% insulin/transferrin/selenium (Invitrogen, 
USA), 1% antibiotic-antimycotic (Invitrogen, USA), and 0.9 µg hydrocortisone (Invitrogen, USA) 
were added [443]. The media was phenol-red free to avoid possible interference of luminescence 
signals through the pH indicator alone [469]. Finally, 100 µl proximal tubule media containing 
approximately 1000 proximal tubules was added to each well of a 96-well plate well. Plates were 
then incubated in cell culture incubators under 5% CO2 and 95% air at 37 °C. 
 
Compound preparation and model exposure 
All bioactive compounds were dissolved in UltraPureTM Distilled Water (ThermoFisher, 
USA) to obtain stock solutions (no insolubility or precipitation was seen with any compounds, 
assessed by visual inspection) and stored according to the manufacturer’s information. For all 
compounds, six concentration dilutions in PT media were prepared fresh prior to addition to cell 
culture wells to obtain final indicated concentrations. Final compound concentration ranges were 
1-1000 µM. Potential compound precipitation was again assessed after dilution in media by visual 
inspection and no precipitation was seen for any of the compounds. Proximal tubule fragments 
were exposed to the various compounds at each concentration in PT media replicates for 24 h in 
cell culture incubators under 5% CO2 and 95% air at 37 °C.  
To analyze the 3D assay model’s ability to reveal kidney tubule epithelial cell substrate-
inhibitor competitive interactions, the toxic drug alone and the same drug in combination with a 
potent, receptor-specific inhibitor/competitor selected from the 9 compounds was tested. In this 
case, each concentration over the full concentration range (1-1000 µM) of toxic drug was co-
administered with 30 µM of the selected, matched inhibitor/competitor in PT media replicates for 
24 h in cell culture incubators under 5% CO2 and 95% air at 37 °C. This 30 µM concentration was 
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chosen as each inhibitor/competitor alone did not exhibit a toxic response at this concentration 
(Figure 5.1). This indicates that any change in toxicity would reflect the coadministration and not 
that from the selected inhibitor/competitor alone. Assays with compounds, controls of vehicle only 
(media), and positive control (1% Triton X-100 in PT media) were screened in biological triplicate 
with three technical replicates. 
 
Cytotoxicity (ATP depletion) assay 
For compound testing, proximal tubule (PT) fragment cultures were seeded at 1000 PT 
fragments/well in solid white 96-well plates in 100 µl PT media and allowed to recover from harvest 
at 37 °C under humidified atmosphere and 5% CO2 and 95% air for 24 h before test compound 
addition/exposure. After 24-h compound exposure, cellular adenosine triphosphate (ATP) 
concentrations were assessed using the CellTiter-Glo® 3D Cell Viability Assay following 
manufacturer’s protocols (Promega, USA): Briefly, an equal amount (100 µl) of assay reagent was 
added to proximal tubule cultures cooled to room temperature, followed by orbital shaking of the 
plate for 5 min and additional 10 min of incubation in the dark. Wells were then read for luminescent 
light intensity using a Synergy 2 Multi-Mode Reader (Biotek, USA). The luminescence assay is 
based on the luciferase/luciferin reaction that determines the number of viable cells based on ATP 
levels. No interference between the test compounds and the assay itself was observed (data not 
shown).  
 
Toxicity assay output parameter profiling 
Three different toxicity output parameters were used to evaluate this model’s ex vivo 
toxicity from the ATP assay concentration-response curves for each compound. The molar 
concentration of each test compound producing 50% inhibition (IC50) was calculated using three-
parameter nonlinear regression with a Hill slope of -1 and upper and lower values constrained to 
100 and 0, respectively. The lowest effective concentration (LEC) of each drug was determined as 
the first compound concentration producing toxicity outside the normal viable cell population (mean 
± 3 standard deviations (SD)) for the negative controls. Area Under the concentration-response 
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Curve (AUC) as well as under the Receiver Operating Characteristic (ROC-AUC) curve were 
calculated and expressed unitless as at least one of the axes is expressed in percent.  
 
Data analysis/statistical analysis 
All data were analyzed with Microsoft Excel® 2013 (Microsoft Corporation, Redmond, USA) 
and GraphPad Prism 6 software (GraphPad Software Inc., San Diego, USA). Concentration-
response curves were plotted for each test compound and expressed relative to vehicle (no drug) 
control ±SD. All experiments were performed on three independent biological samples with three 
technical replicates each. All data are shown with mean (average) and standard deviation (SD). 
One-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison post-hoc test or 
unpaired Student’s t-test were performed to analyze statistically significant differences. Results 
were considered as statistically significant differences with a confidence interval of 95% (p<0.05). 
To consider an assay response as positive, the following criteria had to be fulfilled: 1) statistically 
significant change compared to vehicle control (no drug), 2) unless the statistically significant 
response change was seen at the highest concentration, the compound had to follow a 
concentration-response relationship, and 3) a biologically meaningful (e.g., decrease in 
mitochondrial function, decrease in ATP level) result had to be shown. If a response did not meet 
these criteria, it was considered to be negative.  
Therapeutic index (TI) was calculated by dividing the acquired cytotoxicity parameter (IC50, 
LEC and AUC) by each compound’s maximum therapeutic plasma concentration (Cmax). F-tests to 
compare the concentration-response curves were performed in Graphpad Prism. The Z’-factor, a 
measurement of assay quality (signal dynamic range and data variation) [471] was derived from 
the raw data using Microsoft Excel® 2013. A Z’ value between 0.5 and 1 indicates good, robust and 
reliable assay quality [471]. Receiver operator characteristic (ROC) curves were plotted using 
Graphpad Prism and used to examine paired true positive (sensitivity) and false-positive 
(specificity) rates for all TI thresholds of the model [472]. True positives (TP) are defined as 
nephrotoxic compounds that provide positive 3D assay results, while true negatives (TN) are those 
for nonnephrotoxic compounds that provide negative results in the 3D culture model. Assay 
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sensitivity was calculated by dividing the TP value by the total number of nephrotoxins used in this 
study. Specificity was calculated by dividing the TN value by the total number of nonnephrotoxic 
compounds used in this study. The Youden’s index was calculated to determine the optimal cut-off 
value, which is defined as the maximum value of the index [473]. The ROC curves were generated 
by plotting sensitivity against 1-specificity at different Cmax threshold levels. Additionally, the positive 
predictive value (PPV) was calculated by dividing the TP value by the total number of positive 
results and the negative predictive value (NPV) was calculated by dividing the TN value by the total 
number of negative results [474]. 
 
Results 
3D proximal tubule model for ex vivo toxicity profiling 
The cellular ATP-based CellTiter-Glo® 3D Cell Viability (Promega, USA) assay is used to 
determine ex vivo drug-induced nephrotoxicity testing in the 3D proximal tubule fragment culture 
model. To validate the linear range of the assay to avoid saturation of signal intensity or other 
artifacts, assay signal versus proximal tubule seeding density was first determined and analyzed 
using Z’-factor calculation (value between 0.5-1.0 required [471]) prior to testing selected 
compounds (data not shown). Subsequently, compound concentration-response curves (Figure 
5.1) for 9 different drugs (nephrotoxic and nonnephrotoxic) and respective IC50, LEC, and AUC 
values were calculated as described in Materials and methods (Table 5.1). While it has been 
previously recommended that drugs in such in vitro assays be tested at 30-100 times the human 
therapeutic Cmax [470, 475, 476], all drugs were tested at fixed concentrations ranging from 1-1000 
µM to account for the observation that in early drug development phases, clinical Cmax values are 
unknown. This facilitates seamless adoption of the model for routine ex vivo toxicity screening in 
early drug development stages. A full overview of the results from validation of this drug set is 






Correlation of different toxicity output parameters and zone classification  
of compounds with similar toxicity profiles based on IC50 and LEC 
To compare different toxicity output parameters commonly used in ex vivo toxicity studies, 
three different parameters (IC50, LEC, AUC) are calculated. Figure 5.2 compares the Cmax-
normalized IC50 against the Cmax-normalized LEC values, exhibiting a good correlation (0.9998-1 
linear correlation factor, Figure 5.2). Additionally, IC50 (Figure 5.3 A) and LEC (Figure 5.3 B) results 
are plotted against the clinical Cmax values, and the model identifies one zone that only includes 
nephrotoxic drugs (i.e., below the divider line shown in each plot). Therefore, the model correctly 
identified compounds in this validation set as nephrotoxic (e.g., cidofovir, cisplatin, polymyxin B, 
polymyxin B nonapeptide, doxorubicin, and gentamicin) and nonnephrotoxic (e.g., cimetidine and 
probenecid) within the tested concentration range using the IC50 toxicity output parameter (Figure 
5.3 A) and one false negative outlier is observed when using the LEC toxicity output parameter 
(Figure 5.3 B). 
 
Determination of safe drug exposure values based on different toxicity  
output parameters 
To determine safe drug exposure values from our model, TI threshold analysis was 
performed. Visualization of the relationship between the IC50 and Cmax for each tested compound 
is shown in Figure 5.4: the higher the IC50 value the less toxic a compound is. Additionally, Figure 
5.4 shows that very toxic drugs either demonstrate similar IC50 and Cmax values (e.g., polymyxin B 
and cisplatin) or very low Cmax values (e.g., doxorubicin). Use of multiplied Cmax values leads to 
more robust and predictive toxicity assessments, especially the 100x Cmax [470, 475-477]. Using 
this approach, a drug producing an in vitro response below 100x of its in vivo Cmax is considered 
toxic [470, 475-477]. To determine if the 100x Cmax threshold is also appropriate for the 3D proximal 
tubule nephrotoxicity model (or if perhaps a different threshold is more applicable), the assay 
sensitivity and specificity for multiple different-fold increases of Cmax (range 1-1000-fold) was 
determined. This analysis was performed for two different toxicity output parameters: IC50 and LEC 
(calculated as previously described in Materials and methods). These predictions are shown in 
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Table 5.2. Overall, at high TI thresholds, classification of nephrotoxic compounds by the 3D assay 
is more correct (i.e., higher number of true positives), while at lower TI thresholds the correct 
classification of nonnephrotoxic compounds dominates (i.e., lower number of false positives).  
ROC curves for the two output parameters (IC50 and LEC) were then generated in Figure 
5.5. The ROC curve for IC50 is closer to the upper-left corner, indicating that this parameter offers 
better predictive value for nephrotoxicity in the 3D ex vivo kidney model. The calculated ROC-AUC 
values of 0.9638 and 0.9400 for the IC50 and LEC, respectively, are shown in Table 5.3. The higher 
the ROC-AUC, the more predictive the toxicity model (i.e., values >0.5 indicate predictability greater 
than chance [472]).  
ROC curves can be also used to determine the appropriate cut-off levels for compound 
toxicity. In this 3D proximal tubule ex vivo model, a 100-fold Cmax provided the highest combination 
of sensitivity and specificity, calculated by the Youden’s index, and therefore, the optimal cut-off 
value. Using this threshold, the assay sensitivity was 96.6% for both IC50 and LEC values, and 
assay specificity was 88% and 66.7% for IC50 and LEC, respectively. Comparing between different 
Cmax TI cutoff values, assay sensitivity increases significantly from 6.9% at 1x Cmax to 75% at 30x 
Cmax and finally 96.6% at 100x Cmax for IC50. Assay specificity decreases from 100% at 1x and 30x 
Cmax to 88% at 100x Cmax. A similar trend was seen for LEC: sensitivity increases significantly from 
37.9% (1x Cmax) to 93.1% (30x Cmax) to 96.6% (100x Cmax), and specificity decreases from 100% 
(1x Cmax) to 77.8% (30x Cmax) to 66.7% (100x Cmax) – see Table 5.2. Therefore, both toxicity output 
parameters achieved good assay sensitivity values at 100x Cmax (96.6%) but the IC50 parameter 
showed better specificity (88%) compared to that for the LEC parameter (66.7%). Additionally, the 
positive predictive value (PPV, defined as the probability that the compound is toxic when the 3D 
model result is positive) and negative predictive value (NPV, defined as the probability that the 
compound is nontoxic when the 3D model result is negative) were also determined. These values 
also show better results for the IC50 parameter (96.6% PPV, 88.9% NPV) compared to the LEC 





Validation of the 3D proximal tubule model for compound nephrotoxicity testing 
To validate whether nephrotoxicity can be reliably predicted with this 3D proximal tubule 
ex vivo model, the calculated IC50 values were normalized by different clinical Cmax literature data 
and plotted against documented clinical nephrotoxicity incidences at that specific Cmax 
concentration (Figure 5.6). Each dot represents data from a different clinical drug exposure level 
and the resulting toxicity incidence percent (y-axis) compared to normalized IC50 values from the 
3D toxicity model (x-axis). This correlation provides a valuable comparison of the outcomes of the 
3D toxicity model parameters with known human effects in vivo. The closer the dot is located to the 
top right corner, the higher the risk of clinical nephrotoxicity, indicated by the arrow (Figure 5.6). 
 
Mechanistic (substrate-inhibitor) insights from the 3D proximal tubule model  
using paired compounds 
The influence of coadministration of selected clinically relevant inhibitors/competitors with 
single compounds reveals kidney tubule epithelial substrate-inhibitor interactions. To analyze the 
3D model’s ability to discriminate kidney tubule epithelial cell substrate-inhibitor interactions, the 
toxic drug alone and the drug combined with a potent, receptor-specific inhibitor/competitor 
selected from the 9 compounds was tested: Figure 5.7 shows the concentration-response curves 
for A) cidofovir (OAT1 substrate) alone versus in combination with probenecid (OAT1 inhibitor), B) 
cisplatin (OCT2 substrate) alone versus cisplatin in combination with cimetidine (OCT2 inhibitor), 
and C) polymyxin B (megalin substrate) versus the combination of polymyxin B with polymyxin B 
nonapeptide, a known, less-toxic polymyxin B analog [478]. All three plots show shifts in the 
concentration-response curves to the right in the presence of the inhibitor/competitor compared to 
curves of each compound alone, equating to reduced toxicity. The respective IC50 values from each 
compound condition were calculated, with these data expressed as the ratio of IC50 of toxic drug 
co-administrated with inhibitor/competitor to IC50 of toxic drug alone (Figure 5.7 D). A ratio of ≥ 1 
indicates that the inhibitor is protective against the compound’s nephrotoxicity or that a competitor 
(i.e., the case of polymyxin B/polymyxin B nonapepetide) can reduce toxicity by competing for the 
same receptor. In all three cases, the specific inhibitor/competitor displays nephron-protection to 
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varying degrees.  
 
Discussion 
Kidney proximal tubules play a major role in xenobiotic and metabolite secretion from the 
body, and are the primary target site of drug-induced nephrotoxicity. Active transport of toxin into 
the proximal tubule cells concentrates the toxin, producing cell damage and necrosis [423, 424]. 
Reliable active transport is important to recapitulate in kidney epithelial cell models to reproduce 
clinical toxicity effects. Previous work has shown that 2D primary proximal tubule cells lose their 
polarization sometimes within minutes of monoculture [102] and that secondary, immortalized cell 
lines are often missing important kidney transporters needed for drug toxicity responses [98]. This 
led to a shift away from monolayer-cultured 2D cells on plastic to 3D cell culture systems that more 
closely resemble in vivo tissue conditions (i.e. organoids, micro-tissues and spheroids) [39, 103, 
104].  
The 3D ex vivo murine kidney organoid toxicity model used here [12, 19, 60] out-performs 
the current 2D kidney cell cultures on plastic, as relevant drug transporter expression and 
maintenance in this system was recently shown to be superior to 2D cultures [12]. This present 
study focused on leveraging these transporter profiles and prior proof-of-concept for this 3D culture 
to analyze drug toxicity prediction by this model using the CellTiter-Glo® 3D Cell Viability Assay 
(Promega, USA). ATP is a marker of mitochondrial function, and therefore cell viability [479]. 
Beyond the high-throughput screening (HTS) compatibility, low fluorescence interference issues 
and excellent sensitivity and reproducibility [470], the CellTiter-Glo® 3D Cell Viability Assay exhibits 
an intensified cell lytic capability important to assure lysis of the 3D proximal tubule fragments and 
facilitating stronger, more sensitive signal generation compared to normal CellTiter-Glo® Cell 
Viability Assay (data not shown). Assay validation showed consistent mean values and low 
standard deviations for assay responses under test conditions. Various toxicity assay output 
parameters (e.g., IC50, LEC, AUC) were previously shown to provide more accurate insight into 
drug toxicity [480]. All of these parameters are derived from the Hill equation [481] and commonly 
used in toxicity assessments. IC50 is considered the classical measurement parameter for drug 
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potency, and LEC is used to determine drug efficacy. AUC is the combination of potency and 
efficacy [480]. As all of these parameters are commonly used, we calculated and analyzed all three 
values in our model from compound concentration-response curves (Figure 5.1).A good correlation 
between the Cmax-normalized IC50 and LEC values was produced (R2=0.9998-1, Figure 5.2).  
As it is important for a reliable drug toxicity model to avoid excluding potentially promising 
compounds early in development, a low false positive rate is essential for assay reliability. The zone 
classification attempt based on the IC50 or LEC and Cmax values (shown in Figures 5.3 A, B) 
identified an area with only toxic drugs and no false positive answers. While it can be seen that the 
IC50 parameter also produces a zone with only nonnephrotoxic compounds (Figure 5.3 A), the LEC 
parameter includes a false negative outlier (Figure 5.3 B). This can be explained by the less 
sensitive nature of the LEC determination compared to the IC50 parameter. While the IC50 
parameter is defined by the Hill equation and therefore a curve fit value with a lot of statistical 
precision, the LEC is dependent on the amount of chosen concentration test points in the assay 
and therefore increases in precision with increased test concentrations per compound. Therefore, 
the false negative outliner is an artefact of the LEC determination and the IC50 zone classification 
plot is more precise and accurate. 
An important factor for toxicity assessment is determining proper thresholds to assess a 
compound as nephrotoxic or nonnephrotoxic at therapeutic concentrations. Previous studies 
determine a toxicity threshold from the determined therapeutic index (TI), defined as the toxicity-
indicating parameter from the in vitro study divided by the therapeutic maximum plasma 
concentration (Cmax) from clinical data. This method has been shown to reliably classify a drug as 
toxic or nontoxic [470, 475-477, 482].  
Notably, in the absence of any clinical Cmax experience (i.e., early preclinical drug 
development), others have reported that in vitro efficacious concentration can be used to normalize 
the IC50 values [483, 484]. Also, Cmax values from animal studies could be used in preclinical stages. 
If these kind of data are absent, IC50 values can only be used to rank the compounds [470, 475, 
483].  
For our model the best sensitivity was evident at a threshold of 100x Cmax while maintaining 
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a low false positive rate. While sensitivity values are the same, the false positive rate values are 
superior for the IC50 parameter over LEC. Data in Table 5.2 indicates that 100x Cmax is the most 
appropriate threshold in the 3D model for both toxicity parameters, demonstrating a high positive 
predictive value of 96.6% for IC50 (90.3% for LEC) and also a high negative predictive value of 
88.9% for IC50 (85.7% for LEC). This high predictive value is important so that potential drug 
candidates can be identified correctly early in the development process. At this 100x Cmax cut-off 
value the 3D proximal tubule model correctly identified nephrotoxic (cidofovir, cisplatin, polymyxin 
B, polymyxin B nonapeptide, doxorubicin, gentamicin), and nonnephrotoxic (cimetidine, 
probenecid) drugs within the concentration range of 1-1000 µM using the IC50 toxicity output 
parameter. The 100x Cmax threshold is consistent with that found in other studies [475-477]. The 
ROC-AUC values (Figure 5.5, Table 5.3) in both parameter cases are high (i.e., 0.9638 for IC50 and 
0.94 for LEC), much higher than the 0.5 value for random probability, validating their predictive 
accuracy for toxicity in the 3D proximal tubule model. Comparisons to parameters from other cell 
culture models (Table 5.4) indicate that our models ROC-AUC values are superior to porcine LLC-
PK1 cells (ROC-AUC of 0.73) [62] and human-derived cell line HK-2 (ROC-AUC of 0.71) [62]. 
Human primary cells (HPTC1, HPTC-like and HPTEC) show ROC-AUC values around 90% [62, 
107, 485] but still less than the ROC-AUC values for the 3D model (Table 5.4). 
Our 3D assay also shows higher sensitivities for toxic compound detection than previously 
reported in cell lines in adherent 2D monoculture [486]. Cisplatin, an antineoplastic agent well 
known for dose-limiting nephrotoxicity [487] showed little relevant cytotoxicity in HK-2 cells (i.e., 
lowest cytotoxic concentration fulfilling the positive response was 1000 µM) [486], compared to the 
3D ex vivo model (i.e., cisplatin IC50 of 11 µM and LEC of 1 µM), a clinically much more realistic 
value (Tables 5.1 and 5.4). This prior 2D study [486] also reported no cytotoxicity after 24 h of 
gentamicin exposure, while the 3D proximal tubule model determined a gentamicin IC50 of 0.4 mM 
and a LEC of 100 µM. Also, a complete lack of gentamicin cytotoxicity detected in the 2D assay of 
cell line LLC-PK1 [488] counters the well-known human aminoglycoside (gentamicin) acute 
nephrotoxicity with clinical incidence rates as high as 30% [489]. The sensitivity value of these 2D 
toxicity models are only between 50 and 64% and their positive predictive values only reach 73% 
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(HK-2) and 74% (LLC-PK1), respectively, with even lower negative predictive values of 60% and 
67%, respectively (Table 5.4), compared to higher positive and negative predictive values in our 
3D model (96.6% and 88.9%, respectively).  
A recent study analyzed the nephrotoxicity screening potential of primary human proximal 
tubule epithelial cells, reporting high performance metrics with the exception of a low negative 
predictive value of 57% [485]. Even though the predictive performance values looked very 
promising, the amount of toxic drug required to induce nephrotoxic effects was higher than in our 
3D model: their IC50 values for cisplatin was ~8x higher and for gentamicin 23x higher than those 
in our 3D model (Table 5.4) [485]. These findings suggest that the OAT1 transporter expression in 
these 2D cultures for cisplatin, and megalin expression for gentamicin, respectively, are less 
sufficient, slowing the rate of toxicity and explaining the need for higher drug amounts or longer 
drug exposure times.  
Figure 5.4 data support a general observation that known cytotoxic drugs tested here 
exhibit IC50 values below 1.4 mM in this 3D proximal tubule model (Table 5.1), with much lower 
values for known highly nephrotoxic drugs like cisplatin (IC50=11 µM). Comparing published studies 
IC50 values in Table 5.4, only doxorubicin values are higher in the 3D model than the other 2D 
toxicity studies in cell lines. As an anthracycline used in chemotherapy, doxorubicin is general 
known to be highly cytotoxic by generating reactive oxygen species (ROS) [490]. Resulting 
oxidative stress-induced cytotoxicity is reported in various cell types [46, 65, 469, 490]. Doxorubicin 
endocytic cell uptake requires no specific transporters [46, 65, 469, 490]. Based on this and the 
higher cell surface area exposure in 2D cell culture (i.e., spread, flattened cell morphology) 
facilitating drug access and permeability, lower levels of this compound might plausibly produce 
toxicity in 2D cultures compared to the more morphologically protected 3D proximal tubule fragment 
cultures.  
Another study tested nephrotoxicity using 41 nephrotoxic and nonnephrotoxic drugs in HK-
2 and LLC-PK1 cells, showing that the sensitivity in both cell lines is no better than chance 
probability [62]. These discrepancies could be due to the lack of proper transporter functionality in 
cultured 2D cell lines: in vivo proximal tubule toxicity is highly dependent on transporter expression, 
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drug-transporter uptake and increased toxin levels within proximal tubule cells [423, 424]. Previous 
work on the 3D proximal tubule model showing superior transporter expression levels and profiles 
in 3D culture compared to 2D cell lines such as HK-2 and LLC-PK1 supports this assertion [12].  
Predictive drug nephrotoxicity assay validation in humans must correlate to human clinical 
experience with these drugs and in vitro cytotoxicity assays. To probe such a correlation, 3D toxicity 
data were normalized with clinical Cmax values and plotted against their nephrotoxicity incidence 
reported from clinical trial data at different exposure levels. Figure 5.6 shows a scatter plot 
correlating the 3D ex vivo model predictions against actual human clinical nephrotoxicity reports 
where nephrotoxicity risks increase towards the upper right corner. The Cmax-normalized 
cytotoxicity responses correlate with observed adverse event rates in clinical studies. 
Another important factor for early toxicity screen reliability is the capability to easily analyze 
new chemical moieties that might make new compounds safer and also identifying mechanisms 
driving drug nephrotoxicity, and therefore determine their human clinical relevance. These 
structure-activity relationships facilitate more rapid development of safer and more effective drug 
candidates in small scale models more economically and in early drug development stages. Also 
investigating potential treatment options for patients with a particular drug-induced nephrotoxicity 
is a plausible, more specific clinical use for these validated ex vivo nephrotoxicity models. In this 
regard, different substrate-inhibitor combinations were tested coadministered with the compounds 
and compared to assay results for toxic drugs alone. Figure 5.7 data show that for the 
substrate/inhibitor pair of cidofovir and probenecid (OAT1 transporter specific) as well as the 
cisplatin and cimetidine (OCT2 transporter specific) pair, a shift of the drug concentration-response 
curve to the right is seen. These shifts indicate that the toxicity of the compound in the 3D proximal 
tubule model was reduced, and that the IC50 values increased. In the clinic, probenecid, a known 
OAT1 inhibitor, is commonly co-administered with cidofovir to reduce nephrotoxic effects of 
cidofovir, a dose-limiting factor [491], by blocking cidofovir proximal tubule uptake and toxic 
consequences. These 3D assay data suggest that the substrate-inhibitor interactions seen in vivo 
can be modulated and emulated by this 3D model. Additionally, the 3D ex vivo model demonstrated 
reduced toxicity by co-administering a potent toxic drug, polymyxin B, and a related, less toxic 
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derivative of polymyxin B, polymyxin B nonapeptide [492-494]. Figure 5.7 also shows a shift in the 
concentration-response curve to the right for this pairing, indicating that the model is capable of 
reflecting substrate competition for the same kidney epithelial drug transporter.  
 
Conclusion 
This 3D ex vivo kidney proximal tubule assay exhibits high predictive value for a group of 
clinically relevant agents known to be either nephrotoxic or nontoxic in vivo. The approach yields 
assay responses with high sensitivity and specificity, and high correlative value to known clinical 
experiences with the same agents. Importantly, the assay format shown here in multiwell plates is 
amenable to high throughput (i.e., robotics dispensing) in high-density multiwell plates and even 
manifold-interfaced microfluidics designs. It also preserves essential kidney epithelial cell 
transporter functions and phenotypic states in 3D culture much more reliably than 2D kidney cell 
cultures widely used for similar toxicity assessments currently.  
The ex vivo approach currently requires murine sacrifices to yield the kidney proximal 
tubule cultures, but the convergence of this approach with new functional kidney in vitro organoids 
derived from stem cells [106-109] may enable hybrid systems combining the benefits of both 
strategies without proximal tubule supplies from animal or human sources. Taken together, these 
results and those published previously for this 3D ex vivo model [12, 60], prove beneficial for 
improving drug development and structure adjustment studies, and rapid dose-response toxicities 
in vitro, helping to minimize unexpected toxic effects in late stage human drug clinical trials. 
Comparing the results from the 3D proximal tubule assay to known in vivo effects for each drug 
used clinically, 3D proximal tubule cultures are shown to be an improved model over standard 2D 
cell monocultures for predicting nephrotoxicity at therapeutically relevant concentrations. 
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Table 5.1 Compounds used in this study and their multiparametric data after 24h of drug exposure.  
Compound Pharmacologic Category IC50 SD LEC [µM] AUC Cmax [µM] 
Cidofovir Antiviral 1.1 mM 0.2 1000 531.0 11.5 
Cimetidine H2- Antagonist 5.9 mM 1.9 1000 574.3 2.0 
Cisplatin Antineoplastic 11.0 µM 3.6 1 284.8 9.2 
Doxorubicin Antineoplastic 45.0 µM 2.4 1 344.6 0.6 
Gentamicin Antibiotic 0.4 mM 0.05 100 474.3 23.0 
Polymyxin B Antibiotic 10.5 µM 1.0 10 304.5 13.9 
Polymyxin B Nonapeptide Antibiotic 0.7 mM 0.1 100 501.3 13.9 
Probenecid Uricosuric 4.3 mM 0.8 1000 585.6 35.0 
Vancomycin Antibiotic 1.4 mM 0.2 316 534.1 30.0 
 
 
Table 5.2 Important nephrotoxicity prediction performance metrics at 1x Cmax, 30x Cmax and 100x 
Cmax cutoff from the 3D proximal tubule model.
 
Nephrotoxicity prediction with  
IC50 
Nephrotoxicity prediction with 
LEC 
Cmax TI <1x <30x <100X <1x <30x <100X 
Sensitivity [%] 6.9 75 96.6 37.9 93.1 96.6 
Specificity [%] 100 100 88.9 100 77.8 66.7 
Positive predictive value [%] 100 100 96.6 100 93.1 90.3 
Negative predicitive value [%] 25 56.2 88.9 33.3 77.8 85.7 
 
 
Table 5.3 ROC-AUC values from ROC curves shown in 
Figure 5.4.AUC values from the two assay toxicity 
output parameters were used to construct ROC curves. 
ROC-AUC values >0.5 represent a predictive model 
(0.5 is considered chance). 









Table 5.4 In vitro studies on drug-induced nephrotoxicity and their important performance metrics.  
Cell 
type Species 
IC50 values Performance metrics 
References 
Cisplatin Doxorubicin Gentamicin Polymyxin B 
Polymyxin B 
Nonapeptide Vancomycin Sensitivity Specificity PPV NPV 
ROC-
AUC 
PT murine 11 µM 45 µM 0.4 mM 10.5 µm 0.7 mM 1.4 mM 0.97 0.89 0.97 0.89 0.96 this study 
NRK-
52E rat 
> 300 µM 
+
 
0.3 µM + 
25.96 mM * 
> 300 µM + 288.7 µM * 
 










MDCK canine   16.98 mM 1.01 mM        [495] 
HEK293 human 2.7 mM + 2.3 µM + 12.77 mM * 360.97 µM 
* 
       
*[495] 
+[47] 
hRPTEC human 39.6 µM 11.2 µM          [469] 
HK-2 human > 1 mM * 1 µM * > 1 mM * 
> 2.1 mM ¥ 20 µM 
+











NKi-2 human 17 µM > 20 µM 22 mM         [65] 
NKi-2 
tissue human 25 µM 2 µM 9 mM 
        [65] 
HPTC1 human 2.96 mM  > 2.1 mM   > 673 µM 0.91 0.9 0.91 0.94 0.94 [62] [107] 
LLC-
PK1 porcine 2.0 mM 
+









like human 2.26 mM 
 > 2.1 mM   > 673 µM 0.68 0.84 0.83 0.70 0.8 [107] 







Figure 5.1 Impact of different compounds on 3D murine proximal tubule ex vivo cultures. ATP 
content was measured after 24h of compound incubation. Compounds were tested over a 
concentration range of 1-1000 µM per compound: A) cidofovir, B) probenecid, C) gentamicin, D) 
cisplatin, E) cimetidine, F) vancomycin, G) polymyxin B, H) polymyxin B nonapeptide and I) 
doxorubicin. Concentration-response curves were plotted (n=3, mean ±SD) and IC50 values, LEC 
and AUC from each compound were calculated. Values associated with each compound are shown 










Figure 5.2 Correlation analysis of normalized IC50 (y-axis) and LEC (x-axis) values.  IC50 and LEC 
values were normalized by many different published Cmax values from clinical studies
(▼doxurubicin, ● cisplatin, genatmicin, vancomycin, probenecid, cimetidine, polymyxin B 
nonapeptide, ▲ cidofovir, polymyxin B). Correlation coefficients (R2) are provided. 
 
Figure 5.3 Nephrotoxicity classification based on compound IC50 and LEC. IC50 (A) and LEC (B) 
value are plotted against published human therapeutic plasma concentration Cmax. A simple divider 









Figure 5.4 Nephrotoxic effects for each compound on the 3D proximal tubule culture. IC50 values 
from concentration-response curves in (Figure 5.1/Table 5.1) were calculated for each compound 


























































Figure 5.5 Determination of the predictive value of the 3D proximal tubule model by ROC 
analysis.  Two different toxicity output parameters IC50 (A) and LEC (B). The respective 























Figure 5.6 Validation of the 3D proximal tubule model for compound nephrotoxicity testing. Each 
dot represents data from different exposure levels per drug from clinical studies, resulting in 
different levels of toxicity, compared to IC50 values from the 3D proximal tubule model. The arrow 







































Figure 5.7 Impact of receptor competitor addition. ATP content was measured after 24h of 
compound incubation. Full concentration range (1-1000 µM) of toxic compound and 30µM of 
competitor coadministration: A) cidofovir (CDV) and probenecid (PROB), B) cisplatin (CIS) and 
cimetidine (CMT), and C) polymyxin B (PMB) and polymyxin B nonapeptide (PMBN). 
Concentration-response curves were plotted to show the shifts in potency to the right (n=3, mean 
±SD). IC50 values from each compound condition were calculated and the data expressed as the 
ratio of IC50 of toxic drug co-administrated with inhibitor/competitor to IC50 of toxic drug alone (D). 
A ratio of ≥ 1 indicates that the inhibitor/competitor is protective against the compounds 








SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
Currently a significant portion of drug molecules fail in clinical studies because the current 
state of the art in vitro drug toxicity screening tools in combination with animal models do not 
correlate sufficiently with final human in vivo outcomes. This dissertation aimed to validate the 
properties of an ex vivo 3D kidney proximal tubule screening model over standard 2D kidney cell 
cultures to improve the predictability and reliability of kidney toxicity results in drug screening. 
Differences between 2D in vitro drug exposure data from both immortalized and primary kidney cell 
monocultures independent of origin and actual clinical toxicity results obtained from human data 
are likely due limited functional and structural similarities between 2D monocultures and human 
kidney tissues. Specifically, known deficiencies in expression levels of important kidney drug 
transporters [58, 59, 98, 463, 496] and metabolic enzymes (Chapter 4) [47, 497], as well as 
intracellular drug targets [498] in 2D kidney cell culture lines are thought to be problematic, limiting 
their ability to accurately reproduce clinical toxicity responses.  
The model described in this dissertation overcomes the above-mentioned problems by 
using intact, freshly harvested, and isolated murine proximal tubule fragments. Proximal tubule 
epithelial cells lining the proximal tubule lumen retain their native in vivo-like context, environment 
and structure. Data presented in each chapter reflect the importance of this cell native environment 
with cell-cell and cell-matrix interactions and culture-dependent differences. First, a detailed 
analysis of known, toxicity-associated kidney tubule cellular transporter expression profiles was 
reported for 3D cultured proximal tubules. Understanding these expression profiles for critical 
kidney tubule transporters over time in drug screening conditions should facilitate future in vitro-in 
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vivo correlations (IVIVC) and interspecies comparisons to validate nephrotoxicity assays. We 
compare hydrogel-based 3D proximal tubule fragment cultures and their nongel 3D suspension 
cultures for up to one week, demonstrating that 3D tubule cultures exhibit superior gene expression 
levels and profiles for key transporters compared to published commonly used 2D kidney cell line 
monocultures on plastic (Chapter 4). Gel use produced certain limitations, including: 1) interference 
with certain assays, 2) inability to readily recover biological material, 3) inconsistent distribution of 
doses drug throughout the gel, 4) inability to utilize nanoparticle or colloidal drugs due to transport 
limitations and gel binding, 5) possibly incomplete media exchange and catabolic retention 
problems, and 6) poor oxygen transport and exchange. Therefore, specific advantages would have 
to be advocated for gel use in order to offset these limitations.  
Chapter 5 then provides functional confirmation of the ensemble of these transporters and 
enzymes in actual clinical relevant drug compound in vitro testing. Nine compounds with either 
known clinical nephrotoxicity or nontoxicity were assessed in the 3D nongel suspension culture and 
drug concentration-response curves and their molar concentration producing 50% inhibition (IC50), 
lowest effective concentration (LEC) and Area Under the Curve (AUC) values were calculated and 
compared to clinical therapeutic exposure levels (Cmax). Receiver Operating Characteristic (ROC) 
analysis was performed and the toxicity validation using this test group yields high sensitivity 
(96.6%) and specificity (88.9%) as well as high positive (96.6%) and negative (88.9%) predictive 
values in correlating toxicities for these agents with published clinical experiences (Chapter 5). 
Given these metrics, validation of the ex vivo 3D proximal tubule model against actual clinical 
toxicity experience was an important conclusion (Chapter 5). Specifically, the 3D model provided 
toxicity data similar to those seen in vivo at the best determined threshold of 100x Cmax. Additionally, 
benefits from using the 3D proximal tubule model over standard 2D kidney cell monocultures for 
nephrotoxicity predictions at therapeutically relevant drug concentrations are shown (Chapter 5). 
By reliably predicting nephrotoxicity for all compounds tested, this screening model should prove 
useful for more reliable screening of novel compounds during early phases of drug development.  
Overall, the findings show that the 3D kidney organoid fragment culture approach 
preserves essential kidney epithelial cell transporter functions and phenotypic states in 3D culture 
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much more reliably than 2D kidney cell cultures widely used for similar assessments currently. This 
collective outcome then validates critical phenotypic and functional aspects of this 3D culture 
model, providing confidence that it can now move forward to further toxicity testing and be extended 
to study new drug candidate structure-activity relationships (SARs) on proximal tubule 
pharmacology. This model can be further used to gain new insights into the mechanisms that drive 
toxicity from selected toxins and provide rapid screening of different chemical moieties during 
candidate SAR screenings. Data from this dissertation provides new information critical to 
understanding the models’ functionality and sensitivity. Importantly, the assay format is versatile, 
amenable to high throughput in multiwell plates and even interfacing with fluidics designs. It can 
also be adapted to future kidney functional organoid cultures derived from human stem cells, 
eliminating the need for animal sourcing. Taken together, these data from this 3D ex vivo model 
support its utility in drug development, candidate screening, and rapid dose-response toxicities in 
vitro, hopefully better predicting the current unexpected and costly, toxic effects in late-stage human 
drug clinical trials and increasing postmarket drug product withdrawals. 
 
Future directions 
The use of novel clinical predictive markers for drug toxicity 
Most common currently used toxicity markers in clinical trials are blood urea nitrogen (BUN) 
and serum creatinine. The major drawback for these markers is that they are rather insensitive: a 
50-70% reduction in glomerular filtration rate (GFR) must occur to observe increases in BUN and 
serum creatinine levels [100]. This slow response and the lack of better available markers prompted 
the FDA’s Critical Path Initiative call for development of better tools and more predictive, early 
phase nephrotoxicity markers [84, 91]. Based on this initiative, the following novel predictive 
markers were developed and remain under investigation [54, 84]: KIM-1 [68], NGAL [75], GST [69] 
and cytokines IL-6 and IL-8 [86, 132] (see Table 6.1). All of these markers show increased 
sensitivity towards nephrotoxicity and present earlier than BUN and serum creatinine. To facilitate 
developing of more reliable models and to increase the usability/functionality of our 3D proximal 
tubule model to detect drug toxicity at early stage, it would be a great advantage to assess these 
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markers in 3D culture systems. To do so would require the capabilities to evaluate gene expression 
of these markers in 3D cultures in general, and specifically in the 3D kidney proximal tubule model, 
and analyze their toxicity predictive values when exposed to known nephrotoxic and 
nonnephrotoxic drugs over time and concentration. Those data would then be comparable to 
human clinical toxicity responses and ideally, allow sufficient correlations to be seen. With this 
validation, these markers can then be used in combination with cell viability assays described in 
this dissertation for even more reliable and predicable toxicity screenings in early drug development 
phases. 
 
Exploiting a genetically modified mouse for improved nephrotoxicity assays 
A significant technical obstacle in using the 3D proximal tubule model was finding and 
optimizing assays reliable for 3D cell culture. Most current cell toxicity and metabolic assays and 
procedures are developed for flat 2D cell culture applications in plasticware plates, often using line-
of-sight or other optical assay read-outs. Assay use in more complex and voluminous 3D structures, 
especially those without optical transparency, has not been systematically developed or validated 
[39]. Specifically, the two most important technical issues were 3D matrix cell lysis capacity and 
signal detection. The commercial CellTiter-Glo® 3D assay (Promega, USA) used in this study has 
an enhanced cell lytic capability that improves ATP extraction, the assay’s optical signal strength, 
and therefore, the assay sensitivity. Nonetheless, 3D matrix interference with either cell extraction 
or assay reagents (e.g., poor reagent dispersibility, diffusion, exchange, matrix binding, poor 
stringency, cell interference), suboptimal time-dependence or kinetics for assays and matrix optical 
heterogeneity that corrupts assay fidelity or reporting, all produce unresolved issues for 3D cell 
culture assays. Figure 6.1 shows the outcome of three different assays for cell viability/cytotoxicity 
testing that were tested in our 3D proximal tubule system (with and without HA gel). It can be seen 
that the HA gel-embedding of the proximal tubules narrows the assay range dramatically and that 
way better signal-to-background ratios are seen when the 3D proximal tubules are used without 
the matrix (Figure 6.1). Beyond simple end-point cell viability, other desired assay reporting features 
would be real-time and noninvasive feedback on cell phenotype, metabolic information, proliferation 
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rates and cell cycles, and subcellular organelle visualization (e.g., mitochondria, Golgi, endosomes, 
lysosomes, phagosomes). Current 3D culture formats are not yet integrated with these assays, or 
the requisite analytical instrumentation or algorithmic processing, to make them readily amenable 
to these reporters.  
A different approach would be the use of genetically modified signal pathways in 
mammalian cells where toxicity indicators are up-regulated genetically in responses to a given 
specific assault. The KIM-1 reporter C57BL/6 mouse (AstraZeneca, unpublished) upregulates GFP 
and luciferase in response to KIM-1 activation. Since KIM-1 is a primary kidney toxicity marker [52, 
499], the resulting GFP signal produced in the kidney is related to nephrotoxicity. Kidney proximal 
tubule epithelial cells in the KIM-1 mouse express GFP and also secrete luciferase under control 
of the KIM-1 promotor. Therefore, the KIM-1 data should be collected to support initial feasibility for 
exploiting GFP and luciferase expression after exposure to nephrotoxins and calibration against 
the specific toxicity data presented in this dissertation for 3D proximal tubule in vitro assays derived 
from kidneys from the related C57BL/6 wild-type mouse. 
The exploration of the KIM-1 reporter mouse can then be further extended: GFP 
appearance can be tracked using real-time fluorescent imaging of cultured proximal tubule 
fragment harvests both without and with 3D gel matrix, and simultaneous serial sampling of media 
for excreted luciferase activity. Dynamic reporting range, limits of detection, time-to-response (i.e., 
signal up-regulation) and assay fidelity as a function of kidney harvest time, animal-animal variation, 
and assay variables would be vetted. Both of these markers, KIM-1 GFP signal and luciferase 
secretion, could broaden the usability of the PT in vitro assay to permit serial, real-time assessment 
of cell response and viability in live proximal tubules, and therefore also dramatically reduce the 
number of plates and therefore also animals needed to run the assay.  
An additional value would be to compare the ex vivo KIM-1 reporter mouse 3D proximal 
tubule toxicity response data with in vivo KIM-1 reporter mouse response to tail-vein injected and 
orally ingested compounds and dosages. To do so, the KIM-1 reporter mice would be injected with 
different concentrations of known nephrotoxic and nonnephrotoxic drugs and their urine would be 
collected (e.g., metabolic cages or manually) after different time points and analyzed for luciferase 
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activity. This could be done with a commercially available kit (i.e., ONE-GloTM Luciferase Assay 
System, Promega), producing a stable luminescent signal that then can be read on a normal plate 
reader (e.g., Synergy 2 Multi-Mode Reader from Biotek). These in vivo data then could be 
compared to the ex vivo KIM-1 reporter mice 3D proximal tubule data (i.e., GFP optical response, 
CellTiter-Glo® viability, etc.) and an IVIVC can be produced. The urine collection data can 
furthermore be used to identify drug effects depending on exposure times and the strongest 
nephrotoxic time point for each drug can be determined. At specific time points, the mice could be 
euthanized and the kidneys would be harvested and used for histopathological GFP signal 
determination of in vivo drug responses. 
Preliminary data for the GFP signal from harvested KIM-1 reporter mouse 3D proximal 
tubules after drug exposure ex vivo shows that GFP signal is upregulated depending on drug 
concentration and that a concentration-response curve based on the GFP signal can be produced 
(Figure 6.2). GFP signal was detectable visually using normal microscopy as well as using the 
Synergy 2 Multi-Mode reader (Biotek). Overall, the assay range is narrower than that seen with the 
CellTiter-Glo® 3D assay (Promega) and further optimization of PT seeding density must be done in 
order to produce the normal expected assay figures of merit (LOD. LOQ, S/N, reliability, 
reproducibility, dynamic range, specificity, sensitivity).  
 
Further evaluation of ex vivo 3D PT models amenable for mechanistic  
toxicity studies using RNAi 
In Chapter 5, I showed the potential of this ex vivo 3D proximal tubule model for 
mechanistic toxicity studies by comparing the concentration-response curve and IC50 results of 
known nephrotoxic drugs (e.g., cidofovir) alone versus coadministration of the nephrotoxic drug 
with a known inhibitor (e.g., probenecid). The shift of the concentration-response curve to the right 
as well as the higher IC50 values indicated that agent coadministration inhibits kidney uptake of the 
nephrotoxic drug and correlates with known clinical applications. To validate the mechanistic 
hypotheses of this model further and to see if this model may be used with RNAi agents to 
specifically knock out known toxicity pathways, siRNA against a specific receptor or signal molecule 
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driving kidney PT drug accumulation (e.g., OAT1) could be administered, followed by exposure of 
the 3D proximal tubules with a known nephrotoxic drug substrate for this specific transporter (e.g., 
cidofovir). Kidney PTs can be evaluated for their altered drug susceptibility which will provide further 
insight into toxicity mechanisms. Other alternative methods to achieve the same technical objective 
include CRISPR/Cas9 cell transfection, iPS cell selection, and TALEN modified cell cultures. 
 
Harvest optimization to improve the HTS potential of the ex vivo  
3D proximal tubule model 
Use of genetically modified KIM-1 reporter mice should allow use of a previously published 
sorting method to speed up the PT harvesting process and make the model more valuable for HTS. 
Miller et al. developed an automated method to isolate collective ducts of digested kidneys from 
genetically modified mice expressing GFP [444]. They used a complex object parametric analyzer 
and sorter (COPAS) instrument (Union Biometrica, Somerville, USA), commonly known as C. 
elegans “worm sorter,” to sort GFP-expressing collective duct cells from other parts of the nephron. 
The same method could be used with KIM-1 reporter mice with GFP-expressing proximal tubule 
cells to allow automated sorting, as conventional flow cytometry is not possible due to the excessive 
size of the PT organoid fragments (70-250 µM). This process could drastically speed up isolation 
and eliminate the need to identify PTs in the extraction step. Success here would increase the HTS 
potential as currently the isolation process is the main rate-limiting step of the ex vivo 3D proximal 
tubule model. If we focus only on the 96 well plate assay, then throughput could be clearly affected 
by an efficient fluidics interface capable of changing between media, drug and rinsing steps to 
control transport and allow reuse of each well. 
 
Development of an ex vivo 3D human model 
Another future approach would be the expansion of the knowledge gained through the 
development and characterization of the murine ex vivo 3D proximal tubule model to an analogous 
human ex vivo 3D proximal tubule model. To achieve this, prescreened human kidneys from a 
clinical collaborator with IRB approval for research use of discarded kidneys (e.g., from renal 
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carcinoma or transplant discards) could be used. To harvest healthy proximal tubules only kidneys 
with localized, nondisseminated tumors will be used and diseased tissue will be dissected away. 
This would allow direct comparisons of the model and highlight potential interspecies differences 
known to be a problem for toxicity responses [500, 501]. As use of murine proximal tubule 
fragments is less expensive and easier to approach, the ideal case would be that comparable data 
will be retrieved, the mouse-to-human translational relevance validated and that human tissue 
discards would NOT be required to employ the assay. An additional aspect would be that the human 
model could be modified to analyze proximal tubules from diseased kidneys and compare to healthy 
proximal tubules to monitor differences in nephrotoxicity responses as a function of human 
pathology or disease co-morbidities.  
 
Elimination of animal or human PT sources by using stem cell-derived organoids 
The ex vivo approach described in this dissertation currently requires murine sacrifices to 
yield the kidney proximal tubule cultures. To eliminate the need for animal sacrifices in this model, 
a future approach could focus on new functional kidney-like in vitro organoids derived entirely from 
stem cell 3D cultures [106-109]. Over the last 4 years, multiple groups are competing on the 
development of kidney organoid structures from stem cells and multiple protocols were published 
to differentiate pluripotent stem cells into self-organizing kidney organoids in 3D matrices in 
multiwell plates [106, 108]. These stem cell-derived kidney organoids must be further characterized 
and important functionality in toxicity assays must be validated. This approach then may enable 
hybrid systems combining the benefits of both strategies without proximal tubules supplied from 
animal or human sources.  
 
Concluding remarks 
Our 3D PT model is one of multiple current approaches seeking to create more reliable 
and predictive nephrotoxicity models (Table 6.2). While the current setup is under static fluidics 
conditions, applying flow would be a future direction to make the model even more efficient, perhaps 
more relevant, and high-throughput applicable. Applying flow conditions by, e.g., seeding harvested 
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PT fragments on membrane transwell plates will allow for more in vivo-like conditions as well as 
rapid media and drug solution exchange and transport control. This would also possibly allow reuse 
of the same PT fragment culture for different drugs and concentrations by including a rinse-recovery 
period in complete PT media. Effects of adding protective agents or transporter inhibitors could be 
studied seamlessly in a flow setup. The benefit of kidney-on-a-chip models is in retaining their 
functional complexity, and therefore ideally establishing more in vivo-like designs could facilitate 
this goal [61, 133, 134, 502].  
Current results are promising even though more thorough transporter expression as well 
as drug concentration response curve studies need to be performed to get more reliable data to 
support assay sensitivity, specificity, NPV, PPV parameters. Current studies are all currently 
lacking these and are only focusing on a small amount of test compounds for model validation. Full 
performance metrics are necessary to move all current approaches forward to approved 
nephrotoxicity testing systems. While the more complex kidney-on-a-chip models look promising, 
they are also more cost- and labor-intensive. Importantly, that more complicated designs are 
necessary to obtain data that allows accurate toxicity correlations to human in vivo results remains 
to be shown. The higher cost and labor intensity of these experimental systems are reasons why 
only small numbers of test compounds were analyzed and tested in these systems so far [61]. 
Therefore, our simpler PT approach is competitive and also interesting for pharmaceutical 
industries as they pursue rapid, inexpensive, and more reliable toxicity assay methods.  
Different assay approaches could also be used strategically at different times in the drug 
development process: a simple, inexpensive, high-throughput system could be used early, when 
scanning a large quantity of candidates or compounds, while later in the process, a more complex, 
and therefore, more expensive in vivo-like approach could be used to identify toxicity results in an 
already narrowed group of compounds. These microfluidic kidney-on-a-chip approaches could also 
identify toxicity responses of different cell types as they are normally resident in vivo in multicellular 
systems in a combined or serially staggered exposure sequence [133, 134, 502]. Currently, all 
toxicity testing models proposed and published - 3D PT cultures [60], kidney-on-a-chip [1, 61, 134, 
502] and stem cell derived organoids [106, 133, 137-139] remain to be tested and validated in 
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large-scale studies and using different drug classes to obtain accurate, reliable predictability and 
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Table 6.2 Comparison of current in vitro approaches for drug-induced nephrotoxicity screening. 
 2D cell culture Kidney-on-a-chip Stem cell-derived 
kidney organoids 
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Figure 6.1 Cell viability assay signal strength and assay dynamic range. Three different cell assays
are shown: RealTime-GloTM MT Cell Viability Assay, CellToxTM Green Cytotoxicity Assay and 
CellTiter-Glo® 3D Cell Viability Assay. Effect of the 3D matrix on the assay is shown. Negative 
































































































































































































































































Figure 6.2 Impact of different compounds on 3D KIM-1 reporter mouse PT ex vivo cultures.  GFP 
signal in cultures was measured after 24h of compound incubation and the GFP signal was 
converted to a concentration-response curve by normalization to no drug control and conversion 
of cytotoxicity to viability. This allows for comparison to ATP assay concentration-response data 
(Figure 5.1). Compounds were tested over a concentration range of A) 1-10000 µM for gentamicin 
and B) 1-1000 µM for polymyxin B. Concentration-response curves were plotted (n=1 (2 technical 























































































































































A RECOMBINANT HEPARIN-BINDING MAJOR AMPULLATE SPIDROIN 2 
(MASP2) SILK PROTEIN4 
 
                                                     
4
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Peptide units comprising major ampullate spider silk confer a balance of strength and 
extensibility with established structure-property relationships. Small peptides correlated to specific 
functionalities can be recombined within these units to create designer silk fibers. In this study, a 
small basic peptide (ARKKAAKA) known to both bind heparin and mimic an antimicrobial peptide, 
was genetically linked to a protease-resistant, mechanically robust silk peptide, MaSp2, endowing 
spider silk with new properties. Purified silk fusion proteins (two or four silk domains and four 
heparin-binding peptide repeats) were expressed in E. coli. Successful fusion of a MaSp2 spider 
silk peptide with this heparin-binding motif was shown with analytical and functional assays. This 
strategy can link combinations of the two individual genes to create designer recombinant fusion 
proteins, including mechanically robust proteins that alter blood-contacting responses. 
 
Introduction 
Major ampullate spider silk’s intrinsic balance of dichotomous mechanical properties, 
unrivaled strength and impressive recoverable deformation, is provided by structural hierarchy 
rooted in the biochemical composition of two proteins, MaSp1 and MaSp2 [503, 504]. Phylogenetic 
analyses of these major ampullate sequences revealed an evolutionarily conserved sequence of 
repetitive amino acid motifs thought to correlate to specific structural and functional features [505]. 
The component amino acid motifs of major ampullate spider silk have been well-studied by 
producing clones of simplistic monomer motifs [506, 507] to identify and establish overarching 
structure-property relationships [505]. In addition to mechanical properties that can be engineered 
by genetically combining motifs correlated with specific properties [503, 505], several recombinant 
spider silk fusion proteins have been explored to date (i.e., silk-uranium binding proteins [508], silk-
antibiotic [509], silk-silica binding proteins [510, 511], silk-bone sialoprotein [512], silk-elastin [513], 
etc.), providing additional biological functions. Silk was also recently complexed with heparin and 
chitosan to create an anticoagulant, antimicrobial, dual functional protein [514]; however, the 
application is contemplated to capture endogenous heparin from circulating blood, allowing for 
repeated heparin-surface association and disassociation, and endowing intrinsic antimicrobial 
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properties based on the same amino acid motif. Heparin, a hydrophilic, highly sulfonated negatively 
charged polysaccharide copolymer comprising glucosamine and glucuronic acid, is endogenously 
found in the human body (approximately 20 µg/ml in adult plasma) and commonly used as an 
extracorporeal anticoagulant at therapeutic concentrations over 50 nM [515]. Importantly, heparin 
is naturally bound by a diverse family of heparin-binding proteins [516-518], based on electrostatic 
interactions where positively charged, basic amino acid residues in the heparin binding amino acid 
motif (HBM) of these proteins interact through ionic and hydrogen bonds with the strongly 
negatively charged sulfate and carboxylate groups on the heparin polysaccharide [518, 519]. 
Furthermore, the tertiary structure of the HBM is analogous to an antimicrobial peptide (AMP) [520, 
521], with the overall structure XBBBXXBX (X – hydrophobic or uncharged amino acid, B – basic 
amino acid). Previous work has sought to exploit surface-bound HBM to create heparinized 
surfaces [522, 523]. These efforts were able to successfully bind solution-phase heparin, with the 
best binding affinity based on four concatenated repeats of the synthetic motif (ARKKAAKA, 42 ± 
15 nm) [524]. This peptide is analogous to the LL-37 antimicrobial peptide, which can be 
proteolytically degraded by human neutrophil-produced elastase as well as P. aeruginosa elastase 
and S. aureus V8 metalloproteinase and aureolysin [525]. Thus, bound heparin bioactivity was 
shown to be reduced by proteolytic cleavage [526, 527]. Therefore, utilizing a heparin-binding motif 
as a surface capture agent for circulating heparin necessitates embedding the protease-susceptible 
peptide into a protective polymer background. A biological and structural biopolymer fusion, such 
as that using major ampullate spider silk with HBMs, may provide such a suitable background to 
permit heparin capture and stability for possible further technological use in biomaterials. 
In this context, we sought to genetically embed a small heparin-binding amino acid motif 
(HBM) into a recombinant protease-resistant silk peptide, MaSp2 [523, 528-530], to ultimately 
create a chimera with new biomedical properties as conceptually described in Figure A.1. Although 
many other silk fusion proteins have been explored [531] (e.g., antibiotics [522, 532], chitosan [514], 
elastin [513], silica [510, 533, 534], RGD [511], etc.), the recombinant fusion protein target seeks 
to uniquely combine silk’s mechanical properties with the biological activity of the HBM, creating a 
robust naturally heparin-binding biomaterial. By genetically embedding four concatenated repeats 
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of the heparin-binding motif, ARKKAAKA, in a background of MaSp2 amino acid motifs, a 
mechanically robust protein material is created, capable of 1) binding heparin for blood 
anticoagulation properties and also for 2) resisting pathogen colonization and infection [535]. Here 
we report the design and production of a heparin-binding silk recombinant protein chimera as well 




All enzymes were obtained from New England BioLabs or Fermentas, unless otherwise 
noted.  
 
Cloning design  
The Argiope aurantia MaSp2 consensus repeat amino acid sequence was designed and 
synthesized as a 179 base pair oligonucleotide (including restriction sites) while an analogous 
oligonucleotide for the consensus heparin-binding motif (HBM) (105bp including restriction sites, 
stop and start codons, and 6X-histidine tag) was synthesized. Regardless of the specific gene, 
oligonucleotide sequences were optimized for the codon bias of E. coli codon and included 
restriction sites (Figure A.2) to facilitate all downstream cloning steps. Each oligonucleotide was 
synthesized at the University of Utah DNA Sequencing Core Facility and annealed (annealing 
buffer) 10 mM Tris, 50 mM NaCl, 1 mM EDTA) to its complementary strand to create minigenes, 
which were subsequently cloned into pBlueScript II SK(+) (pBSK - Stratagene) (Figure A.2) and 
multimerized using a compatible, nonregenerable cloning strategy, as previously described [536]. 
Concatenated silk repeats, multiple HBM repeats, or HBM/silk combinations were produced and 
transferred to pET 30a (Novagen). Transformants were analyzed by PCR colony screening (95 °C 
2 min; 30 cycles of 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s; final extension at 72 °C for 5 
min). Colonies that screened positive via PCR were subsequently sent for DNA sequencing 
(University of Utah Core Facility, Salt Lake City, UT) using either the M13 or T7 primer sets (Figure 
A.3). Alternatively, the complete genetic sequence (silk2 or silk4 linked with HBM4) was synthesized 
112 
 
and cloned directly into pET 30a by GenScript (USA) (Figure A.4). 
 
Protein Expression and Purification 
All proteins were expressed in E. coli BL21(DE3)pLysS cells (Promega, USA). Cultures 
were grown in 37 °C LB medium containing 100 µg/ml kanamycin with shaking to an OD600 between 
0.8 and 1.0. Isopropyl-β-D-1-thiogalactopyranoside (IPTG, Sigma-Aldrich, I5502) was added at a 
final concentration of 1 mM to induce the expression. After 2 h the culture was centrifuged at 8000 
rpm for 10 min and the media was decanted. Cell pellets were resuspended in 100 mM HEPES 
buffer (1/10 of the final culture volume). To achieve better yields and higher purity, 50 µg/ml DNase 
I (Sigma), and 1 μL of protease inhibitor cocktail (Sigma)/100 μL of harvested expression culture 
was added prior to sonication (30 s at 40 % power) and purification. Proteins were purified using 
nickel affinity chromatography. To identify the highest yield clones from each construct, the 
Maxwell® 16 Polyhistidine Protein Purification system (Promega) was used according to the 
manufacturer’s instructions for the prefilled nickel affinity reagent cartridge (Promega) [537]. 
Purified protein was dialyzed against water overnight and lyophilized [538].  
 
Protein Characterization 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).  Purified 
proteins were analyzed for size and purity by SDS-PAGE. Importantly, solution from each well of 
the Maxwell purification cartridge was also analyzed on SDS-PAGE to assess the efficacy of the 
purification. Each sample was heated with NuPAGE LDS sample buffer (Invitrogen) briefly (<5 min) 
at 95 °C and then loaded into a precast Bis-tris 4-12 % polyacrylamide gradient gel (Invitrogen). 
Protein bands were visualized under white light on a BioRad Chemidoc XRS imaging system after 
AcquaStain Protein Gel Stain (Bulldog Bio. Inc).  
Western blot.  The identity of purified protein products were confirmed via western blotting. 
Purified proteins were run on a denaturing SDS-PAGE and transferred to a nitrocellulose 
membrane at 40 V for 60 min using a standard transfer protocol [536]. After proteins were 
transferred to the nitrocellulose membrane using Invitrogen’s XCellTM Blot Module, the SNAPi.d. 
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protein detection system (Millipore) was used for immunodetection with a 1:4000 dilution of a HRP-
conjugated 6x-His Epitope Tag Polyclonal Antibody (Thermo, PA1-23024) in Tris buffered saline 
plus Tween 20 (0.05 %) (Fisher, TBST, ionic strength = 175mM). Amersham™ ECL™ 
PrimeWestern blotting detection reagent (GE Healthcare Life Sciences, RPN2232) was used as 
detection reagent according to manufacture concentration and the bands were visualized using the 
Bio-Rad ChemiDoc™ XRS camera under varying exposure. 
Mass spectrometry (MS).  Liquid chromatography electrospray ionization mass 
spectrometry (LC-ESI-MS) was performed at the Core Synthesis and Analytical Services Facility 
(Center for Protease Research, North Dakota State University, USA) on purified protein samples. 
Briefly, the intact mass analyses of the specific proteins was performed after desalting them through 
a desalting cartridge followed by LC-ESI-MS analysis on a Waters Synapt G2-Si HDMS. UPLC was 
performed on an Acquity UPLC- I class with Waters BEH C18 (2.1 mm X 100 mm) 1.7 µm column. 
The column was maintained at 35°C throughout the analyses. A linear gradient was performed over 
7 min shifting the ratio of A (0.1 % formic acid in water) to B (0.1% formic acid in acetonitrile) shifted 
from 90/10 (A/B) to 10/90 (A/B). The total gradient run was 13 min. Desalted protein solution (100 
µL) was mixed with 200 µL of 0.1% TFA in water/acetonitrile (50/50) and 10 µL was injected at a 
rate of 0.5 mL/min. Mass spectrometric analysis was performed on a Waters Synapt G2-Si HDMS. 
The collected mass spectrum data in continuum format were processed using MaxEnt1 software 
(Waters Corporation) to obtain the protein mass. The peak width parameter used to obtain the 
result was between 0.45 Da to 0.6 Da depending on the sample. Spectra were processed between 
5000 to 50,000 Da at 1 Da/Channel. 
 
Heparin-binding characterization 
Heparin affinity column chromatography.  Affinity column chromatography was 
performed with HyperD resin (Pall) according to the manufacturer’s protocol to determine the affinity 
of each protein for heparin. Briefly, the column was washed with five column volumes of wash buffer 
(20 mM Tris HCl, 0.3 M NaCl, pH 7.4.) prior to application of the protein. Based on the binding 
capacity of the column, approximately 100 µg of protein in a 2 ml volume of Maxwell elution buffer 
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(500mM imidazole and 100mM HEPES, pH 7.5, ionic strength ≈ 0.73M [539]) was applied to the 
column and allowed to elute drop-wise (flow-through fraction). The column was then washed with 
3 column volumes (6 ml) of wash buffer followed by 2 column volumes of elution buffer (20 mM Tris 
HCl, 2 M NaCl, pH 7.4). Each chromatography fraction was collected separately for analysis.  
Heparin affinity dot blot.  Purified proteins (10 µl at approximated 100 µg/µl) were applied 
to a nitrocellulose membrane (Sigma) and allowed to adsorb for 30 min. The membrane was 
blocked on a rotating platform for an hour in block solution (5 % solution of nonfat instant milk 
(Carnation) in Tris buffered saline plus Tween 20 (0.05%) (Fisher, TBST) ionic strength = 0.175M). 
The membrane was subsequently probed with a biotinylated heparin (Calbiochem) ligand diluted 
at 1:100 in the blocking solution for one hour on a rotating platform. After washing the membrane 
three times for 15 min each in TBST (approximately 75 ml), the blot was probed with HRP-tagged 
streptavidin (Fisher Scientific) at a 1:100 dilution in the blocking solution for one hour on a rotating 
platform. After washing the membrane three times for 15 min each in TBST (approximately 75 ml), 
the membrane was reacted with enhance chemiluminescence reagents (Pierce) for 5 min prior to 
imaging on an Aplegen Omega Lum G over 5 min, acquiring images at varying exposure times. IL-
2 (PeproTech, Rocky Hill, New Jersey) was spotted as a positive control and BSA was spotted as 
a negative control. Additionally, a blot was probed with secondary streptavidin – HRP only using 
an analogous protocol without the addition of biotinylated heparin. 
Heparin affinity enzyme-linked immunosorbent assay (ELISA).  Protein samples were 
aliquoted and one aliquot was processed through a Zeba desalt column (pierce, USA). Biotinylated 
heparin (Calbiochem) was diluted 1:1000 in TBS and incubated for 2 h at room temperature in a 
Thermo Scientific™ Pierce™ High Binding NeutrAvidin™ Coated Plate (Fisher Scientific). 
Subsequently, wells were washed three times with TBST (0.05 % Tween 20) and blocked overnight 
at 4°C with a 5% nonfat instant milk solution (Carnation) in TBST. Protein (100 μl of 15 μg/ml silk2, 
S4H4, or IL-2 (positive control)) was incubated in the prepared wells for 1 h at room temperature. 
Wells were washed three times with TBST and incubated with an HRP conjugated antihistidine 6x 
(Fisher Scientific) diluted 1:2500 in 5% nonfat instant milk solution (Carnation) in TBST for 1 h at 
room temperature. Wells were once again washed and 75 μl TMB substrate (Fisher Scientific) was 
115 
 
added and allowed to incubate for 18 min at which time the reaction was stopped using 2M HCl 
according to the manufacturer’s instructions. Sample optical absorbance was read at 480 nm on a 
Biotek Epoch plate reader. 
 
Results 
Capitalizing on the molecular hierarchy of spider major ampullate silk, the repetitive 
sequence for Argiope aurantia major ampullate spidroin 2 (MaSp2), one of the key structural spider 
silk proteins, was genetically linked with the consensus sequence for binding heparin (HBM) (Figure 
A.2), thereby endowing MaSp2 with the ability to bind heparin. MaSp2 (silk) and HBM sequences 
were designed and engineered in a cloning plasmid not only to optimize expression in E. coli, but 
also to facilitate the genetic linkage and polymerization of each gene individually (HBM n=1, 2, and 
4 repeats, and silk n=1, 2, 4 and 6 repeats) using a compatible nonregenerable cloning strategy 
(Figure A.2 A-C). Silk2 constructs were genetically polymerized to HBM4 constructs to create a 
silk/heparin fusion protein (S2H4, Figure A.2). All produced clones were screened via colony PCR 
(Figure A.2 D) and sequence confirmed by the University of Utah core sequencing facility (Figure 
A.3). Subsequently, genes were PCR-cloned into pET30a for protein expression. After constructs 
were transferred into pET30a, expression was induced in BL21-DE3 E. coli using IPTG. 
Alternatively, silk4HBM4 (S4H4) fusion constructs were synthesized and cloned into pET30a by 
GenScript. Fusion protein production was confirmed by: (1) the slight shift in molecular weight upon 
addition of the HBM4 peptide (Silk2 = 14766 Da, S2H4 = 15146 Da, S4H4 = 16355 Da, Figure A.5), 
(2), mass spectrometry (Figure A.5) and (3) the reaction with an anti-histidine – HRP conjugated 
antibody (Figure A.6).  
Following confirmation that the HBM4 peptide was in fact attached to the silk2 or the silk4 
peptide (Figures A.5 and A.6), functional assays were used to determine the capability of fusion 
peptide to bind heparin in both solid phase (Figure A.7) and from solution as a surface-bound 
protein film (Figure A.8). In each assay, bovine serum albumin (BSA) was used as negative control, 
having no reported ability to bind heparin [540], while antithrombin III (ATIII) or IL-2 was used as 
the positive control [541, 542]. HyperD heparin affinity resin has heparin covalently bound to the 
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column solid phase, allowing interaction with recombinant proteins under flow through the column. 
Presence of non-HBM containing silk protein in the eluted unbound wash fraction (Figure A.7) 
confirms that recombinant silk solution alone has limited affinity for immobilized heparin. 
Alternatively, when HBM is grafted to the MaSp2 silk repeats, the resulting fusion protein is seen 
in the elution fraction, reflecting the dramatically increased ability of this recombinant protein to bind 
immobilized heparin on the column. Despite this result anomalous nonspecific protein affinity 
interactions can occur in affinity column chromatography; therefore, a dot blot assay on 
nitrocellulose was used to confirm the ability of surface-adsorbed silk-HBM constructs to bind 
biotinylated heparin (Figure A.8B). Both IL-2 (positive control) and S4H4 were detected by 
biotinylated heparin; whereas heparin did not bind to either the silk2 or the BSA negative control. 
An analogous blot was probed with secondary streptavidin – HRP only (data not shown). This assay 
format exhibited limited sensitivity: approximately 0.3 mg of protein applied to each 10 µl spot was 
required for subsequent heparin detection. Thus, both kinetic and endpoint Enzyme Linked 
Immunosorbant Assays (ELISA) were conducted to determine the dissociation constant of heparin 
with S4H4 and silk (Figure A.8A). Although the endpoint ELISA was able to validate the interaction 
of heparin with S4H4 and the lack of significant interaction with silk2, kinetic determination was 
inconsistent and did not yield significant results (data not shown).  
The mechanics of MaSp2 silk protein have been extensively evaluated in the past; 
however, each protein was dissolved in HFIP and wet spun into methanol to create fibers. The 




Tailored surface coatings have been used for over four decades to improve materials 
performance in blood, tissue or biological milieu [543]. Historically, several strategies – either 
actively or passively pharmaceutical – have been exploited specifically to combat either materials 
thrombosis or biofilm formation [544]. For over 30 years, heparin’s use as a surface-immobilized 
prophylactic agent has been reported in many forms on to improve hemocompatibility [545, 546] in 
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vitro and in vivo on numerous commercial medical devices [547, 548]. Recent advances in 
heparinized surfaces (e.g., Carmeda BioActive Surface, BioInteractions Biba-Hepcoat technology 
(Tyco Healthcare) licensed by Medtronic) and the relative success of chemically defined polymer 
surface coatings in providing a versatile cassette for pharmaceutical immobilization is a driving 
force behind using biological-based biomimetic therapeutics [549-551], or synthetic polymer [552, 
553] materials as surface coatings [554]. Furthermore, several groups have recently explored 
heparin silk complexes by covalently linking heparin to silk (often silkworm silk) or via mixing prior 
to processing via electrospinning or film casting [555-557]. Unfortunately with all these coatings, 
once heparin is lost, the surface properties desired for heparinized materials are clinically sub-
standard. A “self-renewable” multifunctional coating, such as could be created using the fusion 
protein described herein, relying on biological mechanisms and thrombosis signaling pathways 
offers a feasible alternative [558]. 
Using a compatible nonregenerable cloning strategy [536, 538, 559] silk2 and HBM4 
constructs were created and genetically linked to create the S2H4 fusion protein (Figure A.2); 
whereas S4H4 was directly synthesized in pET30a for expression. Based on anticipated 
intermolecular hydrogen binding, two polymerized MaSp2 silk monomers were predicted to provide 
a sufficient mechanical background in which to embed a heparin-binding motif and to provide 
enough flexibility to allow the heparin-binding domain to bind heparin with minimal steric hindrance 
and potentially even provide antimicrobial efficacy based on its AMP-like residues and structure. It 
is important to note that while alanine and arginine can promote heparin binding, the presence of 
proline is disruptive, further necessitating a minimal silk component of the fusion protein [524]. 
Unfortunately, using only two silk repeats was insufficient to reduce lysine molar fraction in the 
construct sufficiently to overcome dismal yields (data not shown). It is possible that yields could be 
increased with the addition of a periplasmic localization signal [560]. Therefore, four silk repeats 
were genetically linked with the heparin-binding motif, improving the recombinant protein yield.  
Based on previous reports of heparin’s dissociation constant with the ARKKAAKA peptide 
(KD = 42±15 nm, MW 7298), four uninterrupted heparin-binding motifs were used to optimize 
possible heparin interactions [524], suggesting that a recombinant silk MaSp2 peptide genetically 
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fused with four repeats of the HBM peptide would be capable of binding heparin from ionic 
solutions. Support for this design was evident using a recombinant silk/heparin fusion protein in 
several heparin-binding assays (Figures A.5 and A.6). Although the genetic sequence of the S2H4 
clone was confirmed and the peptide was functionally active, mass spectrometry and amino acid 
analysis were unable to confirm the exact protein identity, attributed to poor yields and 
concentration. After derivatizing recombinant proteins with o-phthaldehyde, high performance liquid 
chromatography (HPLC) of S2H4, showed the emergence of a new peak, indicating an increase in 
the number of primary amino acids. Nevertheless, due to this unconventional use of HPLC, this 
analysis was not considered sequence confirmation of S2H4 (Figure A.4). Alternatively, S4H4 protein 
identity was confirmed via mass spectrometry (Figure A.5). 
Although antimicrobial peptides receive substantial research interest amidst the rising tide 
of antimicrobial resistant bacteria and their recombinant production, like most peptides, is cost 
effective in E.coli, it is necessary to proteolytically stabilize them as a fusion peptide [561, 562]. 
Thus, it was not surprising that bacterial expression was negatively affected by the addition of 
structurally analogous HBM; nevertheless, the fusion was not thought to be a toxic construct due 
to the presence of the silk peptide. Observed low but finite levels of protein expression confirmed 
this suspicion. Expression of the HBM peptide alone in the absence of the MaSp2 silk peptide in 
any measurable quantity was not feasible (data not shown), likely due to the high molar percent of 
lysine in the peptide and the bacteria’s innate ability to respond to AMPs [561, 563]. Thus, the HBM 
peptide was expressed only as a fusion with proteolytically stable silk. Unfortunately, expression of 
the S2H4 fusion protein was also significantly hampered apparently by the higher lysine content, 
indicating that the silk peptide with its extended stretches of alanine, predicted to support heparin 
binding [524], may not have been of significant length when considering the ratio of the fusion 
components. This supposition was supported by the increased protein expression when the silk 
peptide was expanded to four repeats. Recently, Yang et al. produced a Cecropin AD (a cationic 
AMP) elastin like peptide (ELP) fusion protein similar to that being reported in this study and 
demonstrated the link between the length of the ELP sequence and the yield of the fusion [564-
566]. Thus, efforts to increase levels of recombinant protein expression of S2H4 fusion by effectively 
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“diluting” out the molar percent of lysine using a larger purification tag (GST) (ProMab) (data not 
shown) demonstrated increased expression, confirming the utility of a large fusion tag. 
Unfortunately, the GST fusion was unstable to even a single freeze/ thaw cycle, and storage at 4°C 
also proved susceptible to rapid degradation (within 1-3 days), as indicated by a laddering effect in 
SDS PAGE. Therefore, the lower expressing 6xHis tag version of the fusion was used for all 
heparin-binding assays. The fact that expression was significantly increased by the presence of the 
large GST tag (~25kD) compared to the smaller silk peptide (~15kD) may indicate that the silk 
peptide was not of sufficient length the mask the cationic heparin binding peptide.  
In addition to using a larger fusion tag or additional silk repeats to increase the yield of the 
heparin-binding motif, evidence suggests that promoting the sequestration of the recombinant 
cationic fusion protein, such as may occur when using a periplasmic signal peptide, may also 
improve the yield. A lower induction temperature was also found to improve expression (Figure 
A.6). Contrary to Luan et al. who recently demonstrated the ability of E.coli to recombinantly 
express AMPs as a self-cleaving fusion that was sequestered as aggregates [562], the HBM silk 
fusion was not sequestered in inclusion bodies in any measurable amount (data not shown) or 
aggregated. This may have been a detriment to efficient protein production as Zorko et al. recently 
demonstrated the ability to produce large quantities of recombinant AMP by forcing sequestration 
in inclusion bodies [563]. Considering the chimera protein sequence analogy with an AMP, the 
resulting fusion protein remains to be evaluated for antimicrobial efficacy although preliminary Kirby 
Bauer zone of inhibition assays suggest there may be some efficacy against E.coli (data not 
shown). Future work will modify the ratio of the MaSp2 silk to heparin-binding motifs in attempts to 
optimize both mechanical and biological properties while increasing recombinant protein yield.  
The ability of the fusion proteins to bind heparin was utilized as the final distinguishing 
feature of the silk fusion protein. ATIII or IL2 was used in these assays as a positive control while 
BSA was used as the negative control [540, 567]. Surface-bound heparin such as presented by 
HyperD heparin affinity resin was capable of retaining S2H4 and S4H4 (Figure A.7) although the S2H4 
fusion did not appear capable of binding heparin with the same robustness as ATIII [567]. This 
observation was confirmed using dot blot analysis on the elution fractions from the S2H4 (data not 
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shown) and S4H4 columns, which also had a more diffuse dot blot signal. Interestingly, S4H4 did 
bind biotinylated heparin with the same intensity as IL-2 (Figure A.8). Additionally, endpoint ELISA 
indicated that there was no significant difference in heparin binding when compared to the IL-2 
positive control.  
Even though heparin bound to the fusion protein with very little nonspecific binding to silk2 
determining the kinetics of this binding through kinetic ELISA was inconsistent, not allowing 
accurate determination. Previous indirect efforts using labeled heparin have been used 
successfully; however, direct label-free kinetic determination is challenging at best [541, 568, 569]. 
The challenge is two-fold: (1) heparin is an anionic polyelectrolyte and (2) electrostatic binding to 
heparin is not a specific interaction. Since heparin is polyvalent, it may bind multiple protein partners 
simultaneously, making it difficult to resolve single binding kinetics. Thus, the observed binding rate 
will be dependent on the surface density of the protein, yielding a complex profile. In an attempt to 
decipher and determine kinetic heparin binding profiles, two designs were evaluated via kinetic 
ELISAs, in which heparin was either the capture ligand and the protein was added in solution, or 
the protein was the capture molecule and heparin was added in solution. Unfortunately, although 
this design allowed confirmation that the heparin-binding modified silk can bind heparin, the 
disassociation constant could not be determined. Additionally, since many proteins bind heparin 
through charge/charge interactions similar to an ion exchange resin and not specifically, binding 
site saturation, a key principle for label free affinity measurements, cannot be achieved.  
The ionic strength of the various buffers used in all heparin-binding experiments could 
potentially reduce or disrupt the predominant electrostatic interactions [570] between negatively 
charged heparin and its positively charged binding partners (i.e., silk and silk fusion constructs) and 
must be considered during analysis. The ionic strength of the buffer, particularly the wash buffer 
used in all immunoassays (i.e., dot blot and ELISA), must provide sufficient stringency to prevent 
nonspecific background interactions. Thus, TBS Tween, with an ionic strength of 0.175M, well 
below the concentration used to disrupt nonspecific electrostatic interactions in the HyperD heparin 
column, was used and provided sufficient stringency to reduce nonspecific background interactions 
at pH 7.5 as evidenced by the minimal or absent signal in the silk and the negative control and the 
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overall low background of the blot (Figure A.8 B). ELISAs were also run with both desalted and 
buffered (Maxwell elution buffer) samples with no significant difference in performance (data not 
shown), indicating that ionic strength based on buffer composition was not a significant factor that 
altered heparin interactions. Importantly, using Promega’s Maxwell 16 system required elution in 
the Maxwell elution buffer; however, as the interactions being probed are specifically electrostatic 
interactions, we were concerned that the ionic strength of the buffer may interfere or provide 
artificial results. Therefore, ELISAs were also run with desalted samples, showing no significant 
differences between directly eluted samples and those desalted.  Furthermore, since all 
recombinant proteins were purified the same way they all would have experienced the effect of an 
ionic solution similarly. Finally, the Maxwell elution buffer (500mM Imidazole and 100mM HEPES, 
pH 7.5) had an ionic strength well below the manufacturer’s recommended elution buffer (I=2M) for 
that of the HyperD heparin column. As a zwitterion, HEPES is proposed not to contribute to solution 
ionic strength [571]. Imidazole, is partially protonated at pH 7.4, indicating that at physiological pH 
it has limited ionic strength and is used primarily to stabilize proteins [572]. Therefore, although the 
potential interference of the buffer in the binding of heparin to its binding partner cannot be 
completely discounted, experimental and theoretical evidence would suggest that such an effect is 
limited. 
Although a complete stoichiometric analysis and binding pair dissociation constant were 
not determined, a titration of the protein across the heparin affinity column (data not shown) 
indicated that at the highest concentration of 100 µg of loaded protein, the reported binding capacity 
of resin (25-35 µg/ml) was not exceeded, supported by no protein observed in the flow-through 
fraction of the fusion protein. Furthermore, lack of protein in the flow-through fraction and minimal 
protein in the wash fraction also indicated that the time to dissociation of heparin and the HBM/silk 
fusion protein did not exceed the time necessary to perform the column chromatography (~2 hours). 
This observed robustness of binding may reflect the limited length of the component peptides when 
compared to the natural full-length protein. Thus, this aspect of the protein fusion could be altered 
in the future to optimize heparin binding and disassociation events. Future efforts will continue to 




A new protein fusion comprising spider silk-derived MaSp2 peptides fused with a 
consensus heparin-binding peptide was cloned, expressed, purified, and shown to bind soluble 
heparin both at surfaces and in buffer solutions. While fusion protein affinity with heparin was 
demonstrated under certain in vitro conditions, the precise stoichiometry and binding kinetics 
remain to be determined as does verification of heparin’s bioactivity. Utility of this protein as a 
biomaterial, exploiting both the recombinant protein-bound heparin and also the intrinsic 
antimicrobial potential based on its AMP-like structure, represents the next application for this newly 
engineered recombinant chimera. 
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Supplementary information 
Materials and methods 
High performance liquid chromatography (HPLC).  Purified proteins were dialyzed 
against water for 2 days using a 3 kDa-cutoff dialysis membrane and concentration was determined 
via absorbance at 280 nm as well as on SDS PAGE by comparison with BSA protein standards 
using optical densitometry. Subsequently, silk and silk-HBM recombinant proteins were derivatized 
with o-phthaldehyde (OPA, Sigma), which binds to primary amines and fluoresces (ex = 360 nm, 
em = 460 nm) to allow detection [573]. A stock OPA solution was prepared as previously described 
[573]. Briefly, 50 mg of OPA (powder, Sigma) was dissolved in 4 ml of methanol, 0.5 ml of potassium 
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borate (0.5 M boric acid adjusted to pH of 10.4 with potassium hydroxide), and 50 µl 2-
mercaptoethanol (Sigma) was added. This solution was kept at 4°C in the dark. Working reagent 
was prepared fresh by adding 50 µl OPA stock solution to 1 ml of 0.5 M potassium buffer. Each 
reaction contained 100 µl of protein solution in water, 100 µl of isopropanol and 200 µl of OPA 
reagent. Reactions were allowed to incubate at room temperature protected from light for 30 min 
prior to injecting on the HPLC column. Each reaction (10 µl) was injected on a C-18 Gold column 
with an inline guard column (ThermoFisher Scientific). A blend of acetonitrile and phosphate buffer 
(52:48) was used as the mobile phase (flow rate = 1 ml/min). Column temperature was set to 22°C. 
 
Results and discussion 
Since sizes of the MaSp2 silk alone versus that of the silk-HBM fusions were difficult to 
confidently distinguish by SDS-PAGE alone, each protein was derivatized with fluorescent tag, 
OPA, for detection with HPLC. OPA reagent derivatizes primary amines, producing a fluorogenic 
compound, which can then be detected [573]. Pure MaSp2 silk protein is only expected to have a 
single free amine available for such derivatization on its N-terminus; whereas, the addition of the 
HBM peptide (ARKKAAKA) provides three lysine residues, equivalent to three additional primary 
amines (12 primary amines total) available for derivatization. Thus, HPLC was not used to detect a 
change in the molecular weight of the protein, but merely a change in the sequence of the protein 
as a confirmation that the HBM peptide was added. Precolumn OPA derivatization followed by 
separation with a C18 HPLC column provided separation of a new protein peak eluting at 
approximately 32 min (Figure A.4). The presence of this peak in an S2H4 sample is again likely the 
result of the increased number of primary amines corresponding to an increased molar percent of 
lysine in the S2H4 fusion. Unfortunately, degradation seemed to significantly impact the HBM 
fraction of the fusion as storing the protein at 4°C for 4 months caused the HPLC peak to not only 
broaden but also to shift to the left (i.e., retention time = 2-4 min), making it only slightly greater 
than the minimal peak detected for pure silk (data not shown). Replicate SDS-PAGE analysis run 
on these protein samples after storage validated the HPLC results, demonstrating not only a slightly 
higher concentration of silk but also the apparent degradation of the fusion protein, as indicated by 
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a slight decrease in molecular weight (data not shown). Thus, this OPA fluorogenic detection 
method exploiting the increase in number of available primary amines for protein product 







Figure A.1 Infection and thrombosis are intimately connected (problem). This is of particular 
concern for hemodialysis catheters and other blood-contacting medical devices. The heparin-
binding motif (HBM) can both bind heparin to prevent blood clots and also act as an antimicrobial 
peptide. Thus, genetically linking a heparin-binding motif with a protease-resistant silk protein will 
bind heparin, both when in solution as well as when bound to a surface (steps 1-3 as described in 
this dissertation). Ultimately, using this new fusion protein as a medical device coating will not only 
bind endogenous and exogenous heparin from the blood stream, but will also prevent infection 
(solution).  
 
Figure A.2 Schematic showing the compatible nonregenerable cloning design. The design is used 
to genetically polymerize the A) Argiope aurantia MaSp2 consensus repeat motif using BsrFI and 
BspEI to produce compatible ends, which after being ligated together cannot be cleaved by either 
BsrFI or BspEI; B) HBM consensus repeat motif using MluI and BssHI to produce compatible ends, 
which after being ligated together cannot be cleaved by either MluI or BssHI; C) the Argiope 
aurantia MaSp2 consensus repeat motif concatenated with the HBM consensus repeat motif using 
BanII and SacI. D) Agarose gel electrophoresis showing the successful linkage of silk2 and HBM4. 
Bands of interest are highlighted by the boxes. Each band represents a different clone. E) Amino 
acid sequences for each clone. Note that a 6xHis tag was included in each construction for 









Figure A.4 HPLC analysis of both the recombinant MaSp2 silk protein (flat grey line) and the s2H4 
chimera protein (black peak). Each protein was derivatized with OPA to detect an increase in the 
number of primary amines present in the proteins. Notice the distinct peak at 32 min for the chimera 
that is absent in the silk protein, indicating an increase in primary amines as a result of the lysine 











Figure A.5 Liquid chromatography electrospray ionization mass spectrometric validation of the 
desired recombinant modified silk fusion protein sequences. (A) Based on the amino acid 
sequence shown for silk2, predicted to be 14766.56, the silk2 protein was confirmed. (B) Based 
on the amino acid sequence shown for S4H4, predicted to be 16355.56, the S4H4 protein was 
confirmed.  
 
Figure A.6 Western blot of (A) Silk2 protein, (B) S2H4, and (C) S4H4 (2 clones) using a HRP 
conjugated anti-His antibody. To improve yield two different induction temperatures were 
assessed for S2H4. Only in the Silk2 blot can the molecular weight marker be seen. Note that 






Figure A.7 SDS PAGE showing a solid phase functional assay using heparin affinity 
chromatography. Notice the increased ability of the recombinant S2H4 and S4H4 protein to 
bind heparin as indication by its elution in the finial high salt buffer. Two clones of S4H4 are 
shown. The binding capacity of the column was likely exceeded in the first clone, thereby 
giving rise to a band in the flow through fraction (FT). Bands of interest are highlighted by 
the boxes.  
 
Figure A.8 (A) ELISA to detect the interaction of IL-2 (positive control), S4H4, silk2, and BSA 
(negative control) with heparin. Notice that there is no statistical significance between the 
binding of heparin with S4H4 and the positive control and there is only a small amount of 
binding to silk. (B) S4H4 spotted on nitrocellulose binds heparin similar to the positive control 
IL-2. Notice that silk2 was unable to bind heparin, similar to the BSA negative control. Areas 
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